# EDGAR Filing Document

**Accession Number:** 0001576018
**File Stem:** 0001576018-26-000065
**Filing Date:** 2026-5
**Character Count:** 330994
**Document Hash:** 808c5b58cef72a7a2c3f78b42b800f90
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001576018-26-000065.hdr.sgml**: 20260507

**ACCESSION NUMBER**: 0001576018-26-000065

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 96

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260507

**DATE AS OF CHANGE**: 20260507

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SiriusPoint Ltd
- **CENTRAL INDEX KEY:** 0001576018
- **STANDARD INDUSTRIAL CLASSIFICATION:** FIRE, MARINE & CASUALTY INSURANCE [6331]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 000000000
- **STATE OF INCORPORATION:** D0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36052
- **FILM NUMBER:** 26953717

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** POINT BUILDING
- **STREET 2:** 3 WATERLOO LANE
- **CITY:** PEMBROKE
- **PROVINCE COUNTRY:** D0
- **ZIP:** HM 08
- **BUSINESS PHONE:** 1 441 542 3300

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** POINT BUILDING
- **STREET 2:** 3 WATERLOO LANE
- **CITY:** PEMBROKE
- **PROVINCE COUNTRY:** D0

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Third Point Reinsurance Ltd.
- **DATE OF NAME CHANGE:** 20130503

?xml version='1.0' encoding='ASCII'? spnt-20260331

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

___________________________

**FORM 10-Q** 

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended March 31, 2026

OR

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)** **OF THE SECURITIES EXCHANGE ACT OF 1934** For the transition period from to

**Commission File Number 001-36052**

**SIRIUSPOINT LTD.** 

(Exact name of registrant as specified in its charter)

Bermuda 98-1599372 <br> (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

Point Building

3 Waterloo Lane

Pembroke HM 08, Bermuda

+1 441 542-3300

(Address of Principal Executive Offices) (Registrant's Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
| Common Shares, $0.10 par value | SPNT | New York Stock Exchange |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes&nbsp;&nbsp;&nbsp;&nbsp;☒&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&nbsp;&nbsp;☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes&nbsp;&nbsp;&nbsp;&nbsp;☒&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&nbsp;&nbsp;☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| | | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &nbsp;&nbsp;&nbsp;&nbsp;☐

As of May 4, 2026, the registrant had 117,542,130 common shares issued and outstanding.

------

**SiriusPoint Ltd.**

**INDEX**

---

| | |
|:---|:---|
| | Page |
| [PART I](#i31a8d8967ea4414aa9d7225accfbc817_13). FINANCIAL INFORMATION | <u>[1](#i31a8d8967ea4414aa9d7225accfbc817_13)</u> |
| [Item 1.](#i31a8d8967ea4414aa9d7225accfbc817_16) Financial Statements | <u>[1](#i31a8d8967ea4414aa9d7225accfbc817_16)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;[Consolidated Balance Sheets](#i31a8d8967ea4414aa9d7225accfbc817_19) as of March 31, 2026 (unaudited) and December 31, 2025 | <u>[1](#i31a8d8967ea4414aa9d7225accfbc817_19)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;[Consolidated Statements of Income](#i31a8d8967ea4414aa9d7225accfbc817_25) for the three months ended March 31, 2026 and 2025 (unaudited) | <u>[2](#i31a8d8967ea4414aa9d7225accfbc817_25)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;[Consolidated Statements of Comprehensive Income](#i31a8d8967ea4414aa9d7225accfbc817_28) for the three months ended March 31, 2026 and 2025 (unaudited) | <u>[3](#i31a8d8967ea4414aa9d7225accfbc817_28)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;[Consolidated Statements of Shareholders' Equity](#i31a8d8967ea4414aa9d7225accfbc817_31) for the three months ended March 31, 2026 and 2025 (unaudited) | <u>[4](#i31a8d8967ea4414aa9d7225accfbc817_31)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;[Consolidated Statements of Cash Flows](#i31a8d8967ea4414aa9d7225accfbc817_34) for the three months ended March 31, 2026 and 2025 (unaudited) | <u>[5](#i31a8d8967ea4414aa9d7225accfbc817_34)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Notes to the Consolidated Financial Statements](#i31a8d8967ea4414aa9d7225accfbc817_40)  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Note](#i31a8d8967ea4414aa9d7225accfbc817_43) 1. Organization | <u>[6](#i31a8d8967ea4414aa9d7225accfbc817_43)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Note](#i31a8d8967ea4414aa9d7225accfbc817_46) 2. Significant accounting policies | <u>[6](#i31a8d8967ea4414aa9d7225accfbc817_46)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Note](#i31a8d8967ea4414aa9d7225accfbc817_49) 3. Significant transactions | <u>[7](#i31a8d8967ea4414aa9d7225accfbc817_49)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Note](#i31a8d8967ea4414aa9d7225accfbc817_52) 4. Segment reporting | <u>[8](#i31a8d8967ea4414aa9d7225accfbc817_52)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Note](#i31a8d8967ea4414aa9d7225accfbc817_58) 5. Cash, cash equivalents, restricted cash and restricted investments | <u>[12](#i31a8d8967ea4414aa9d7225accfbc817_58)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Note](#i31a8d8967ea4414aa9d7225accfbc817_61) 6. Fair value measurements | <u>[12](#i31a8d8967ea4414aa9d7225accfbc817_61)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Note](#i31a8d8967ea4414aa9d7225accfbc817_64) 7. Investments | <u>[17](#i31a8d8967ea4414aa9d7225accfbc817_64)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Note](#i31a8d8967ea4414aa9d7225accfbc817_70) 8. Derivatives | <u>[21](#i31a8d8967ea4414aa9d7225accfbc817_70)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Note](#i31a8d8967ea4414aa9d7225accfbc817_73) 9. Variable and voting interest entities | <u>[22](#i31a8d8967ea4414aa9d7225accfbc817_73)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Note](#i31a8d8967ea4414aa9d7225accfbc817_76) 10. Loss and loss adjustment expense reserves | <u>[24](#i31a8d8967ea4414aa9d7225accfbc817_76)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Note](#i31a8d8967ea4414aa9d7225accfbc817_79) 11. Allowance for expected credit losses | <u>[25](#i31a8d8967ea4414aa9d7225accfbc817_79)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Note](#i31a8d8967ea4414aa9d7225accfbc817_82) 12. Debt and letter of credit facilities | <u>[26](#i31a8d8967ea4414aa9d7225accfbc817_82)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Note](#i31a8d8967ea4414aa9d7225accfbc817_85) 13. Income taxes | <u>[27](#i31a8d8967ea4414aa9d7225accfbc817_85)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Note](#i31a8d8967ea4414aa9d7225accfbc817_88) 14. Shareholders' equity | <u>[28](#i31a8d8967ea4414aa9d7225accfbc817_88)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Note](#i31a8d8967ea4414aa9d7225accfbc817_91) 15. Earnings per share available to SiriusPoint common shareholders | <u>[29](#i31a8d8967ea4414aa9d7225accfbc817_91)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Note](#i31a8d8967ea4414aa9d7225accfbc817_94) 16. Related party transactions | <u>[29](#i31a8d8967ea4414aa9d7225accfbc817_94)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Note](#i31a8d8967ea4414aa9d7225accfbc817_97) 17. Commitments and contingencies | <u>[30](#i31a8d8967ea4414aa9d7225accfbc817_97)</u> |
| [Item 2.](#i31a8d8967ea4414aa9d7225accfbc817_103)Management's Discussion and Analysis of Financial Condition and Results of Operations | <u>[32](#i31a8d8967ea4414aa9d7225accfbc817_103)</u> |
| [Item 3.](#i31a8d8967ea4414aa9d7225accfbc817_157)Quantitative and Qualitative Disclosures About Market Risk | <u>[50](#i31a8d8967ea4414aa9d7225accfbc817_157)</u> |
| [Item 4.](#i31a8d8967ea4414aa9d7225accfbc817_160)Controls and Procedures | <u>[51](#i31a8d8967ea4414aa9d7225accfbc817_160)</u> |
| <u>[PART II. OTHER INFORMATION](#i31a8d8967ea4414aa9d7225accfbc817_163)</u> | <u>[52](#i31a8d8967ea4414aa9d7225accfbc817_166)</u> |
| [Item](#i31a8d8967ea4414aa9d7225accfbc817_166)1. Legal Proceedings | <u>[52](#i31a8d8967ea4414aa9d7225accfbc817_166)</u> |
| [Item](#i31a8d8967ea4414aa9d7225accfbc817_169)1A. Risk Factors | <u>[52](#i31a8d8967ea4414aa9d7225accfbc817_169)</u> |
| &nbsp;&nbsp;[Item](#i31a8d8967ea4414aa9d7225accfbc817_172)2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities | <u>[53](#i31a8d8967ea4414aa9d7225accfbc817_172)</u> |
| [Item](#i31a8d8967ea4414aa9d7225accfbc817_175)3. Defaults Upon Senior Securities | <u>[53](#i31a8d8967ea4414aa9d7225accfbc817_175)</u> |
| [Item](#i31a8d8967ea4414aa9d7225accfbc817_178)4. Mine Safety Disclosures | <u>[53](#i31a8d8967ea4414aa9d7225accfbc817_178)</u> |
| [Item](#i31a8d8967ea4414aa9d7225accfbc817_181)5. Other Information | <u>[53](#i31a8d8967ea4414aa9d7225accfbc817_181)</u> |
| [Item](#i31a8d8967ea4414aa9d7225accfbc817_184)6. Exhibits | <u>[54](#i31a8d8967ea4414aa9d7225accfbc817_184)</u> |

---

------

**PART I - Financial Information**

**ITEM 1. Financial Statements**

**SIRIUSPOINT LTD.**

**CONSOLIDATED BALANCE SHEETS (UNAUDITED)**

**As of March 31, 2026 and December 31, 2025**

 **(expressed in millions of U.S. dollars, except per share and share amounts)**

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| **Assets** | | |
| Debt securities, available for sale, at fair value, net of allowance for credit losses of $0.0 (2025 - $0.0) (cost - $4,896.1; 2025 - $5,118.3) | $4892.9 | $5168.6 |
| Debt securities, trading, at fair value (cost - $111.3; 2025 - $114.6) | 86.0 | 90.3 |
| Short-term investments, at fair value (cost - $32.2; 2025 - $28.4) | 32.5 | 28.3 |
| Other long-term investments, at fair value (cost - $410.4; 2025 - $421.9) (includes related party investments at fair value of $203.8 (2025 - $216.1)) | 295.4 | 315.1 |
| Total investments | 5306.8 | 5602.3 |
| Cash and cash equivalents | 856.9 | 731.2 |
| Restricted cash and cash equivalents | 153.8 | 171.2 |
| Due from brokers | 40.1 | 7.5 |
| Interest and dividends receivable | 41.4 | 47.1 |
| Insurance and reinsurance balances receivable, net | 2420.8 | 2260.3 |
| Deferred acquisition costs, net | 403.4 | 384.1 |
| Unearned premiums ceded | 573.3 | 487.4 |
| Loss and loss adjustment expenses recoverable, net | 2020.2 | 2102.3 |
| Deferred tax asset | 256.7 | 267.7 |
| Goodwill | 18.6 |  |
| Intangible assets | 139.8 | 121.2 |
| Other assets | 251.2 | 272.1 |
| Assets held for sale |  | 115.2 |
| **Total assets** | $12483.0 | $12569.6 |
| **Liabilities** |  |  |
| Loss and loss adjustment expense reserves | $5732.7 | $5782.5 |
| Unearned premium reserves | 1991.2 | 1855.4 |
| Reinsurance balances payable | 1455.0 | 1447.6 |
| Debt | 679.6 | 688.6 |
| Due to brokers | 3.4 | 5.5 |
| Deferred tax liability | 73.4 | 73.0 |
| Other liabilities | 244.3 | 246.1 |
| **Total liabilities** | 10179.6 | 10098.7 |
| Commitments and contingent liabilities (refer to Note 17) |  |  |
| **Shareholders' equity** |  |  |
| Series B preference shares (2025 - par value $0.10; authorized and issued: 8,000,000) |  | 200.0 |
| Common shares (issued and outstanding: 115,936,935 (2025 - 116,989,799)) | 11.6 | 11.7 |
| Additional paid-in capital | 956.4 | 967.7 |
| Retained earnings | 1328.1 | 1228.5 |
| Accumulated other comprehensive income, net of tax | 6.3 | 61.9 |
| **Shareholders' equity attributable to SiriusPoint shareholders** | 2302.4 | 2469.8 |
| Noncontrolling interests | 1.0 | 1.1 |
| **Total shareholders' equity** | 2303.4 | 2470.9 |
| **Total liabilities, noncontrolling interests and shareholders' equity** | $12483.0 | $12569.6 |
| **The accompanying Notes to the Consolidated Financial Statements are<br>an integral part of the Consolidated Financial Statements.** | **The accompanying Notes to the Consolidated Financial Statements are<br>an integral part of the Consolidated Financial Statements.** | **The accompanying Notes to the Consolidated Financial Statements are<br>an integral part of the Consolidated Financial Statements.** |

---

------

**SIRIUSPOINT LTD.**

**CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)**

**For the three months ended March 31, 2026 and 2025**

**(expressed in millions of U.S. dollars, except per share and share amounts)** 

---

| | | |
|:---|:---|:---|
| | **2026** | **2025** |
| **Revenues** |  |  |
| Net earned premium | $638.9 | $626.7 |
| Net investment income | 66.4 | 71.2 |
| Net investment gains (losses) | 11.4 | (0.3) |
| Other revenues | 57.9 | 29.7 |
| Total revenues | 774.6 | 727.3 |
| **Expenses** |  |  |
| Loss and loss adjustment expenses incurred, net | 362.9 | 401.8 |
| Acquisition costs, net | 147.8 | 129.7 |
| Other underwriting expenses | 50.5 | 41.1 |
| Net corporate and other expenses | 71.2 | 60.6 |
| Intangible asset amortization | 2.6 | 2.9 |
| Interest expense | 16.8 | 18.1 |
| Foreign exchange (gains) losses | 1.3 | (2.2) |
| Total expenses | 653.1 | 652.0 |
| Income before income tax expense | 121.5 | 75.3 |
| Income tax expense | (19.2) | (13.3) |
| **Net income** | 102.3 | 62.0 |
| Net income attributable to noncontrolling interests | (0.1) | (0.4) |
| **Net income available to SiriusPoint** | 102.2 | 61.6 |
| Dividends on Series B preference shares | (2.6) | (4.0) |
| **Net income available to SiriusPoint common shareholders** | $99.6 | $57.6 |
| **Earnings per share available to SiriusPoint common shareholders** |  |  |
| Basic earnings per share available to SiriusPoint common shareholders | $0.85 | $0.50 |
| Diluted earnings per share available to SiriusPoint common shareholders | $0.82 | $0.49 |
| **Weighted average number of common shares used in the determination of earnings per share** |  |  |
| Basic | 116725419 | 115975961 |
| Diluted | 121695056 | 118555166 |
| **The accompanying Notes to the Consolidated Financial Statements are<br>an integral part of the Consolidated Financial Statements.** | **The accompanying Notes to the Consolidated Financial Statements are<br>an integral part of the Consolidated Financial Statements.** | **The accompanying Notes to the Consolidated Financial Statements are<br>an integral part of the Consolidated Financial Statements.** |

---

------

**SIRIUSPOINT LTD.**

**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)**

**For the three months ended March 31, 2026 and 2025**

**(expressed in millions of U.S. dollars)**

---

| | | |
|:---|:---|:---|
| | **2026** | **2025** |
| **Comprehensive income** |  |  |
| Net income | $102.3 | $62 |
| **Other comprehensive income (loss), net of tax** |  |  |
| Change in foreign currency translation adjustment | (5.3) | (0.2) |
| Unrealized gains (losses) from debt securities held as available for sale investments | (57.3) | 32.7 |
| Reclassifications from accumulated other comprehensive income (loss) | 7.0 | (2.0) |
| **Total other comprehensive income (loss)** | (55.6) | 30.5 |
| **Comprehensive income** | 46.7 | 92.5 |
| Net income attributable to noncontrolling interests | (0.1) | (0.4) |
| **Comprehensive income available to SiriusPoint** | $46.6 | $92.1 |
| **The accompanying Notes to the Consolidated Financial Statements are<br>an integral part of the Consolidated Financial Statements.** | **The accompanying Notes to the Consolidated Financial Statements are<br>an integral part of the Consolidated Financial Statements.** | **The accompanying Notes to the Consolidated Financial Statements are<br>an integral part of the Consolidated Financial Statements.** |

---

------

**SIRIUSPOINT LTD.**

**CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (UNAUDITED)**

**For the three months ended March 31, 2026 and 2025**

**(expressed in millions of U.S. dollars)**

---

| | | |
|:---|:---|:---|
| | **2026** | **2025** |
| **Series B preference shares** |  |  |
| Balance, beginning of period | $200 | $200 |
| Redemption of preference shares | (200.0) |  |
| Balance, end of period |  | 200.0 |
| **Common shares** |  |  |
| Balance, beginning of period | 11.7 | 11.6 |
| Issuance of common shares, net |  | 0.1 |
| Common shares repurchased and retired | (0.1) | (0.1) |
| Balance, end of period | 11.6 | 11.6 |
| **Additional paid-in capital** |  |  |
| Balance, beginning of period | 967.7 | 945.0 |
| Issuance of common shares, net | 0.2 | (0.2) |
| Share compensation | 10.3 | 7.6 |
| Common shares repurchased and retired | (21.8) | (7.7) |
| Balance, end of period | 956.4 | 944.7 |
| **Retained earnings** |  |  |
| Balance, beginning of period | 1228.5 | 784.9 |
| Net income | 102.3 | 62.0 |
| Net income attributable to noncontrolling interests | (0.1) | (0.4) |
| Dividends on preference shares | (2.6) | (4.0) |
| Balance, end of period | 1328.1 | 842.5 |
| **Accumulated other comprehensive income, net of tax** |  |  |
| Balance, beginning of period | 61.9 | (4.1) |
| &nbsp;&nbsp;Change in foreign currency translation adjustment |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Balance, beginning of period | (0.9) | (3.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in foreign currency translation adjustment | (5.3) | (0.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Balance, end of period | (6.2) | (3.2) |
| &nbsp;&nbsp;Unrealized gains (losses) from debt securities held as available for sale investments |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Balance, beginning of period | 62.8 | (1.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized gains (losses) from debt securities held as available for sale investments | (57.3) | 32.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Reclassifications from accumulated other comprehensive income (loss) | 7.0 | (2.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Balance, end of period | 12.5 | 29.6 |
| Balance, end of period | 6.3 | 26.4 |
| **Shareholders' equity attributable to SiriusPoint shareholders** | 2302.4 | 2025.2 |
| Noncontrolling interests | 1.0 | 1.5 |
| **Total shareholders' equity** | $2303.4 | $2026.7 |
| **The accompanying Notes to the Consolidated Financial Statements are<br>an integral part of the Consolidated Financial Statements.** | **The accompanying Notes to the Consolidated Financial Statements are<br>an integral part of the Consolidated Financial Statements.** | **The accompanying Notes to the Consolidated Financial Statements are<br>an integral part of the Consolidated Financial Statements.** |

---

------

**SIRIUSPOINT LTD.**

**CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)**

**For the three months ended March 31, 2026 and 2025**

**(expressed in millions of U.S. dollars)**

---

| | | |
|:---|:---|:---|
| | **2026** | **2025** |
| **Operating activities** |  |  |
| Net income | $102.3 | $62 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: |  |  |
| Share compensation | 10.5 | 7.6 |
| Net realized and unrealized (gain) loss on investments and derivatives | (11.4) | 0.3 |
| Amortization of premium and accretion of discount, net | (8.8) | (9.3) |
| Amortization of intangible assets | 2.6 | 2.9 |
| Other items, net | (14.0) | 16.8 |
| **Changes in assets and liabilities:** |  |  |
| Insurance and reinsurance balances receivable, net | (160.4) | (187.3) |
| Deferred acquisition costs, net | (19.3) | (41.8) |
| Unearned premiums ceded | (85.9) | (50.4) |
| Loss and loss adjustment expenses recoverable, net | 82.1 | (20.4) |
| Deferred tax asset/liability | 20.0 | 20.0 |
| Other assets | 24.9 | (12.7) |
| Interest and dividends receivable | 5.7 | 1.9 |
| Loss and loss adjustment expense reserves | (49.8) | 108.7 |
| Unearned premium reserves | 135.8 | 177.6 |
| Deferred gain on retroactive reinsurance |  | (1.9) |
| Reinsurance balances payable | 7.4 | (74.1) |
| Other liabilities | (15.0) | (88.8) |
| Held for sale asset | 115.2 |  |
| Net cash provided by (used in) operating activities | 141.9 | (88.9) |
| **Investing activities** |  |  |
| Purchases of debt securities, available-for-sale | (274.2) | (487.2) |
| Purchases of short-term investments | (13.8) | (27.6) |
| Purchases of other investments | (3.0) | (8.0) |
| Proceeds from sales and maturities of debt securities, available-for-sale | 504.9 | 1028.2 |
| Proceeds from sales and maturities of debt securities, trading and short-term investments | 11.0 | 120.8 |
| Proceeds from sales and maturities of other investments | 28.2 | 3.7 |
| Change in due to/from brokers, net | (34.7) | (19.0) |
| Business acquisitions, net (cash and restricted cash acquired of $4.9) | (29.4) |  |
| Net cash provided by investing activities | 189.0 | 610.9 |
| **Financing activities** |  |  |
| Redemption of preference shares | (200.0) |  |
| Purchases of SiriusPoint common shares under share repurchase program | (21.9) | (490.8) |
| Net proceeds from deposit liability contracts | 3.6 | 3.9 |
| Cash dividends paid to preference shareholders | (3.9) | (4.0) |
| Taxes paid on withholding shares | (0.2) | (0.2) |
| Change in total noncontrolling interests, net | (0.2) | (0.3) |
| Net cash used in financing activities | (222.6) | (491.4) |
| Net increase in cash, cash equivalents and restricted cash | 108.3 | 30.6 |
| Cash, cash equivalents and restricted cash at beginning of period | 902.4 | 894.6 |
| **Cash, cash equivalents and restricted cash at end of period** | $1010.7 | $925.2 |
| **The accompanying Notes to the Consolidated Financial Statements are<br> an integral part of the Consolidated Financial Statements.** | **The accompanying Notes to the Consolidated Financial Statements are<br> an integral part of the Consolidated Financial Statements.** | **The accompanying Notes to the Consolidated Financial Statements are<br> an integral part of the Consolidated Financial Statements.** |

---

------

**SiriusPoint Ltd.** 

**Notes to the Consolidated Financial Statements (UNAUDITED)**

***(Expressed in U.S. Dollars)***

**1. Organization** 

SiriusPoint Ltd. (together with its consolidated subsidiaries, "SiriusPoint" or the "Company") was incorporated under the laws of Bermuda on October 6, 2011. Through its subsidiaries, the Company is a provider of global multi-line insurance and reinsurance products and services.

These unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 in Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete annual financial statements. This Quarterly Report on Form 10-Q ("Form 10-Q") should be read in conjunction with the audited financial statements and related footnotes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Form 10-K") filed with the U.S. Securities and Exchange Commission on February 24, 2026.

In the opinion of management, these unaudited consolidated financial statements reflect all adjustments (consisting of normal recurring accruals) considered necessary for a fair statement of the Company's financial position and results of operations as at the end of and for the periods presented. All intercompany balances and transactions have been eliminated.

The results for the three months ended March 31, 2026 are not necessarily indicative of the results for the full calendar year.

Tabular amounts are in U.S. Dollars in millions, except share amounts, unless otherwise noted.

**2. Significant accounting policies** 

Other than the items listed below, there were no significant updates to the Company's significant accounting policies as described in its 2025 Form 10-K.

**Business combinations**

The Company accounts for business combinations using the acquisition method of accounting, under which the purchase price of the acquisition is allocated to the assets acquired and liabilities assumed using the fair values determined by management as of the acquisition date.

**Goodwill**

Goodwill represents the excess of acquisition cost over the fair value of the identifiable assets acquired and liabilities assumed in connection with an acquisition. The Company tests goodwill for potential impairment annually, or more frequently if events or changes in circumstances indicate that the asset is impaired. For the purpose of evaluating goodwill for impairment, the Company may first perform a qualitative assessment to determine whether it is necessary to perform a quantitative goodwill impairment test. If determined to be necessary, the quantitative test compares the fair value of a reporting unit with its carrying amount, including goodwill. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired. If the carrying amount of the reporting unit exceeds the fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit.

**Recently issued accounting standards**

***Issued and effective as of March 31, 2026***

***Management of Credit Losses for Accounts Receivable and Contract Assets***

In July 2025, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update 2025-05, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets ("ASU 2025-05"). The amendment provides guidance for estimating expected credit losses on current accounts receivable and current contract assets. ASU 2025-05 is effective for all entities for annual periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. The Company adopted this accounting standard effective January 1, 2026 and its adoption did not have a material impact on the Company's consolidated financial statements.

------

***Issued but not yet effective as of March 31, 2026***

***Expense Disaggregation Disclosures***

In November 2024, the FASB issued Accounting Standards Update 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"). The ASU requires a public business entity to provide disaggregated disclosures of certain categories of expenses on an annual and interim basis including employee compensation, depreciation, and intangible asset amortization for each income statement line item that contains those expenses. ASU 2024-03 is effective for annual periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. Management is in the process of reviewing this update to assess the impact on its consolidated financial statements and disclosures.

***Internal-Use Software***

In September 2025, the FASB issued Accounting Standards Update 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software ("ASU 2025-06"). The amendment updates accounting guidelines around capitalizing software costs. ASU 2025-06 is effective for all entities for annual periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Management is in the process of reviewing this update to assess the impact on its consolidated financial statements and disclosures.

The Company considers the applicability and impact of all accounting standard updates ("ASUs") issued by the FASB. ASUs issued during the three months ended March 31, 2026 and not listed above were assessed and either determined to be not applicable or expected to have minimal impact on the Company's consolidated financial statements and disclosures.

**Reclassifications** 

Certain comparative figures have been reclassified to conform to the current year presentation. These reclassifications had no impact on the previously reported net income (loss) or shareholders' equity attributable to SiriusPoint shareholders.

**3. Significant transactions**

**Sale of Arcadian**

On October 3, 2025, the Company entered into an agreement to sell its 49% equity stake in Arcadian Risk Capital Ltd. ("Arcadian") to Lee Equity Partners for total consideration of $140.4 million, inclusive of a pre-close dividend. The Company also renewed and extended its capacity agreement with Arcadian until the end of 2031. On January 30, 2026, the transaction closed following the satisfaction of customary closing conditions and the Company recognized a gain of $25.2 million in Other revenues in its consolidated income statement during the three months ended March 31, 2026.

During 2025, the Company accounted for its 49% ownership in Arcadian under the equity method of accounting and recorded its share of net income in Other revenues in its consolidated income statement. As of December 31, 2025, a held for sale asset of $115.2 million was recorded in the Company's consolidated balance sheet.

**Acquisition of Assist America**

On December 31, 2025, the Company, through its wholly owned subsidiaries, entered into an agreement to acquire Assist America Inc. and its affiliates ("Assist America") for $44.0 million in cash and other contingent considerations. Pursuant to the agreement, Assist America became a consolidated subsidiary of the Company effective as of January 1, 2026 and the acquisition was accounted for as a business combination. The consideration was allocated to Assist America's assets acquired and liabilities assumed based on their fair value as of the acquisition date. The consideration transferred is subject to customary post-closing adjustments, which could affect the preliminary goodwill recognized.

Goodwill of $18.6 million was recognized within the Insurance & Services segment and is primarily attributable to the Company's third-party medical and travel assistance capacities and the synergies that can be achieved subsequent to the Assist America acquisition. A majority of the goodwill recognized is expected to be deductible for tax purposes.

**Acquisition of World Nomads**

On February 12, 2026, Sirius International UK Holdings II Ltd, a subsidiary of SiriusPoint Ltd. ("SIUK II"), entered into a purchase agreement with nib Travel Pty Ltd., an Australian proprietary limited company ("nib"), in which SIUK II or its

------

subsidiaries will purchase equity interests and assets comprising the World Nomads travel insurance business currently operated by nib (collectively, "World Nomads"). An initial closing on the majority of the World Nomads business is expected to occur in the second or third quarter of 2026, and a final closing is expected to occur in the second half of 2027, subject to receipt of regulatory approvals and satisfaction of other customary closing conditions.

**4. Segment reporting**

The determination of the Company's business segments is based on the manner in which management monitors the performance of its operations. The Company reports two operating segments: Insurance & Services and Reinsurance. The Company's segments each have managers who are responsible for the overall profitability of their segments and who are directly accountable to the Company's chief operating decision maker ("CODM"), the Chief Executive Officer. The CODM assesses segment operating performance, allocates capital, and makes resource allocation decisions based on Segment income (loss). Further, the CODM does not manage the Company's assets by segment; accordingly, total assets are not allocated to the segments, excluding goodwill recognized due to the Assist America acquisition on January 1, 2026 which is allocated to the Insurance & Services segment.

**Insurance & Services**

In the Insurance & Services segment, the Company underwrites primary insurance in several sectors. The Insurance & Services segment includes Accident & Health, Property & Casualty, and Other Specialties.

Accident and Health ("A&H") – the Company provides insurance products to meet the risk management needs of diverse populations in select markets. This includes employer groups, associations, affinity groups, higher education and other niche markets. The Company also owns 100% of International Medical Group, Inc. ("IMG"), who receive fees for services provided within the Insurance & Services segment and to third parties. IMG offers a full line of international medical insurance products, travel insurance programs, medical management services and 24/7 emergency medical and travel assistance. The Company owned 100% of ArmadaCorp Capital, LLC ("Armada") through October 31, 2025, when it was sold to Ambac Financial Group Inc. and deconsolidated as of November 1, 2025. SiriusPoint will continue its underwriting capacity partnership with Armada until the end of 2030. Armada operates as a supplemental medical insurance managing general agent ("MGA").

Property & Casualty – the Company is a carrier for program administrators and MGAs. The majority of its P&C insurance business is written through partners in the Property & Casualty space, covering Financial and Professional Liability, General Liability, Environmental and Commercial Auto lines around the world, including Bermuda, Europe, London and the U.S.

Other Specialties – SiriusPoint's business encompasses a broad range of worldwide insurance coverages. Other Specialties business lines in the Insurance & Services segment include Aviation, Marine & Energy, Credit, Surety and Mortgage.

**Reinsurance**

In the Reinsurance segment, the Company provides reinsurance products to insurance and reinsurance companies, government entities, and other risk bearing vehicles on a treaty or facultative basis. For reinsurance assumed, the Company participates in the reinsurance market with a global focus through the broker market distribution channel. The Company primarily writes treaty reinsurance, on both a proportional and excess of loss basis, and provides facultative reinsurance in some of its business lines. In the United States and Bermuda, the Company's core focus is on distribution, risk and clients located in North America, while our international operation is focused primarily on distribution, risks and clients located in Europe.

The Reinsurance segment predominantly underwrites Casualty, Property and Other Specialties lines of business.

Casualty – the Company provides reinsurance to casualty insurers who underwrite a diverse range of casualty classes. The Company works with clients all over the world, including multi-national, nationwide and regional carriers, as well as risk retention groups and captives. The Company's underwriting focus is on all major commercial casualty lines, including Financial and Professional Liability and General Liability lines, with an emphasis on specialty niche classes of business, including personal lines.

Property – the Company works with leading global brokers as well as large national writers and regional companies. Underwriting is focused on providing critical catastrophe protection and worldwide coverage for natural perils, underwriting residential, commercial, and industrial risks in the United States, Europe and Asia.

------

Other Specialties – the Company's business encompasses a broad range of worldwide reinsurance coverages, including proportional and excess of loss, treaty and facultative. Other Specialties business lines in the Reinsurance segment include Aviation & Space, Marine & Energy and Credit.

Management uses segment income (loss) as the primary basis for assessing segment performance. Segment income (loss) is comprised of two components, underwriting income (loss) and net services income (loss). The Company calculates underwriting income (loss) by subtracting loss and loss adjustment expenses incurred, net, acquisition costs, net, and other underwriting expenses from net earned premium. Net services income (loss) consists of services revenues (fees for services revenues), services expenses, and services non-controlling (income) loss. This definition of segment income (loss) aligns with how business performance is managed and monitored. We continue to evaluate our segments as our business evolves and may further refine our segments and segment income (loss) measures. Certain items are presented in a different manner for segment reporting purposes than in the consolidated statements of income. These items are reconciled to the consolidated presentation in the segment measure reclass column below. Included in Insurance & Services segment income (loss) are services noncontrolling loss (income) attributable to minority shareholders on non-wholly-owned subsidiaries. In addition, services revenues and services expenses are reconciled to other revenues and net corporate and other expenses, respectively.

Segment results are shown prior to corporate eliminations. Corporate eliminations are included in the elimination column below as necessary to reconcile to underwriting income (loss), net services income (loss), and segment income (loss) to the consolidated statements of income.

Corporate includes the results of all run off business, which represents certain classes of business that the Company ceased underwriting as part of fundamental changes to its business strategy, including the effect of the restructuring of the underwriting platform announced in 2022 and certain reinsurance contracts that have interest crediting features. Corporate results also include asbestos and environmental and other latent liability exposures on a gross basis, which have mostly been ceded, as well as specific workers' compensation and cyber programs which the Company no longer writes. In addition, revenue and expenses managed at the corporate level, including realized and unrealized gains (losses) and other investment income, non services-related other revenues, non services-related net corporate and other expenses, intangible asset amortization, interest expense, foreign exchange (gains) losses and income tax (expense) benefit are reported within Corporate. The CODM does not manage segment results or allocate resources to segments when considering these items and they are therefore excluded from our definition of segment income (loss).

------

The following is a summary of the Company's operating segment results for the three months ended March 31, 2026 and 2025:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** |
| | **Insurance & Services** | **Reinsurance** | **Core** | **Eliminations** <sup>(2)</sup> | **Corporate** | **Segment Measure Reclass** | **Total** |
| Gross written premium | $684.6 | $319.2 | $1003.8 | $— | $(0.9) | $— | $1002.9 |
| Net written premium | 461.1 | 235.7 | 696.8 |  | (1.6) |  | 695.2 |
| Net earned premium | 380.1 | 258.2 | 638.3 |  | 0.6 |  | 638.9 |
| Loss and loss adjustment expenses incurred, net | 215.7 | 134.0 | 349.7 | (1.8) | 15.0 |  | 362.9 |
| Acquisition costs, net | 108.0 | 63.8 | 171.8 | (23.8) | (0.2) |  | 147.8 |
| Other underwriting expenses | 26.3 | 19.6 | 45.9 |  | 4.6 |  | 50.5 |
| **Underwriting income (loss)** | 30.1 | 40.8 | 70.9 | 25.6 | (18.8) |  | 77.7 |
| Services revenues | 54.0 |  | 54.0 | (23.1) |  | (30.9) |  |
| Services expenses | 46.1 |  | 46.1 |  |  | (46.1) |  |
| **Net services fee income** | 7.9 |  | 7.9 | (23.1) |  | 15.2 |  |
| Services noncontrolling loss | 0.5 |  | 0.5 |  |  | (0.5) |  |
| **Net services income** | 8.4 |  | 8.4 | (23.1) |  | 14.7 |  |
| **Segment income (loss)** | 38.5 | 40.8 | 79.3 | 2.5 | (18.8) | 14.7 | 77.7 |
| Net investment income | Net investment income | Net investment income | Net investment income | Net investment income | 66.4 |  | 66.4 |
| Net investment gains (losses) | Net investment gains (losses) | Net investment gains (losses) | Net investment gains (losses) | Net investment gains (losses) | 11.4 |  | 11.4 |
| Other revenues |  |  |  |  | 27.0 | 30.9 | 57.9 |
| Net corporate and other expenses |  |  |  |  | (25.1) | (46.1) | (71.2) |
| Intangible asset amortization |  |  |  |  | (2.6) |  | (2.6) |
| Interest expense |  |  |  |  | (16.8) |  | (16.8) |
| Foreign exchange losses |  |  |  |  | (1.3) |  | (1.3) |
| **Income before income tax expense** | $38.5 | $40.8 | 79.3 | 2.5 | 40.2 | (0.5) | 121.5 |
| Income tax expense |  |  |  |  | (19.2) |  | (19.2) |
| **Net income** |  |  | 79.3 | 2.5 | 21.0 | (0.5) | 102.3 |
| Net income attributable to noncontrolling interest | Net income attributable to noncontrolling interest | Net income attributable to noncontrolling interest |  |  | (0.6) | 0.5 | (0.1) |
| **Net income available to SiriusPoint** | **Net income available to SiriusPoint** | **Net income available to SiriusPoint** | $79.3 | $2.5 | $20.4 | $— | $102.2 |
| Attritional losses | $230.8 | $145.7 | $376.5 | $(1.8) | $0.7 | $— | $375.4 |
| Catastrophe losses |  | 5.4 | 5.4 |  |  |  | 5.4 |
| Prior year loss reserve development | (15.1) | (17.1) | (32.2) |  | 14.3 |  | (17.9) |
| Loss and loss adjustment expenses incurred, net | $215.7 | $134.0 | $349.7 | $(1.8) | $15.0 | $— | $362.9 |
| **Underwriting Ratios:** <sup>(1)</sup> |  |  |  |  |  |  |  |
| Attritional loss ratio | 60.7% | 56.4% | 59.0% |  |  |  | 58.8% |
| Catastrophe loss ratio | —% | 2.1% | 0.8% |  |  |  | 0.8% |
| Prior year loss development ratio | (4.0)% | (6.6)% | (5.0)% |  |  |  | (2.8)% |
| Loss ratio | 56.7% | 51.9% | 54.8% |  |  |  | 56.8% |
| Acquisition cost ratio | 28.4% | 24.7% | 26.9% |  |  |  | 23.1% |
| Other underwriting expenses ratio | 6.9% | 7.6% | 7.2% |  |  |  | 7.9% |
| Combined ratio  | 92.0% | 84.2% | 88.9% |  |  |  | 87.8% |

---

(1)Underwriting ratios are calculated by dividing the related expense by net earned premium.

(2)Insurance & Services MGAs recognize fees for service using revenue from contracts with customers accounting standards, whereas insurance companies recognize acquisition expenses using insurance contract accounting standards. While ultimate revenues and expenses recognized will match, there will be recognition timing differences based on the different accounting standards.

------

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** |
| | **Insurance & Services** | **Reinsurance** | **Core** | **Eliminations** <sup>(2)</sup> | **Corporate** | **Segment Measure Reclass** | **Total** |
| Gross written premium | $635.1 | $354.8 | $989.9 | $— | $(5.2) | $— | $984.7 |
| Net written premium | 483.5 | 268.5 | 752.0 |  | (9.0) |  | 743.0 |
| Net earned premium | 336.2 | 289.6 | 625.8 |  | 0.9 |  | 626.7 |
| Loss and loss adjustment expenses incurred, net | 209.9 | 195.3 | 405.2 | (2.0) | (1.4) |  | 401.8 |
| Acquisition costs, net | 87.3 | 67.1 | 154.4 | (28.0) | 3.3 |  | 129.7 |
| Other underwriting expenses | 18.9 | 18.8 | 37.7 |  | 3.4 |  | 41.1 |
| **Underwriting income (loss)** | 20.1 | 8.4 | 28.5 | 30.0 | (4.4) |  | 54.1 |
| Services revenues | 62.1 |  | 62.1 | (30.2) |  | (31.9) |  |
| Services expenses | 43.1 |  | 43.1 |  |  | (43.1) |  |
| **Net services fee income** | 19.0 |  | 19.0 | (30.2) |  | 11.2 |  |
| Services noncontrolling income | (0.1) |  | (0.1) |  |  | 0.1 |  |
| **Net services income** | 18.9 |  | 18.9 | (30.2) |  | 11.3 |  |
| **Segment income (loss)** | 39.0 | 8.4 | 47.4 | (0.2) | (4.4) | 11.3 | 54.1 |
| Net investment income | Net investment income | Net investment income | Net investment income | Net investment income | 71.2 |  | 71.2 |
| Net investment gains (losses) | Net investment gains (losses) | Net investment gains (losses) | Net investment gains (losses) | Net investment gains (losses) | (0.3) |  | (0.3) |
| Other revenues |  |  |  |  | (2.2) | 31.9 | 29.7 |
| Net corporate and other expenses |  |  |  |  | (17.5) | (43.1) | (60.6) |
| Intangible asset amortization |  |  |  |  | (2.9) |  | (2.9) |
| Interest expense |  |  |  |  | (18.1) |  | (18.1) |
| Foreign exchange gains |  |  |  |  | 2.2 |  | 2.2 |
| **Income before income tax expense** | $39.0 | $8.4 | 47.4 | (0.2) | 28.0 | 0.1 | 75.3 |
| Income tax expense |  |  |  |  | (13.3) |  | (13.3) |
| **Net income** |  |  | 47.4 | (0.2) | 14.7 | 0.1 | 62.0 |
| Net income attributable to noncontrolling interests | Net income attributable to noncontrolling interests | Net income attributable to noncontrolling interests |  |  | (0.3) | (0.1) | (0.4) |
| **Net income available to SiriusPoint** | **Net income available to SiriusPoint** | **Net income available to SiriusPoint** | $47.4 | $(0.2) | $14.4 | $— | $61.6 |
| Attritional losses | $207.6 | $164.0 | $371.6 | $(2.0) | $(1.5) | $— | $368.1 |
| Catastrophe losses | 4.8 | 63.1 | 67.9 |  |  |  | 67.9 |
| Prior year loss reserve development | (2.5) | (31.8) | (34.3) |  | 0.1 |  | (34.2) |
| Loss and loss adjustment expenses incurred, net | $209.9 | $195.3 | $405.2 | $(2.0) | $(1.4) | $— | $401.8 |
| **Underwriting Ratios:** <sup>(1)</sup> |  |  |  |  |  |  |  |
| Attritional loss ratio | 61.7% | 56.6% | 59.3% |  |  |  | 58.8% |
| Catastrophe loss ratio | 1.4% | 21.8% | 10.9% |  |  |  | 10.8% |
| Prior year loss development ratio | (0.7)% | (11.0)% | (5.5)% |  |  |  | (5.5)% |
| Loss ratio | 62.4% | 67.4% | 64.7% |  |  |  | 64.1% |
| Acquisition cost ratio | 26.0% | 23.2% | 24.7% |  |  |  | 20.7% |
| Other underwriting expenses ratio | 5.6% | 6.5% | 6.0% |  |  |  | 6.6% |
| Combined ratio | 94.0% | 97.1% | 95.4% |  |  |  | 91.4% |

---

(1)Underwriting ratios are calculated by dividing the related expense by net earned premium.

(2)Insurance & Services MGAs recognize fees for service using revenue from contracts with customers accounting standards, whereas insurance companies recognize acquisition expenses using insurance contract accounting standards. While ultimate revenues and expenses recognized will match, there will be recognition timing differences based on the different accounting standards.

------

**5. Cash, cash equivalents, restricted cash and restricted investments** 

The following table provides a summary of cash and cash equivalents, restricted cash and restricted investments as of March 31, 2026 and December 31, 2025:

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| Cash and cash equivalents | $856.9 | $731.2 |
| Restricted cash securing letter of credit facilities <sup>(1)</sup> | 52.7 | 69.1 |
| Restricted cash securing reinsurance contracts <sup>(2)</sup> | 89.1 | 89.3 |
| Restricted cash held by managing general underwriters | 12.0 | 12.8 |
| Total cash, cash equivalents and restricted cash <sup>(3)</sup> | 1010.7 | 902.4 |
| Restricted investments securing reinsurance contracts and letter of credit facilities <sup>(1) (2) (4)</sup> | 1835.5 | 2040.7 |
| Total cash, cash equivalents, restricted cash and restricted investments | $2846.2 | $2943.1 |

---

(1)Restricted cash and restricted investments securing letter of credit facilities primarily pertains to letters of credit that have been issued to the Company's clients in support of its obligations under reinsurance contracts. The Company will not be released from the obligation to provide these letters of credit until the reserves underlying the reinsurance contracts have been settled. The time period for which the Company expects each letter of credit to be in place varies from contract to contract but can last several years.

(2)Restricted cash and restricted investments securing reinsurance contracts pertain to trust accounts securing the Company's contractual obligations under certain reinsurance contracts that the Company will not be released from until the underlying risks have expired or have been settled. Restricted investments include certain investments in debt securities and short-term investments. The time period for which the Company expects these trust accounts to be in place varies from contract to contract, but can last several years.

(3)Cash, cash equivalents and restricted cash as reported in the Company's consolidated statements of cash flows.

(4)Restricted investments include required deposits with certain insurance state regulatory agencies in order to maintain insurance licenses.

**6. Fair value measurements** 

U.S. GAAP disclosure requirements establish a framework for measuring fair value, including a three-level hierarchy for fair value measurements based upon the transparency of inputs to the valuation of an asset or liability. The three-level hierarchy of inputs is summarized below:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 1 – Quoted prices available in active markets/exchanges for identical investments as of the reporting date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 2 – Observable inputs to the valuation methodology other than unadjusted quoted market prices for identical assets or liabilities in active markets. Level 2 inputs include, but are not limited to, prices quoted for similar assets or liabilities in active markets/exchanges, prices quoted for identical or similar assets or liabilities in markets that are not active and fair values determined through the use of models or other valuation methodologies.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 3 – Inputs are based all or in part on significant unobservable inputs for the investment, and include situations where there is little, if any, market activity for the investment. The inputs applied in the determination of fair value require significant management judgment and estimation.

Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including, but not limited to, assumptions about risk inherent in a particular valuation technique used to measure fair value such as a pricing model and/or the risk inherent in the inputs to the valuation technique. Inputs may be observable or unobservable.

Observable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability based on market data obtained from sources other than those of the reporting entity. Unobservable inputs are inputs that reflect the reporting entity's own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an investment's level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The Company's assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment.

------

The following tables present the Company's investments measured and reported at fair value, categorized by the level of the fair value hierarchy as of March 31, 2026 and December 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** |
| | | | | **Total** |
| | **Quoted prices in active markets**<br> **(Level 1)** | **Significant other observable inputs**<br> **(Level 2)** | **Significant unobservable inputs**<br> **(Level 3)** | **Total** |
| **Assets** | | | | |
| Asset-backed securities | $— | $866.2 | $— | $866.2 |
| Residential mortgage-backed securities |  | 943.0 |  | 943.0 |
| Commercial mortgage-backed securities |  | 211.6 |  | 211.6 |
| Corporate debt securities |  | 2040.1 |  | 2040.1 |
| U.S. government and government agency | 811.8 |  |  | 811.8 |
| Non-U.S. government and government agency |  | 20.2 |  | 20.2 |
| Total debt securities, available for sale | 811.8 | 4081.1 |  | 4892.9 |
| Asset-backed securities |  | 5.2 |  | 5.2 |
| Residential mortgage-backed securities |  | 43.5 |  | 43.5 |
| Commercial mortgage-backed securities |  | 29.9 |  | 29.9 |
| Corporate debt securities |  | 3.6 |  | 3.6 |
| U.S. government and government agency | 3.8 |  |  | 3.8 |
| Total debt securities, trading | 3.8 | 82.2 |  | 86.0 |
| Short-term investments | 32.5 |  |  | 32.5 |
| Other long-term investments |  |  | 63.7 | 63.7 |
| Derivative assets |  |  | 8.9 | 8.9 |
|  | $848.1 | $4163.3 | $72.6 | 5084.0 |
| Cost and equity method investments |  |  |  | 72.9 |
| Investments in funds valued at NAV |  |  |  | 158.8 |
| **Total assets** |  |  |  | $5315.7 |
| **Liabilities** |  |  |  |  |
| Derivative liabilities | $— | $— | $40.6 | $40.6 |
| **Total liabilities** | $— | $— | $40.6 | $40.6 |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| | | | | **Total** |
| | **Quoted prices in active markets**<br> **(Level 1)** | **Significant other observable inputs**<br> **(Level 2)** | **Significant unobservable inputs**<br> **(Level 3)** | **Total** |
| **Assets** | | | | |
| Asset-backed securities | $— | $921.1 | $— | $921.1 |
| Residential mortgage-backed securities |  | 963.1 |  | 963.1 |
| Commercial mortgage-backed securities |  | 231.9 |  | 231.9 |
| Corporate debt securities |  | 2198.2 |  | 2198.2 |
| U.S. government and government agency | 835.7 |  |  | 835.7 |
| Non-U.S. government and government agency |  | 18.6 |  | 18.6 |
| Total debt securities, available for sale | 835.7 | 4332.9 |  | 5168.6 |
| Asset-backed securities |  | 5.9 |  | 5.9 |
| Residential mortgage-backed securities |  | 45.0 |  | 45.0 |
| Commercial mortgage-backed securities |  | 31.9 |  | 31.9 |
| Corporate debt securities |  | 3.7 |  | 3.7 |
| U.S. Government and government agency | 3.8 |  |  | 3.8 |
| Total debt securities, trading | 3.8 | 86.5 |  | 90.3 |
| Short-term investments | 28.3 |  |  | 28.3 |
| Other long-term investments |  | 5.2 | 82.9 | 88.1 |
| Derivative assets |  |  | 14.4 | 14.4 |
|  | $867.8 | $4424.6 | $97.3 | 5389.7 |
| Cost and equity method investments |  |  |  | 69.3 |
| Investments in funds valued at NAV |  |  |  | 157.7 |
| **Total assets** |  |  |  | $5616.7 |
| **Liabilities** |  |  |  |  |
| Derivative liabilities | $— | $— | $9.0 | $9.0 |
| **Total liabilities** | $— | $— | $9.0 | $9.0 |

---

During the three months ended March 31, 2026, the Company did not reclassify its assets or liabilities between Levels 2 and 3 (December 31, 2025 - no reclassifications).

**Valuation techniques**

The Company uses independent pricing services to assist in determining fair values for its investments. For investments in active markets, the Company uses the quoted market prices provided by independent pricing services to determine fair value. In circumstances where quoted market prices are unavailable or are not considered reasonable, the Company estimates the fair value using industry standard pricing models and observable inputs such as benchmark yields, reported trades, broker-dealer quotes, issuer spreads, benchmark securities, bids, offers, prepayment speeds, reference data including research publications, and other relevant inputs. Given that many debt securities do not trade on a daily basis, the independent pricing services evaluate a wide range of fixed maturity investments by regularly drawing parallels from recent trades and quotes of comparable securities with similar features. The characteristics used to identify comparable debt securities vary by asset type and take into account market convention.

The techniques and inputs specific to asset classes within the Company's debt securities and short-term investments for Level 2 securities that use observable inputs are as follows:

***Asset-backed and mortgage-backed securities***

The fair value of mortgage and asset-backed securities is primarily priced by independent pricing services using a pricing model that uses information from market sources and leveraging similar securities. Key inputs include benchmark yields, reported trades, underlying tranche cash flow data, collateral performance, plus new issue data, as well as broker-dealer

------

quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including issuer, vintage, loan type, collateral attributes, prepayment speeds, default rates, recovery rates, cash flow stress testing, credit quality ratings and market research publications.

***Corporate debt securities***

Corporate debt securities consist primarily of investment-grade debt of a wide variety of U.S. and non-U.S. corporate issuers and industries. The corporate fixed maturity investments are primarily priced by independent pricing services. When evaluating these securities, the independent pricing services gather information from market sources regarding the issuer of the security and obtain credit data, as well as other observations, from markets and sector news. Evaluations are updated by obtaining broker dealer quotes and other market information including actual trade volumes, when available. The independent pricing services also consider the specific terms and conditions of the securities, including any specific features which may influence risk.

***U.S. government and government agency***

U.S. government and government agency securities consist primarily of debt securities issued by the U.S. Treasury and mortgage pass-through agencies such as the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation and the Government National Mortgage Association. Fixed maturity investments included in U.S. government and government agency securities are primarily priced by independent pricing services. When evaluating these securities, the independent pricing services gather information from market sources and integrate other observations from markets and sector news. Evaluations are updated by obtaining broker dealer quotes and other market information including actual trade volumes, when available. The fair value of each security is individually computed using analytical models which incorporate option adjusted spreads and other daily interest rate data.

***Non-U.S. government and government agency***

Non-U.S. government and government agency securities consist of debt securities issued by non-U.S. governments and their agencies along with supranational organizations (also known as sovereign debt securities). Securities held in these sectors are primarily priced by independent pricing services who employ proprietary discounted cash flow models to value the securities. Key quantitative inputs for these models are daily observed benchmark curves for treasury, swap and high issuance credits. The independent pricing services then apply a credit spread for each security which is developed by in-depth and real time market analysis. For securities in which trade volume is low, the independent pricing services utilize data from more frequently traded securities with similar attributes. These models may also be supplemented by daily market and credit research for international markets.

***U.S. states, municipalities, and political subdivisions***

The U.S. states, municipalities and political subdivisions portfolio contains debt securities issued by U.S. domiciled state and municipal entities. These securities are generally priced by independent pricing services using the techniques for U.S. government and government agency securities described above.

***Short-term investments***

Short-term investments consist of U.S. treasury bills, certificates of deposit and other securities, which, at the time of purchase, mature within a period of greater than three months but less than one year. These investments are generally priced by independent pricing services using the techniques for U.S. government and government agency securities and Corporate debt securities described above.

**Investments measured using Net Asset Value** 

The Company values its investments in limited partnerships, including its investments in related party investment funds, at fair value. The Company has elected the practical expedient for fair value for these investments which is estimated based on the Company's share of the net asset value ("NAV") of the limited partnerships, as provided by the independent fund administrator, as the Company believes it represents the most meaningful measurement basis for the investment assets and liabilities. The NAV represents the Company's proportionate interest in the members' equity of the limited partnerships.

The fair value of the Company's investments in certain hedge funds and certain private equity funds are also determined using NAV. The hedge fund's administrator provides quarterly updates of fair value in the form of the Company's proportional interest in the underlying fund's NAV, which is deemed to approximate fair value, generally with a three month delay in

------

valuation. The private equity funds provide monthly, quarterly, or semi-annual partnership capital statements primarily with a one- or three-month delay which are used as a basis for valuation. These private equity investments vary in investment strategies and are not actively traded in any open markets. Due to a lag in reporting, some of the fund managers, fund administrators, or both, are unable to provide final fund valuations as of the Company's reporting date. This includes utilizing preliminary estimates reported by its fund managers and using other information that is available to the Company with respect to the underlying investments, as necessary.

In order to assess the reasonableness of the NAVs, the Company performs a number of monitoring procedures on a monthly, quarterly and annual basis, to assess the quality of the information provided by the investment manager and fund administrator underlying the preparation of the NAV. These procedures include, but are not limited to, regular review and discussion of the fund's performance with the investment manager.

These investments are included in investment in funds valued at NAV and excluded from the presentation of investments categorized by the level of the fair value hierarchy.

**Level 3 Investments**

Level 3 valuations are generated from techniques that use assumptions not observable in the market. These unobservable assumptions reflect the Company's assumptions that market participants would use in valuing the investment. Generally, certain securities may start out as Level 3 when they are originally issued but as observable inputs become available in the market, they may be reclassified to Level 2.

The Company employs a number of procedures to assess the reasonableness of the fair value measurements for its other long-term investments, including obtaining and reviewing the audited annual financial statements of hedge funds and private equity funds and periodically discussing each fund's pricing with the fund manager. However, since the fund managers do not provide sufficient information to evaluate the pricing inputs and methods for each underlying investment, the inputs are considered to be unobservable.

The fair values of the Company's investments in private equity securities, private debt instruments, certain private equity funds, and certain hedge funds have been classified as Level 3 measurements. Private equity securities and private debt instruments are initially valued based on transaction price and their valuation is subsequently estimated based on available evidence such as a market transaction in similar instruments and other financial information for the issuer.

For strategic investments carried at fair value, management either engages a third-party valuation specialist to assist in determination of the fair value based on commonly accepted valuation methods (e.g., income approach, market approach) as of the valuation date or performs valuation internally. In addition, investors' fair value analyses prepared by third party valuation specialists working with strategic investment operating management are referenced where available. Where criteria to be accounted for under the equity method is not met, we have elected to value our strategic investments at the cost adjusted for market observable events less impairment method, a measurement alternative in which the investment is measured at cost and remeasured to fair value when determined to be impaired or upon observable transactions prices becoming available.

See Note 8 for additional information on the fair values of derivative financial instruments used for both risk management and investment purposes.

***Underwriting-related derivatives***

Underwriting-related derivatives include reinsurance contracts that are accounted for as derivatives. These derivative contracts are initially valued at cost which approximates fair value. In subsequent measurement periods, the fair values of these derivatives are determined using internally developed discounted cash flow models. As the significant inputs used to price these derivatives are unobservable, the fair values of these contracts are classified as Level 3.

------

The following tables present the reconciliation of investments measured at fair value using Level 3 inputs for the three months ended March 31, 2026 and 2025:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **January 1,<br>2026** | **Transfers in to (out of) Level 3** | **Sales & Settlements** | **Realized and Unrealized Gains (Losses)** <sup>(1)</sup> | **March 31,<br>2026** |
| Other long-term investments | $82.9 | $– $– $| (22.7) | $3.5 | $63.7 |
| Net derivatives <sup>(2)</sup> | $5.4 | $– $– $| (1.3) | $(35.8) | $(31.7) |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **January 1,<br>2025** | **Transfers in to (out of) Level 3** | **Sales & Settlements** | **Realized and Unrealized Gains(Losses)** <sup>(1)</sup> | **March 31,<br>2025** |
| Other long-term investments | $86.6 | $– $– $|  | $0.4 | $87.0 |
| Net derivatives <sup>(2)</sup> | $(13.4) | $– $– $| 5.4 | $29.7 | $21.7 |

---

(1)Total change in realized and unrealized gains (losses) recorded on Level 3 financial instruments is included in net investment gains (losses) in the consolidated statements of income. Realized and unrealized gains (losses) related to underwriting related derivative assets and liabilities are included in other revenues, net of foreign exchange (gains) losses, in the consolidated statements of income. See Note 8 "Derivatives" for classifications of gains (losses) on derivatives.

(2)Derivative assets are presented within Other assets on the consolidated balance sheets and derivative liabilities are presented within Other liabilities on the consolidated balance sheets. The amounts are presented net in the tables above for the purposes of the rollforward.

For assets and liabilities that were transferred into Level 3 during the period, gains (losses) are presented as if the assets or liabilities had been transferred into Level 3 at the beginning of the period; similarly, for assets and liabilities that were transferred out of Level 3 during the period, gains (losses) are presented as if the assets or liabilities had been transferred out of Level 3 at the beginning of the period.

The following table includes financial instruments for which the carrying value differs from the estimated fair values as of March 31, 2026 and December 31, 2025. The fair values of the below financial instruments are based on observable inputs and are considered Level 2 measurements.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** |
| | **Fair Value** | **Carrying Value** | **Fair Value** | **Carrying Value** |
| 2024 Senior Notes | $418.0 | $396.3 | $424.2 | $396.0 |
| 2017 SEK Subordinated Notes | 285.8 | 283.3 | 293.3 | 292.6 |
| Series B preference shares <sup>(1)</sup> | $— | $— | $202.2 | $200.0 |

---

(1)The Series B preference shares were fully redeemed on February 26, 2026. See Note 14 for further discussion on the redemption.

**7. Investments** 

The Company's invested assets consist of investment securities and other long-term investments held for general investment purposes. The portfolio of investment securities includes debt securities available for sale, debt securities held for trading, short-term investments, and other long-term investments. Realized investment gains and losses on debt securities are reported in pre-tax revenues. Unrealized investment gains and losses on debt securities are reported based on classification. Trading securities flow through pre-tax revenues, whereas securities classified as available for sale ("AFS") flow through other comprehensive income.

For debt securities classified as AFS for which a decline in the fair value between the amortized cost is due to credit-related factors, an allowance is established for the difference between the estimated recoverable value and amortized cost with a corresponding impact to the consolidated statements of income. The allowance is limited to the difference between amortized cost and fair value. A credit loss impairment assessment is performed on securities using both quantitative and qualitative factors. Qualitative factors include significant declines in fair value below amortized cost. Additionally, a qualitative assessment is also performed over debt securities to evaluate potential credit losses. Examples of qualitative indicators include issuer credit downgrades as well as changes to credit spreads.

Declines in fair value related to a debt security that do not relate to a credit loss are recorded as a component of accumulated other comprehensive income.

------

**Debt securities** 

The following tables provide the cost or amortized cost, gross unrealized investment gains (losses), net foreign currency gains (losses), and fair value of the Company's debt securities as of March 31, 2026 and December 31, 2025:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** |
| | **Cost or<br>amortized<br>cost** | **Gross<br>unrealized<br>gains** | **Gross<br>unrealized<br>losses** | **Net foreign <br>currency <br>gains (losses)** | **Fair value** |
| **Debt securities, available for sale** | | | | | |
| Asset-backed securities | $873.6 | $4.4 | $(11.8) | $— | $866.2 |
| Residential mortgage-backed securities | 939.0 | 12.5 | (8.5) |  | 943.0 |
| Commercial mortgage-backed securities | 211.9 | 1.8 | (2.1) |  | 211.6 |
| Corporate debt securities | 2038.9 | 13.8 | (10.0) | (2.6) | 2040.1 |
| U.S. government and government agency | 812.7 | 2.6 | (3.5) |  | 811.8 |
| Non-U.S. government and government agency | 20.0 | 0.1 | (0.1) | 0.2 | 20.2 |
| **Total debt securities, available for sale** <sup>(1)</sup> | $4896.1 | $35.2 | $(36.0) | $(2.4) | $4892.9 |
| **Debt securities, trading** |  |  |  |  |  |
| Asset-backed securities | $7.9 | $— | $(2.7) | $— | $5.2 |
| Residential mortgage-backed securities | 49.4 | 0.1 | (6.0) |  | 43.5 |
| Commercial mortgage-backed securities | 33.1 | 0.1 | (3.3) |  | 29.9 |
| Corporate debt securities | 17.0 |  | (13.4) |  | 3.6 |
| U.S. government and government agency | 3.9 |  | (0.1) |  | 3.8 |
| **Total debt securities, trading** | $111.3 | $0.2 | $(25.5) | $— | $86.0 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| | **Cost or<br>amortized<br>cost** | **Gross<br>unrealized<br>gains** | **Gross<br>unrealized<br>losses** | **Net foreign <br>currency <br>gains (losses)** | **Fair value** |
| **Debt securities, available for sale** | | | | | |
| Asset-backed securities | $917.1 | $7.3 | $(3.3) | $— | $921.1 |
| Residential mortgage-backed securities | 950.1 | 17.7 | (4.7) |  | 963.1 |
| Commercial mortgage-backed securities | 231.3 | 3.1 | (2.5) |  | 231.9 |
| Corporate debt securities | 2170.8 | 32.3 | (2.4) | (2.5) | 2198.2 |
| U.S. government and government agency | 830.5 | 5.6 | (0.4) |  | 835.7 |
| Non-U.S. government and government agency | 18.5 | 0.2 |  | (0.1) | 18.6 |
| **Total debt securities, available for sale** <sup>(1)</sup> | $5118.3 | $66.2 | $(13.3) | $(2.6) | $5168.6 |
| **Debt securities, trading** |  |  |  |  |  |
| Asset-backed securities | $8.3 | $— | $(2.4) | $— | $5.9 |
| Residential mortgage-backed securities | 50.7 | 0.1 | (5.8) |  | 45.0 |
| Commercial mortgage-backed securities | 34.6 | 0.4 | (3.1) |  | 31.9 |
| Corporate debt securities | 17.1 |  | (13.4) |  | 3.7 |
| U.S. government and government agency | 3.9 |  | (0.1) |  | 3.8 |
| **Total debt securities, trading** | $114.6 | $0.5 | $(24.8) | $— | $90.3 |

---

(1)As of March 31, 2026 and December 31, 2025, the Company did not record an allowance for credit losses on the AFS portfolio.

------

As of March 31, 2026, 377 unique debt securities classified as AFS were in a gross unrealized loss position for greater than 12 months (December 31, 2025 - 379 unique debt securities). Refer to the tables below for the Company's breakdown of AFS debt securities in a gross unrealized loss position as of March 31, 2026 and December 31, 2025.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** |
| | **12 Months or Less** | **12 Months or Less** | **Greater than 12 Months** | **Greater than 12 Months** | **Total** | **Total** |
| | **Fair value** | **Gross unrealized losses** | **Fair value** | **Gross unrealized losses** | **Fair value** | **Gross unrealized losses** |
| **Debt securities, available for sale** | | | | | | |
| Asset-backed securities | $332.0 | $(4.4) | $59.7 | $(6.6) | $391.7 | $(11.0) |
| Residential mortgage-backed securities | 206.8 | (3.4) | 167.9 | (5.1) | 374.7 | (8.5) |
| Commercial mortgage-backed securities | 85.7 | (1.5) | 8.6 | (1.3) | 94.3 | (2.8) |
| Corporate debt securities | 849.6 | (9.6) | 51.5 | (0.4) | 901.1 | (10.0) |
| U.S. government and government agency | 489.5 | (3.3) | 24.2 | (0.3) | 513.7 | (3.6) |
| Non-U.S. government and government agency | 11.2 | (0.1) |  |  | 11.2 | (0.1) |
| **Total debt securities, available for sale**  | $1974.8 | $(22.3) | $311.9 | $(13.7) | $2286.7 | $(36.0) |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| | **12 Months or Less** | **12 Months or Less** | **Greater than 12 Months** | **Greater than 12 Months** | **Total** | **Total** |
| | **Fair value** | **Gross unrealized losses** | **Fair value** | **Gross unrealized losses** | **Fair value** | **Gross unrealized losses** |
| **Debt securities, available for sale** | | | | | | |
| Asset-backed securities | $184.5 | $(1.5) | $20.6 | $(1.8) | $205.1 | $(3.3) |
| Residential mortgage-backed securities | 84.5 | (0.5) | 190.5 | (4.2) | 275.0 | (4.7) |
| Commercial mortgage-backed securities | 46.2 | (1.2) | 9.0 | (1.3) | 55.2 | (2.5) |
| Corporate debt securities | 309.4 | (1.8) | 54.5 | (0.6) | 363.9 | (2.4) |
| U.S. government and government agency | 107.9 | (0.1) | 42.2 | (0.2) | 150.1 | (0.3) |
| Non-U.S. government and government agency | 7.1 |  |  |  | 7.1 |  |
| **Total debt securities, available for sale**  | $739.6 | $(5.1) | $316.8 | $(8.1) | $1056.4 | $(13.2) |

---

The weighted average duration of the Company's debt securities, net of short positions in U.S. treasuries, as of March 31, 2026 was approximately 3.1 years, including short-term investments (December 31, 2025 - approximately 3.2 years).

The following table provides the cost or amortized cost and fair value of the Company's debt securities bifurcated into debt securities held for trading and AFS as of March 31, 2026 and December 31, 2025 by contractual maturity. Actual maturities could differ from contractual maturities because borrowers may have the right to call or prepay certain obligations with or without call or prepayment penalties.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| | **Debt securities, AFS** | **Debt securities, AFS** | **Debt securities, trading** | **Debt securities, trading** | **Debt securities, AFS** | **Debt securities, AFS** | **Debt securities, trading** | **Debt securities, trading** |
| | **Cost or<br>amortized cost** | **Fair value** | **Cost or<br>amortized cost** | **Fair value** | **Cost or<br>amortized cost** | **Fair value** | **Cost or<br>amortized cost** | **Fair value** |
| Due in one year or less | $245.1 | $244.8 | $3.9 | $3.9 | $202.6 | $203.9 | $4.1 | $3.9 |
| Due after one year through five years | 2005.5 | 2009.8 | 2.5 | 2.3 | 1954.5 | 1974.7 | 2.4 | 2.3 |
| Due after five years through ten years | 569.6 | 565.6 |  |  | 713.7 | 723.6 |  |  |
| Due after ten years | 51.4 | 51.7 | 14.5 | 1.2 | 149.1 | 150.4 | 14.5 | 1.2 |
| Mortgage-backed and asset-backed securities | 2024.5 | 2021.0 | 90.4 | 78.6 | 2098.4 | 2116.0 | 93.6 | 82.9 |
| Total debt securities | $4896.1 | $4892.9 | $111.3 | $86.0 | $5118.3 | $5168.6 | $114.6 | $90.3 |

---

------

**Other long-term investments**

The cost or amortized cost, gross unrealized investment gains and losses, net foreign currency gains, and fair values of the Company's other long-term investments as of March 31, 2026 and December 31, 2025 were as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Cost or<br>amortized<br>cost** | **Gross<br>unrealized<br>gains** | **Gross<br>unrealized<br>losses** | **Net foreign<br>currency<br>gains** | **Fair value** |
| **March 31, 2026** | | | | | |
| Other long-term investments | $410.4 | $31.0 | $(147.6) | $1.6 | $295.4 |
| **December 31, 2025** |  |  |  |  |  |
| Other long-term investments | $421.9 | $35.1 | $(143.3) | $1.4 | $315.1 |

---

The Company's other long-term investments may be accounted for under either the equity method ("equity method investments") or the fair value option ("equity method eligible unconsolidated entities"). The following table presents the components of other long-term investments as of March 31, 2026 and December 31, 2025:

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| Equity method eligible unconsolidated entities, using the fair value option | $66.2 | $66.3 |
| Equity method investments | 41.7 | 33.1 |
| Other unconsolidated investments, at fair value <sup>(1)</sup> | 156.4 | 179.5 |
| Other unconsolidated investments, at cost <sup>(2)</sup> | 31.1 | 36.2 |
| Total other long-term investments <sup>(3)</sup> | $295.4 | $315.1 |

---

(1)Includes other long-term investments that are not equity method eligible and are measured at fair value.

(2)The Company has elected to apply the cost adjusted for market observable events impairment measurement alternative to investments that do not meet the criteria to be accounted for under the equity method, in which the investment is measured at cost and remeasured to fair value when impaired or upon observable transaction prices.

(3)As of March 31, 2026, the Company had $34.6 million of unfunded commitments relating to these investments (December 31, 2025 - $58.5 million).

**Net investment income**

Net investment income for the three months ended March 31, 2026 and 2025 consisted of the following:

---

| | | |
|:---|:---|:---|
| | **2026** | **2025** |
| Debt securities, available for sale | $64.7 | $61.3 |
| Debt securities, trading | 1.8 | 3.1 |
| Short-term investments | 0.3 | 1.2 |
| Other long-term investments | 0.3 | 1.6 |
| Cash, cash equivalents and other | 5.3 | 9.3 |
| &nbsp;&nbsp;Gross investment income | 72.4 | 76.5 |
| Investment expenses | (6.0) | (5.3) |
| &nbsp;&nbsp;Net investment income | $66.4 | $71.2 |

---

------

**Net investment gains (losses)**

Net investment gains (losses) for the three months ended March 31, 2026 and 2025 consisted of the following:

---

| | | |
|:---|:---|:---|
| | **2026** | **2025** |
| Debt securities, available for sale |  |  |
| &nbsp;&nbsp;Gross realized gains | $10.0 | $7.1 |
| &nbsp;&nbsp;Gross realized losses | (3.0) | (9.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net realized gains (losses) on Debt securities, available for sale | 7.0 | (2.0) |
| Debt securities, trading |  |  |
| &nbsp;&nbsp;Net realized gains (losses) |  | (1.5) |
| &nbsp;&nbsp;Net unrealized gains (losses) | (1.6) | 1.8 |
| Other long-term investments |  |  |
| &nbsp;&nbsp;Net realized gains (losses) | 14.4 | (2.1) |
| &nbsp;&nbsp;Net unrealized gains (losses) | (8.4) | 2.6 |
| Other <sup>(1)</sup> |  | 0.9 |
| Net investment gains (losses) | $11.4 | $(0.3) |

---

(1)Includes short-term investments, cash and cash equivalents, and derivatives.

**8. Derivatives**

The Company holds derivatives for both risk management and investment purposes.

**Foreign currency exchange rate derivatives**

The Company executes foreign currency forwards, swaps, and futures to manage foreign currency exposure. The foreign currency exchange rate derivatives are not designated or accounted for under hedge accounting. The fair value of the swaps and forwards are estimated using a single broker quote, and accordingly, are classified as a Level 3 measurement. The fair value of the futures is widely available and have quoted prices in active markets, and accordingly, were classified as a Level 1 measurement. As of March 31, 2026, the Company pledged no securities collateral associated with the foreign currency derivatives (December 31, 2025 - none). Securities pledged as collateral are included in debt securities, available for sale, in the Company's consolidated balance sheets.

**Weather derivatives**

The Company holds assets and assumes liabilities related to weather and weather contingent risk management products. Weather and weather contingent derivative contracts are entered into with the objective of generating profits in normal climatic conditions. Accordingly, the Company's weather and weather contingent derivatives are not designed to meet the criteria for hedge accounting under U.S. GAAP. The Company receives payment of premium at the contract inception in exchange for bearing the risk of variations in a quantifiable weather index. Management uses available market data and internal pricing models based upon consistent statistical methodologies to estimate the fair value. Because of the significance of the unobservable inputs used to estimate the fair value of the Company's weather risk contracts, the fair value measurements of the contracts are deemed to be Level 3 measurements in the fair value hierarchy. The Company does not provide or hold any collateral associated with the weather derivatives.

**Credit default swap**

Credit default swaps protect the buyer against the loss of principal on one or more underlying bonds, loans, or mortgages in the event the issuer suffers a credit event. The Company uses its credit default swap to provide a client with protection against financial non-performance of a subsidiary. The fair value of the swap is estimated using a single broker quote, and accordingly, is classified as a Level 3 measurement. As of March 31, 2026, the Company has $13.9 million pledged in securities collateral associated with the credit default swap (December 31, 2025 - $15.0 million). Securities pledged as collateral are included in debt securities, available for sale, in the Company's consolidated balance sheets.

------

The following table summarizes information on the classification and amount of the fair value of derivatives not designated as hedging instruments within the Company's consolidated balance sheets as of March 31, 2026 and December 31, 2025:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| **Derivatives not designated as hedging instruments** | **Derivative assets**<br>**at fair value**<sup>(1)</sup> | **Derivative liabilities**<br>**at fair value**<sup>(2)</sup> | **Notional <br>Value** | **Derivative assets**<br>**at fair value**<sup>(1)</sup> | **Derivative liabilities**<br>**at fair value**<sup>(2)</sup> | **Notional<br>Value** |
| Foreign currency forwards | $8.3 | $33.9 | $1038.7 | $13.8 | $3.6 | $853.7 |
| Interest rate swaps |  |  | 29.8 |  |  | 29.8 |
| Credit default swap | 0.6 |  | 73.1 | 0.6 |  | 73.1 |
| Reinsurance contracts accounted for as derivatives | $— | $6.7 | $89.7 | $— | $5.4 | $77.7 |

---

(1)Derivative assets are classified within Other assets in the Company's consolidated balance sheets.

(2)Derivative liabilities are classified within Other liabilities in the Company's consolidated balance sheets.

The following table summarizes information on the classification and net impact on earnings, recognized in the Company's consolidated statements of income relating to derivatives during the three months ended March 31, 2026 and 2025:

---

| | | | |
|:---|:---|:---|:---|
| **Derivatives not designated as hedging instruments** | **Classification of gains (losses) recognized in earnings** | **March 31,<br>2026** | **March 31,<br>2025** |
| Foreign currency forwards | Foreign exchange (gains) losses | $(16.0) | $40.8 |
| Weather derivatives | Other revenues | 0.1 | 0.3 |
| Interest rate swaps | Net investment gains (losses) | $— | $(0.2) |

---

**9. Variable and voting interest entities** 

The Company consolidates the results of operations and financial position of every voting interest entity ("VOE") in which it has a controlling financial interest and variable interest entities ("VIE") in which it is considered to be the primary beneficiary in accordance with guidance in ASC 810, Consolidation. The consolidation assessment, including the determination as to whether an entity qualifies as a VOE or VIE, depends on the facts and circumstances surrounding each entity.

**Consolidated variable interest entities**

***Alstead Re***

Alstead Reinsurance Ltd. ("Alstead Re") is considered a VIE and the Company has concluded that it is the primary beneficiary of Alstead Re because the Company can exercise control over the activities that most significantly impact the economic performance of Alstead Re. As a result, the Company has consolidated the results of Alstead Re in its consolidated financial statements. As of March 31, 2026, Alstead Re's assets and liabilities included in the Company's consolidated balance sheets were $7.1 million and $1.6 million, respectively (December 31, 2025 - $6.8 million and $0.9 million, respectively).

**Consolidated voting interest entities**

***Alta Signa***

Alta Signa Holdings ("Alta Signa") is considered a VOE and the Company holds a majority of the voting interests through its seats on Alta Signa's board of directors. As a result, the Company has consolidated the results of Alta Signa in its consolidated financial statements. The Company's ownership in Alta Signa as of March 31, 2026 was 75.1%. As of March 31, 2026, Alta Signa's assets and liabilities, before intercompany eliminations, included in the Company's consolidated balance sheets were $2.3 million and $1.3 million, respectively (December 31, 2025 - $1.8 million and $1.3 million, respectively).

**Non-consolidated variable interest entities**

The Company is a passive investor in certain third-party-managed hedge and private equity funds, some of which are VIEs. The Company is not involved in the design or establishment of these VIEs, nor does it actively participate in the management of the VIEs. The exposure to loss from these investments is limited to the carrying value of the investments at the balance sheet date.

------

The Company calculates maximum exposure to loss to be (i) the amount invested in the debt or equity of the VIE, (ii) the notional amount of VIE assets or liabilities where the Company has also provided credit protection to the VIE with the VIE as the referenced obligation, and (iii) other commitments and guarantees to the VIE. The Company does not have any VIEs that it sponsors, nor any VIEs where it has recourse to it or has provided a guarantee to the VIE interest holders.

The following table presents the carrying amount of unconsolidated VIEs in which the Company holds a variable interest, as well as the maximum exposure to loss associated with these VIEs as of March 31, 2026 and December 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** |
| | **Carrying Amount** | **Maximum Exposure to Loss** <sup>(1)</sup> | **Carrying Amount** | **Maximum Exposure to Loss** <sup>(1)</sup> |
| Debt securities, available for sale | $65.8 | $99.8 | $54.1 | $78.8 |
| Other long-term investments <sup>(2)</sup> | 202.0 | 259.9 | 210.1 | 293.9 |
|  | $267.8 | $359.7 | $264.2 | $372.7 |

---

(1)Maximum exposure to loss is equal to the carrying amounts plus any unfunded commitments.

(2)Includes investments in related parties, which are also VIEs and are discussed below.

***Third Point Enhanced LP***

As of March 31, 2026, the Company and Third Point Advisors LLC ("TP GP") hold interests of approximately 89.0% and 11.0%, respectively, of the net asset value of TP Enhanced Fund. As a result, both entities hold significant financial interests in TP Enhanced Fund. However, TP GP controls all of the investment decision-making authority and the Company does not have the power to direct the activities which most significantly impact the economic performance of TP Enhanced Fund. As a result, the Company is not considered the primary beneficiary and does not consolidate TP Enhanced Fund. The Company has no unfunded commitments on this investment, and its maximum exposure to loss on this investment corresponds to the carrying amount, which is included in Other long-term investments in the table above.

On February 28, 2025, the Company provided notice to Third Point LLC of its intent to redeem all of its capital accounts for TP Enhanced Fund. The redemptions will occur over time and may be in cash or underlying investments.

***Investment in Third Point Venture Offshore Fund I LP***

Third Point Venture GP LLC controls all of the investment decision-making authority of the TP Venture Fund. The Company does not have the power to direct the activities which most significantly impact the economic performance of the TP Venture Fund. As of March 31, 2026, the Company's maximum exposure to loss on this investment corresponds to the carrying amount plus unfunded commitments of $7.1 million (December 31, 2025 - $7.1 million), which is included in Other long-term investments in the table above.

***Investment in Third Point Venture Offshore Fund II LP***

Third Point Venture GP II LLC controls all of the investment decision-making authority of the TP Venture Fund II. The Company does not have the power to direct the activities which most significantly impact the economic performance of the TP Venture Fund II. As of March 31, 2026, the Company's maximum exposure to loss on this investment corresponds to the carrying amount plus unfunded commitments of $18.2 million (December 31, 2025 - $18.2 million), which is included in Other long-term investments in the table above.

***Investment in Third Point Insurance Solutions Fund I LLC***

Third Point GP controls all of the investment decision making authority of Third Point Insurance Solutions Fund I LLC ("TP ISF"). The Company does not have the power to direct the activities which most significantly impact the economic performance of TP ISF. As of March 31, 2026, the Company's maximum exposure to loss on this investment corresponds to the carrying amount plus unfunded commitments of $16.2 million (December 31, 2025 - $25.0 million), which is included in Other long-term investments in the table above.

------

**10. Loss and loss adjustment expense reserves** 

The following table represents the activity in the loss and loss adjustment expense reserves for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **March 31,<br>2025** |
| Gross reserves for loss and loss adjustment expenses, beginning of period | $5782.5 | $5653.9 |
| Less: loss and loss adjustment expenses recoverable, beginning of period | (2102.3) | (2315.3) |
| Less: deferred gains on retroactive reinsurance contracts <sup>(1)</sup> |  | 8.5 |
| Net reserves for loss and loss adjustment expenses, beginning of period | 3680.2 | 3347.1 |
| Increase (decrease) in net loss and loss adjustment expenses incurred in respect of losses occurring in: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Current year | 380.8 | 436.0 |
| &nbsp;&nbsp;&nbsp;&nbsp; Prior years | (17.9) | (34.2) |
| Total incurred loss and loss adjustment expenses | 362.9 | 401.8 |
| Net loss and loss adjustment expenses paid in respect of losses occurring in: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Current year | (129.8) | (123.6) |
| &nbsp;&nbsp;&nbsp;&nbsp; Prior years | (190.4) | (201.9) |
| Total net paid losses | (320.2) | (325.5) |
| Foreign currency translation | (10.4) | 10.1 |
| Net reserves for loss and loss adjustment expenses, end of period | 3712.5 | 3433.5 |
| Plus: loss and loss adjustment expenses recoverable, end of period | 2020.2 | 2335.7 |
| Plus: deferred gains on retroactive reinsurance <sup>(1)</sup> |  | (6.6) |
| Gross reserves for loss and loss adjustment expenses, end of period | $5732.7 | $5762.6 |

---

(1)Deferred gains on retroactive reinsurance were previously presented as a separate line item on the Company's consolidated balance sheets. As of March 31, 2026 and December 31, 2025, the deferred gain is fully amortized.

The Company's prior year reserve development arises from changes to estimates of losses and loss adjustment expenses related to loss events that occurred in previous calendar years.

For the three months ended March 31, 2026, the Company recorded $17.9 million of net favorable prior year loss reserve development primarily driven by favorable development in Credit, mainly from better than expected loss experience, as well as favorable development in A&H, due to lower than expected reported attritional losses.

For the three months ended March 31, 2025, the Company recorded $34.2 million of net favorable prior year loss reserve development primarily resulting from favorable development in Property, mainly from reserve releases relating to prior year's catastrophe events, as well as favorable development in A&H, due to lower than expected reported attritional losses.

**Loss Portfolio Transfers**

***Workers' Compensation Loss Portfolio Transfer***

On October 1, 2024, SiriusPoint America Insurance Company ("SiriusPoint America"), a subsidiary of the Company, and Clarendon National Insurance Company ("Clarendon National"), an insurer domiciled in Texas and an affiliate of Enstar Group Limited, a Bermuda exempted company ("Enstar") entered into a Loss Portfolio Transfer Reinsurance Agreement (the "2024 LPT"), pursuant to which SiriusPoint America cedes and Clarendon National assumes 100% of the net liability with respect to certain worker's compensation insurance exposures of SiriusPoint America on a funds withheld basis.

The transaction price of approximately $400 million covered SiriusPoint loss and unearned premium reserves, including commuted liabilities, and the reinsurance premium as of the December 31, 2023 valuation date. The subject loss reserves are included in Loss and loss adjustment expenses recoverable in the Company's consolidated balance sheets. The agreement between SiriusPoint America and Clarendon National is on a funds withheld basis, and the funds held liability (including reinsurance premium) of $198.4 million as of March 31, 2026 is included within Reinsurance balances payable in the Company's consolidated balance sheets. The aggregate limit under the 2024 LPT is 150% of the premium paid.

------

***SiriusPoint International Loss Portfolio Transfer***

On March 2, 2023, the Company agreed, subject to applicable regulatory approvals and other closing conditions, to enter into a loss portfolio transfer transaction (the "2023 LPT"), on a funds withheld basis, with Pallas Reinsurance Company Ltd., a subsidiary of the Compre Group, an insurance and reinsurance legacy specialist. The transaction covered loss reserves ceded initially estimated at $1.3 billion as of the valuation date of September 30, 2022, which were reduced to $905.6 million as of June 30, 2023 at closing, as a result of paid losses and favorable prior accident year reserve development recognized during the interim period. As of March 31, 2026, the Company recorded funds held payable of $325.9 million in Reinsurance balances payable and reinsurance recoverable of $328.8 million. The 2023 LPT comprises several classes of business from 2021 and prior underwriting years. The aggregate limit under the 2023 LPT is 130% of roll forward reserves at the inception of the contract.

**11. Allowance for expected credit losses**

The Company is exposed to credit losses primarily through sales of its insurance and reinsurance products and services. The financial assets in scope of the current expected credit losses impairment model primarily include the Company's insurance and reinsurance balances receivable and loss and loss adjustment expenses recoverable. The Company pools these amounts by counterparty credit rating and applies a credit default rate that is determined based on the studies published by the rating agencies (e.g., AM Best, Standard & Poor's, Fitch Ratings, Demotech). In circumstances where ratings are unavailable, the Company applies an internally developed default rate based on historical experience, reference data including research publications, and other relevant inputs.

The Company's assets in scope of the current expected credit loss assessment as of March 31, 2026 and December 31, 2025 are as follows:

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| Insurance and reinsurance balances receivable, net  | $2420.8 | $2260.3 |
| Loss and loss adjustment expenses recoverable, net | 2020.2 | 2102.3 |
| Other assets <sup>(1)</sup> | 77.9 | 75.2 |
| Total assets in scope | $4518.9 | $4437.8 |

---

(1)Relates to MGA trade receivables (included in Other assets in the Company's consolidated balance sheets), loans receivables (included in Other long-term investments in the Company's consolidated balance sheets) and interest and dividend receivables.

The Company's allowance for expected credit losses was $28.0 million as of March 31, 2026 (December 31, 2025 - $27.6 million). For the three months ended March 31, 2026, the Company recorded a current expected credit loss of $0.4 million (2025 - none). Changes to the current expected credit losses are included in net corporate and other expenses in the consolidated statements of income.

The Company monitors counterparty credit ratings and macroeconomic conditions, and considers the most current ratings from credit rating agencies to determine the allowance each quarter. As of March 31, 2026, approximately 66% of the total gross assets in scope were balances with counterparties rated by major credit rating agencies and, of the total rated, 96% were rated A- or better.

------

**12. Debt and letter of credit facilities**

**Debt obligations**

The following table represents a summary of the Company's debt obligations on its consolidated balance sheets as of March 31, 2026 and December 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** |
| | **Amount** | **Effective rate** <sup>(1)</sup> | **Amount** | **Effective rate** <sup>(1)</sup> |
| 2024 Senior Notes, at face value | $400.0 | 7.4% | $400.0 | 7.4% |
| &nbsp;&nbsp;&nbsp;Unamortized discount and issuance costs | (3.7) |  | (4.0) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2024 Senior Notes, carrying value | 396.3 |  | 396.0 |  |
| 2017 SEK Subordinated Notes, at face value | 288.7 | 6.1% | 298.2 | 7.1% |
| &nbsp;&nbsp;&nbsp;Unamortized discount | (5.4) |  | (5.6) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017 SEK Subordinated Notes, carrying value | 283.3 |  | 292.6 |  |
| Total debt | $679.6 |  | $688.6 |  |

---

(1)Effective rate considers the effect of the debt issuance costs, discount, and premium.

The Company was in compliance with all debt covenants as of and for the periods ended March 31, 2026 and December 31, 2025.

**Interest expense**

For the three months ended March 31, 2026, total interest expense includes $11.7 million associated with debt obligations (2025 - $11.8 million) and $5.7 million of funds withheld interest from loss portfolio transfers (2025 - $8.4 million). See Note 10 - "Loss and loss adjustment expense reserves" for further discussion on the 2024 LPT and 2023 LPT.

**Standby letter of credit facilities**

As of March 31, 2026, the Company had entered into the following letter of credit facilities:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Letters of Credit** | **Letters of Credit** | **Collateral** | **Collateral** |
| | **Committed Capacity** | **Issued** | **Cash and Cash Equivalents** | **Debt securities** |
| Committed - Secured letters of credit facilities | $330.0 | $223.5 | $5.7 | $128.4 |
| Uncommitted - Secured letters of credit facilities | n/a | 631.4 | 47.0 | 778.5 |
|  | $330.0 | $854.9 | $52.7 | $906.9 |

---

The Company's secured letter of credit facilities are bilateral agreements that generally renew on an annual basis. The letters of credit issued under the secured letter of credit facilities are fully collateralized. The above referenced facilities are subject to various affirmative, negative and financial covenants that the Company considers to be customary for such borrowings, including certain minimum net worth and maximum debt to capitalization standards. See Note 5 for additional information.

**Revolving credit facility**

In addition to the letter of credit facilities above, the Company entered into a four-year, $400.0 million senior unsecured revolving credit facility (the "Facility") with JPMorgan Chase Bank, N.A. as administrative agent, effective December 19, 2024. The Facility includes an option for the Company to request a 12-month extension, subject to satisfaction of certain conditions including, but not limited to, the consent of lenders representing a majority-in-interest of commitments, of the Facility maturity date. Subject to customary conditions precedent upon any Company borrowing request, the Facility provides access to loans for working capital and general corporate purposes, and letters of credit to support obligations under insurance and reinsurance agreements, retrocessional agreements and for general corporate purposes. As of March 31, 2026, there were no outstanding borrowings under the Facility. In addition, as of and for the periods ended March 31, 2026 and December 31, 2025, the Company was in compliance with all of the covenants under the Facility.

------

**Federal Home Loan Bank**

On September 25, 2025, SiriusPoint America, a subsidiary of the Company, was approved as a new member to the Federal Home Loan Bank of New York ("FHLBNY"). As a member of the FHLBNY, the Company will have access to FHLBNY borrowings to support general corporate purposes. The Company has the ability to obtain this funding from the FHLBNY based on a percentage of the value of its admitted assets in the State of New York, and its ability to borrow is subject to availability of eligible collateral. The borrowing limit for this program is 5% of the admitted assets of SiriusPoint America. As of December 31, 2025, SiriusPoint America's admitted assets were $3.2 billion. The Company did not receive advances or make repayments of FHLBNY borrowings during the three months ended March 31, 2026. There were no advances from the FHLBNY outstanding at March 31, 2026.

**13. Income taxes**

The Company has subsidiaries and branches that operate in various other jurisdictions around the world that are subject to tax in the jurisdictions in which they operate. The jurisdictions in which the Company's subsidiaries and branches are subject to tax are Belgium, Bermuda, Canada, Luxembourg, Sweden, Switzerland, the United Kingdom, and the United States. The Company recognizes income tax expense or benefit based upon pre-tax income or loss reported in the consolidated statements of income and the provisions of currently enacted tax laws. Effective January 1, 2025, a 15% corporate income tax is applied to the Company's Bermuda operations as a result of the enactment of the Corporate Income Tax Act 2023 (the "Bermuda CIT") on December 27, 2023.

For the three months ended March 31, 2026, the Company recorded income tax expense of $19.2 million (2025 - $13.3 million) on pre-tax income of $121.5 million (2025 - $75.3 million). The effective tax rate for the three months ended March 31, 2026 was 15.8%. The difference between the effective tax rate on income from continuing operations and the Bermuda statutory tax rate of 15% is primarily due to income recognized in higher-tax jurisdictions, non-taxable investment gains, and adjustments pursuant to applicable U.S. GAAP guidance on interim period financial reporting of taxes, which are based on the annual estimated effective tax rate.

In arriving at the estimated annual effective tax rate for the three months ended March 31, 2026 and 2025, the Company took into consideration all year-to-date income and expense items including the change in unrealized investment gains (losses) and realized investment gains (losses) and such items on a forecasted basis for the remainder of each year.

The Organisation for Economic Co-Operation and Development ("OECD") has published global anti-base erosion model rules under Pillar Two (the "GloBE Rules"), which implement a 15% global minimum tax applicable for in-scope multinational groups ("GMT"). Since January 1, 2024, the GloBE Rules have been in effect in the EU and other jurisdictions, including a minimum top-up tax rate of 15% for multinational companies, with many E.U. member states enacting corollary legislation as part of their respective domestic tax laws. Consistent with accounting guidance, the Company will treat the GMT as an in-period tax charge when incurred for which no deferred taxes need to be provided. The Company has recorded top-up tax of less than $0.6 million for the period ended March 31, 2026, based on its current estimation of 2026 GMT applied to the Company's facts and financial data. The Company will continue to reassess and re-estimate 2026 GMT.

**Uncertain tax positions**

Recognition of the benefit of a given tax position is based upon whether a company determines that it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. In evaluating the more likely than not recognition threshold, the Company must presume that the tax position will be subject to examination by a taxing authority with full knowledge of all relevant information. If the recognition threshold is met, then the tax position is measured at the largest amount of benefit that is more than 50% likely of being realized upon ultimate settlement.

The total reserve for unrecognized tax benefits is $0.2 million as of March 31, 2026, which did not materially change compared to December 31, 2025. If the Company determines in the future that its reserves for unrecognized tax benefits on permanent differences and interest and penalties are not needed, the reversal of $0.1 million of such reserves as of March 31, 2026 would be recorded as an income tax benefit and would impact the effective tax rate. The remaining balance is accrued interest and penalties.

------

**14. Shareholders' equity** 

**Common shares**

The following table presents a summary of the common shares issued and outstanding and shares repurchased as of and for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
| | **2026** | **2025** |
| Common shares issued and outstanding, beginning of period | 116989799 | 116429057 |
| Issuance of common shares, net of forfeitures and shares withheld | (254) | 91469 |
| Shares repurchased | (1052610) | (500000) |
| Common shares issued and outstanding, end of period | 115936935 | 116020526 |

---

The Company's authorized share capital consists of 300,000,000 common shares with a par value of $0.10 each. During the three months ended March 31, 2026 and 2025, the Company did not pay any dividends to its common shareholders.

**Preference shares**

The Company's authorized share capital also consists of 30,000,000 preference shares with a par value of $0.10 each.

**Series B preference shares**

On January 29, 2026, the Company announced a notice of redemption to the holders of its Series B preference shares. The Series B preference shares were previously listed on the New York Stock Exchange under the symbol "SPNT PB" and the Company had 8,000,000 of Series B preference shares outstanding, par value $0.10. Dividends on the Series B preference shares were cumulative and payable quarterly in arrears at an initial rate of 8.0% per annum. On February 26, 2026, the Company fully redeemed its 8,000,000 Series B preference shares at a redemption price of $25.00 per share plus $0.49 per share, which represented any accrued and unpaid cumulative dividends but excluding the date of redemption, for an aggregated redemption price of $203.9 million in cash, including dividends incurred during the period of $2.6 million (2025 - $4.0 million).

Following the redemption, no Series B preference shares are outstanding and all rights with respect to such Series B preference shares have ceased and terminated, except for the right to receive the redemption price. The Series B preference shares were deregistered under the Securities Exchange Act of 1934 and delisted from the New York Stock Exchange on February 26, 2026.

**Share repurchase program**

Under the Board authorized share repurchase programs, the Company may repurchase its common stock from time to time, in amounts, at prices and at times the Company deems appropriate in its sole discretion, subject to market conditions and a variety of factors, including, but not limited to, legal requirements, price and economic conditions. Shares of common stock may be repurchased in open market purchases, privately negotiated transactions or otherwise. The Company expects that the program will be in effect until the maximum approved dollar amount has been used. The program does not require the Company to repurchase any specific number of shares of common stock, and the program may be suspended, modified or discontinued at any time. As of March 31, 2026, the Company was authorized to repurchase a maximum value of approximately $152.4 million of outstanding common shares under its repurchase program. The share repurchase program does not have an expiration date.

During the three months ended March 31, 2026, the Company repurchased 1,052,610 of its common shares in the open market for a total cost of $21.9 million, at an average cost of $20.78 per share, including commissions of $0.03 per share. Common shares repurchased by the Company during the period were cancelled and retired.

During the three months ended March 31, 2025, the Company completed a previously announced transaction with CM Bermuda and repurchased 45,720,732 of its common shares from CM Bermuda at $14.25 per common share on February 27, 2025. This share repurchase was accounted for during the year ended December 31, 2024 in accordance with U.S. GAAP. For further detail on this transaction, please refer to Note 3 "Significant Transactions" of Part II, Item 8. "Financial Statements and Supplementary Data" included in our 2025 Form 10-K. Also on February 27, 2025, the Company repurchased 500,000 of its common shares from Daniel S. Loeb at the public offering price of $14.00 per share.

------

**15. Earnings per share available to SiriusPoint common shareholders** 

The following sets forth the computation of basic and diluted earnings per share available to SiriusPoint common shareholders for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2025** |
| **Weighted-average number of common shares outstanding:** | | |
| Basic number of common shares outstanding | 116725419 | 115975961 |
| Dilutive effect of restricted share awards and units | 3695084 | 1503925 |
| Dilutive effect of options | 1274553 | 1075280 |
| Diluted number of common shares outstanding | 121695056 | 118555166 |
| **Basic earnings per common share:** |  |  |
| Net income available to SiriusPoint common shareholders | $99.6 | $57.6 |
| Net income allocated to SiriusPoint participating shareholders | (0.1) | (0.1) |
| Net income allocated to SiriusPoint common shareholders | $99.5 | $57.5 |
| Basic earnings per share available to SiriusPoint common shareholders | $0.85 | $0.50 |
| **Diluted earnings per common share:** |  |  |
| Net income available to SiriusPoint common shareholders | $99.6 | $57.6 |
| Net income allocated to SiriusPoint participating shareholders | (0.1) | (0.1) |
| Net income allocated to SiriusPoint common shareholders | $99.5 | $57.5 |
| Diluted earnings per share available to SiriusPoint common shareholders | $0.82 | $0.49 |

---

For the three months ended March 31, 2026 and 2025, no material amounts were excluded from the computation of diluted earnings per share attributable to SiriusPoint common shareholders.

**16. Related party transactions**

In addition to the transactions disclosed in Notes 3, 9, and 14 to these consolidated financial statements, the following transactions are classified as related party transactions, as the counterparties have either a direct or indirect shareholding in the Company or the Company has an investment in such counterparty.

**(Re)insurance contracts**

During the three months ended March 31, 2026, insurance and reinsurance contracts with certain of the Company's insurance and MGA related parties resulted in gross written premium of $22.8 million (2025 - $6.5 million). As of March 31, 2026, the Company had total receivables from these related parties of $84.7 million and no payables (December 31, 2025 - receivables of $86.4 million and no payables).

**Investments managed by related parties**

The following table provides the fair value of the Company's investments managed by related parties as of March 31, 2026 and December 31, 2025:

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| Third Point Enhanced LP <sup>(1)</sup> | $82.4 | $82.2 |
| Third Point Insurance Solutions Fund I LLC | 2.5 | 1.6 |
| Third Point Venture Offshore Fund I LP <sup>(1)</sup> | 27.0 | 27.7 |
| Third Point Venture Offshore Fund II LP <sup>(1)</sup> | 8.2 | 6.3 |
| Third Point Optimized Credit Portfolio <sup>(2)</sup> | 621.2 | 652.8 |
| Total investments managed by related parties | $741.3 | $770.6 |

---

(1)The Third Point Enhanced LP, Third Point Venture Offshore Fund I LP, and Third Point Venture Offshore Fund II LP are reported in Other long-term investments in the consolidated balance sheets.

(2)The Third Point Optimized Credit Portfolio is primarily reported in Debt securities, available for sale and trading, in the consolidated balance sheets.

On February 28, 2025, the Company provided notice to Third Point LLC of its intent to redeem all of its capital accounts for TP Enhanced Fund. The redemptions will occur over time and may be in cash or underlying investments.

------

On September 23, 2025, the Company notified Third Point LLC of its intent to withdraw investments from the Third Point Optimized Credit Portfolio. The liquidation and withdrawal of the investments is proceeding in an orderly manner, pursuant to the existing investment management agreement and consistent with the parties' discussions.

**Management, advisory and performance fees to related parties**

The total management, advisory and performance fees to related parties for the three months ended March 31, 2026 and 2025 were as follows:

---

| | | |
|:---|:---|:---|
| | **2026** | **2025** |
| Management and advisory fees | $1.2 | $1.1 |
| Performance fees |  | (0.2) |
| Total management, advisory and performance fees to related parties <sup>(1)</sup> | $1.2 | $0.9 |

---

(1)Management, advisory and performance fees to related parties, where applicable, are presented within Net investment gains (losses) in the consolidated statements of income.

**17. Commitments and contingencies** 

**Litigation**

From time to time in the normal course of business, the Company may be involved in formal and informal dispute resolution processes, which may include arbitration or litigation, the outcomes of which determine the rights and obligations under the Company's insurance and reinsurance contracts and other contractual agreements. In some disputes, the Company may seek to enforce its rights under an agreement or to collect funds owed to it. In other matters, the Company may resist attempts by others to collect funds or enforce alleged rights. The Company may also be involved, from time to time in the normal course of business, in formal and informal dispute resolution processes that do not arise from, or are not directly related to, claims activity. The Company believes that no individual litigation or arbitration to which it is presently a party is likely to have a material adverse effect on its results of operations, financial condition, business or operations.

**Leases**

The Company operates globally and leases office space under various non-cancelable operating lease agreements.&nbsp;&nbsp;&nbsp;&nbsp;

During the three months ended March 31, 2026, the Company recognized operating lease expense of $2.5 million (2025 - $1.9 million), including property taxes and routine maintenance expense, as well as rental expenses related to short-term leases.

The following table presents the lease balances within the consolidated balance sheets as of March 31, 2026 and December 31, 2025:

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| Operating lease right-of-use assets <sup>(1)</sup> | $20.0 | $20.7 |
| Operating lease liabilities <sup>(2)</sup> | $23.3 | $24.6 |
| Weighted average lease term (years) | 4.3 | 4.6 |
| Weighted average discount rate | 3.3% | 3.2% |

---

(1) Operating lease right-of-use assets are included in Other assets on the Company's consolidated balance sheets.

(2) Operating lease liabilities are included in Other liabilities on the Company's consolidated balance sheets.

------

Future minimum rental commitments as of March 31, 2026 under these leases are expected to be as follows:

---

| | |
|:---|:---|
| | **Future Payments** |
| Remainder of 2026 | $5.1 |
| 2027 | 5.5 |
| 2028 | 5.7 |
| 2029 | 4.6 |
| 2030 and thereafter | 3.0 |
| Total future annual minimum rental payments | 23.9 |
| Less: present value discount | (0.6) |
| Total lease liability as of March 31, 2026 | $23.3 |

---

------

**ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations** 

The following discussion and analysis is intended to help the reader understand our business, financial condition, results of operations, liquidity and capital resources. You should read this discussion in conjunction with our unaudited consolidated financial statements and the related notes contained elsewhere in this Quarterly Report on Form 10-Q ("Form 10-Q") and the information under "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Form 10-K"). The terms "we," "our," "us" and the "Company," as used in this report, refer to SiriusPoint Ltd. ("SiriusPoint") and its directly and indirectly owned subsidiaries as a combined entity, except where otherwise stated or where it is clear that the terms mean only SiriusPoint exclusive of its subsidiaries.

The statements in this discussion regarding business outlook, our expectations regarding our future performance, liquidity and capital resources and other non-historical statements in this discussion are forward-looking statements. These forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, the risks and uncertainties described in "Risk Factors" of our 2025 Form 10-K and in "Cautionary Note Regarding Forward-Looking Statements" below. Our actual results may differ materially from those contained in or implied by any forward-looking statements.

**Cautionary Note Regarding Forward-Looking Statements**

Certain statements contained or incorporated in this Form 10-Q may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include, without limitation, statements regarding prospects for our industry, our business strategy, plans, goals, and expectations concerning our market position, international expansion, investment portfolio expectations, future operations, margins, profitability, efficiencies, capital expenditures, liquidity and capital resources and other non-historical financial and operating information. When used in this discussion, the words "believes," "intends," "seeks," "anticipates," "aims," "plans," "targets," "estimates," "expects," "assumes," "continues," "should," "could," "will," "may" and the negative of these or similar terms and phrases are intended to identify forward-looking statements.

Forward-looking statements reflect our current expectations regarding future events, results, or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to have been correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results, and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties, and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the frequency, severity, and development of insured losses, including natural catastrophes, extreme weather events, epidemics, pandemics, man-made events, and other large loss occurrences across many classes of insurance business, along with the amount of insurance losses that may ultimately be ceded to the reinsurance market, supply chain issues, labor shortages and related increased costs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the adequacy, accuracy and development of pricing or loss and loss adjustment expense reserves, the lack of available capital, and periods characterized by excess underwriting capacity and unfavorable premium rates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to maintain or improve underwriting discipline, risk selection, and portfolio diversification across lines and geographies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the cyclicality of the insurance and reinsurance markets, including changes in pricing, terms, conditions, and capacity;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks relating to our use of reinsurance, retrocessions, alternative capital and third party capital arrangements, including the availability and cost of such protections and the creditworthiness of counterparties;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to compete successfully in the insurance and reinsurance market and the effect of consolidation in the insurance and reinsurance industry;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• operational, cybersecurity, and technology-related risks, including system failures, data breaches, ransomware attacks, supply chain compromises of third party service providers, or other business interruption events, including those resulting from a malicious cyber-attack on us or our business partners or service providers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the effects of global climate change, including increased severity and frequency of weather-related natural disasters and catastrophes, including wildfires, heat waves, and increased coastal flooding in many geographic areas;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• geopolitical uncertainty, including the ongoing conflicts in Europe, South America, and the Middle East;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks related to inflation, social information, and shifts in judicial, legislative, or regulatory environments;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to attract, develop, and retain key personnel, distribution partners, and underwriting talent;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a downgrade or withdrawal of our financial ratings;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• fluctuations in our results of operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the performance of strategic partnerships, joint ventures, delegated underwriting authorities, and other third party relationships, including risks associated with delegating authority to third party managing general agents ("MGAs");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• legal restrictions on certain of SiriusPoint's insurance and reinsurance subsidiaries' ability to pay dividends and other distributions to SiriusPoint;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the outcome of legal and regulatory proceedings;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• regulatory, legal, and compliance developments affecting our insurance, reinsurance, MGAs, Lloyd's or international operations, including capital, solvency, reporting, conduct risk, and data protection requirements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reduced returns or losses in SiriusPoint's investment portfolio, including the impact of market volatility, credit events, interest rate movements, inflation, foreign exchange fluctuations, and changes in asset valuations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our exposure or potential exposure to corporate income tax in Bermuda and the EU, U.S. federal income and withholding taxes and our significant deferred tax assets, which could become devalued if we do not generate future taxable income or applicable corporate tax rates are reduced;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• future strategic transactions such as acquisitions, dispositions, investments, mergers, or joint ventures;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• SiriusPoint's response to any acquisition proposal that may be received from any party, including any actions that may be considered by the Company's Board of Directors or any committee thereof; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• other risks and factors listed under "Risk Factors" in our 2025 Form 10-K and other subsequent periodic reports filed with the Securities and Exchange Commission.

Any one of these factors or a combination of these factors could materially affect our financial condition or future results of operations and could influence whether any forward-looking statements contained in this report ultimately prove to be accurate. Our forward-looking statements are not guarantees of future performance, and you should not place undue reliance on them. All forward-looking statements speak only as of the date made and we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

**Overview** 

We are a global underwriter of insurance and reinsurance, domiciled in Bermuda. We have licenses to write property, casualty and accident & health insurance and reinsurance globally, including admitted & non-admitted licensed companies in the United States, a Bermuda Class 4 company, a Lloyd's of London ("Lloyd's") syndicate and managing agency, and an internationally licensed company domiciled in Sweden. Our operating companies have a financial strength rating of A (Positive) from AM Best, Fitch Ratings ("Fitch"), and Standard & Poor's ("S&P") and A3 (Stable) from Moody's Ratings ("Moody's").

We aim to drive excellence as a best-in-class underwriter, with a diverse and low-volatility portfolio of specialty lines. We seek to apply our underwriting talent, capabilities, and management expertise to underwrite a profitable book of business and identify new opportunities to create value. Our approach is to be nimble and attuned to market opportunities within our segments of Insurance & Services and Reinsurance, allocating capital where we see profitable opportunity, while remaining disciplined and focused on our specified risk tolerances and areas of expertise.

Distribution relationships are particularly important to us. A majority of our premium is produced via MGAs, including both our consolidated MGAs and non-consolidated MGAs. We seek to create capacity partnerships with MGAs that have high integrity and transparent leaders, and teams with deep underwriting expertise and track records of success, and no longer take capital positions in those business partners. Our partnerships are focused on underwriting in concentrated, niche businesses that often offer new exposure to our portfolio, while we provide guidance and oversight. As of March 31, 2026, we had equity stakes in 16 entities (MGAs, Insurtech and Other) which underwrite or distribute a wide range of lines of business, including general liability, professional liability, directors & officers, credit and bond, cyber, commercial automobile, workers' compensation, accident & health, and other specialty insurance classes.

------

***Products & Services***

*Insurance & Services Segment*

In our Insurance & Services segment, we predominantly provide insurance coverage in addition to receiving fees for services provided within Insurance & Services and to third parties. Insurance & Services revenue allows us to diversify our traditional reinsurance portfolio and generally has lower capital requirements. In addition, service fees from MGAs and their insurance provided are generally not as prone to the volatile underwriting cycle that is common in reinsurance marketplace. The Insurance & Services segment provides coverage in Accident & Health ("A&H"), Property & Casualty, and Other Specialties.

*Reinsurance Segment*

In our Reinsurance segment, we provide reinsurance products to insurance and reinsurance companies, government entities, and other risk bearing vehicles. We participate in the reinsurance market with a global focus through the broker market distribution channel. We primarily write treaty reinsurance, on both a proportional and excess of loss basis, and provide facultative reinsurance in some of our business lines. In the United States and Bermuda, our core focus is on distribution, risk and clients located in North America while our international operation is focused primarily on distribution, risks and clients located in Europe. The Reinsurance segment predominantly underwrites Casualty, Property and Other Specialties lines of business.

***Investment Management***

We manage our investment portfolio to balance quality, liquidity, and diversification with asset/liability matching and investment return. Our investment objective is to optimize risk-adjusted net investment income after tax while (1) maintaining a high quality, diversified investment portfolio, (2) maintaining adequate liquidity, and (3) complying with the regulatory, rating agency, and internal risk and capital management requirements, all in support of the company goal of meeting policyholder obligations.

**Recent Developments**

***Acquisition of Assist America***

On December 31, 2025, we, through our wholly owned subsidiaries, entered into an agreement to acquire Assist America Inc. and its affiliates ("Assist America") for $44.0 million in cash and other contingent considerations. Pursuant to the agreement, we consolidated Assist America as of January 1, 2026 and recognized goodwill of $18.6 million in our Insurance & Services segment.

Assist America provides reliable global emergency assistance to over 40 million members across Asia, the Middle East, and North America. The acquisition bolsters our third-party medical and travel assistance revenue, increases our scale in the U.S., and expands our coverage to Asia and the Middle East.

***Ratings***

On February 25, 2026, Fitch upgraded the financial strength rating of our operating subsidiaries to 'A' (Strong) from 'A-', followed by AM Best's upgrade to 'A' (Excellent) from 'A-' on April 16, 2026 and S&P's upgrade to 'A' (Strong) from 'A-' on April 21, 2026.

***Redemption of Series B Preference Shares***

On February 26, 2026, we redeemed all 8,000,000 of our issued and outstanding 8.0% Series B preference shares for a redemption price of $25.00 per share, plus $0.49, which reflects unpaid, accrued cumulative dividends, to, but excluding, February 26, 2026, for an aggregate redemption price of $203.9 million. We delisted the Series B preference shares from the New York Stock Exchange and deregistered the Series B preference shares under the Securities Exchange Act of 1934. The redemption helps simplify and optimize our capital structure and financial leverage, while also eliminating the cost of capital and related cash servicing associated with the Series B preference shares.

------

**Key Performance Indicators**

We believe that the following key financial indicators are the most important in evaluating our performance for the three months ended March 31, 2026 and 2025, and as of March 31, 2026 and December 31, 2025:

---

| | | |
|:---|:---|:---|
| | **2026** | **2025** |
| | **($ in millions, except for ratios)** | **($ in millions, except for ratios)** |
| Combined ratio | 87.8% | 91.4% |
| Core underwriting income ⁽¹⁾ | $70.9 | $28.5 |
| Core net services income ⁽¹⁾ | $8.4 | $18.9 |
| Core income ⁽¹⁾ | $79.3 | $47.4 |
| Core combined ratio ⁽¹⁾ | 88.9% | 95.4% |
| Annualized return on average common shareholders' equity attributable to SiriusPoint common shareholders | 17.4% | 12.9% |

---

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| Book value per common share | $19.86 | $19.40 |
| Book value per diluted common share | $19.03 | $18.61 |
| Tangible book value per diluted common share ⁽¹⁾ | $17.72 | $17.62 |

---

(1)Core underwriting income, Core net services income, Core income, and Core combined ratio are non-GAAP financial measures. See definitions in "Non-GAAP Financial Measures" and reconciliations in "Segment Results" below and Note 4 "Segment reporting" in our unaudited consolidated financial statements included elsewhere in this Form 10-Q. Tangible book value per diluted common share is a non-GAAP financial measure. See definition and reconciliation in "Non-GAAP Financial Measures."

***Core Results***

See "Segment Results" below for additional information.

***Annualized Return on Average Common Shareholders' Equity Attributable to SiriusPoint Common Shareholders***

Annualized return on average common shareholders' equity attributable to SiriusPoint common shareholders is calculated by dividing annualized net income available to SiriusPoint common shareholders for the period by the average common shareholders' equity determined using the common shareholders' equity balances at the beginning and end of the period.

Annualized return on average common shareholders' equity attributable to SiriusPoint common shareholders for the three months ended March 31, 2026 and 2025 was calculated as follows:

---

| | | |
|:---|:---|:---|
| | **2026** | **2025** |
| | **($ in millions)** | **($ in millions)** |
| Net income available to SiriusPoint common shareholders | $99.6 | $57.6 |
| Common shareholders' equity attributable to SiriusPoint common shareholders - beginning of period | 2269.8 | 1737.4 |
| Common shareholders' equity attributable to SiriusPoint common shareholders - end of period | 2302.4 | 1825.2 |
| Average common shareholders' equity attributable to SiriusPoint common shareholders | $2286.1 | $1781.3 |
| Annualized return on average common shareholders' equity attributable to SiriusPoint common shareholders | 17.4% | 12.9% |

---

The increase in annualized return on average common shareholders' equity attributable to SiriusPoint common shareholders was driven by higher net income for the three months ended March 31, 2026, primarily resulting from the gain on the sale of Arcadian Risk Capital Ltd. ("Arcadian") and increased underwriting income.

***Book Value Per Share***

Book value per common share is calculated by dividing common shareholders' equity attributable to SiriusPoint common shareholders by the number of common shares outstanding. Book value per diluted common share is calculated by dividing common shareholders' equity attributable to SiriusPoint common shareholders by the number of diluted common shares outstanding, calculated similar to the treasury stock method.

------

Tangible book value per diluted common share is a non-GAAP financial measure and the most comparable U.S. GAAP measure is book value per common share. See "Non-GAAP Financial Measures" for an explanation and reconciliation.

As of March 31, 2026, book value per common share was $19.86, representing an increase of $0.46 per share, or 2.4%, from $19.40 per share as of December 31, 2025. As of March 31, 2026, book value per diluted common share was $19.03, representing an increase of $0.42 per share, or 2.3%, from $18.61 per share as of December 31, 2025. As of March 31, 2026, tangible book value per diluted common share was $17.72, representing an increase of $0.10 per share, or 0.6%, from $17.62 per share as of December 31, 2025. The increases reflect continued positive underwriting and investment results during the three months ended March 31, 2026.

**Consolidated Results of Operations—Three months ended March 31, 2026 and 2025**

The following table sets forth the key items discussed in the consolidated results of operations section, and the period over period change, for the three months ended March 31, 2026 and 2025:

---

| | | | |
|:---|:---|:---|:---|
| | **2026** | **2025** | **Change** |
| | **($ in millions)** | **($ in millions)** | **($ in millions)** |
| Total underwriting income | $77.7 | $54.1 | $23.6 |
| Net investment income | 66.4 | 71.2 | (4.8) |
| Net investment gains (losses) | 11.4 | (0.3) | 11.7 |
| Other revenues | 57.9 | 29.7 | 28.2 |
| Net corporate and other expenses | (71.2) | (60.6) | (10.6) |
| Intangible asset amortization | (2.6) | (2.9) | 0.3 |
| Interest expense | (16.8) | (18.1) | 1.3 |
| Foreign exchange gains (losses) | (1.3) | 2.2 | (3.5) |
| Income tax expense | (19.2) | (13.3) | (5.9) |
| Net income | $102.3 | $62.0 | $40.3 |

---

The key changes in our consolidated results for the three months ended March 31, 2026 compared to the prior year period are discussed below.

***Underwriting results***

The improvement in net underwriting results for the three months ended March 31, 2026 compared to the three months ended March 31, 2025 was primarily driven by premium growth at a lower attritional loss ratio and a decrease in catastrophe losses of $62.5 million, partially offset by a decrease in favorable prior year development of $16.3 million.

------

***Investments***

*Investment Portfolio*

The following table presents the carrying value of our total investments, cash and cash equivalents and restricted cash and cash equivalents as of March 31, 2026 and December 31, 2025:

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| | **($ in millions)** | **($ in millions)** |
| Debt securities, available for sale | $4892.9 | $5168.6 |
| Debt securities, trading | 86.0 | 90.3 |
| Total debt securities <sup>(1)</sup> | 4978.9 | 5258.9 |
| Short-term investments | 32.5 | 28.3 |
| Other long-term investments <sup>(2)</sup> | 295.4 | 315.1 |
| Total investments | 5306.8 | 5602.3 |
| Cash and cash equivalents | 856.9 | 731.2 |
| Restricted cash and cash equivalents <sup>(3)</sup> | 153.8 | 171.2 |
| Total invested assets and cash | $6317.5 | $6504.7 |

---

(1)Includes $621.2 million of investments in the Third Point Optimized Credit portfolio ("TPOC Portfolio") as of March 31, 2026 (December 31, 2025 - $652.8 million).

(2)Includes $77.5 million of strategic investments as of March 31, 2026 (December 31, 2025 - $102.2 million).

(3)Primarily consists of cash and fixed income securities such as U.S. Treasuries, money markets funds, and sovereign debt, securing our contractual obligations under certain (re)insurance contracts that we will not be released from until the underlying risks have expired or have been settled.

The decrease in total invested assets and cash was primarily driven by the use of investments to fund the redemption of the Series B preference shares of $203.9 million, as well as to fund the common share repurchases of $21.9 million.

The duration of our fixed income portfolio, excluding cash and cash equivalents, is 3.1 years (December 31, 2025 - 3.2 years). The duration remained consistent from the comparative period due to our efforts to match our asset duration with economic liabilities in the current interest rate environment. The average credit rating of our investment portfolio is "AA-" as of March 31, 2026 (December 31, 2025 - "AA-") with no defaults in the investment portfolio.

The following table provides a breakdown of structured products between investment and non-investment grade securities as of March 31, 2026 and December 31, 2025. These are fixed income investments which are included in debt securities in the table above. Refer to Note 7 "Investments" to our unaudited consolidated financial statements included elsewhere in this Form 10-Q for further discussion of these securities.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** |
| | **Investment Grade** <sup>(1)</sup> | **Non-investment Grade** <sup>(2)</sup> | **Investment Grade** <sup>(1)</sup> | **Non-investment Grade** <sup>(2)</sup> |
| | **($ in millions)** | **($ in millions)** | **($ in millions)** | **($ in millions)** |
| Asset-backed securities | $508.5 | $32.6 | $583.5 | $18.9 |
| Collateralized loan obligations | 330.3 |  | 324.6 |  |
| Total asset-backed securities | 838.8 | 32.6 | 908.1 | 18.9 |
| Agency residential mortgage-backed securities | 773.7 |  | 799.2 |  |
| Non-agency residential mortgage-backed securities | 194.5 | 18.3 | 186.7 | 22.2 |
| Total residential mortgage-backed securities | 968.2 | 18.3 | 985.9 | 22.2 |
| Agency commercial mortgage-backed securities | 47.7 |  | 48.1 |  |
| Non-agency commercial mortgage-backed securities | 193.3 | 0.5 | 215.2 | 0.5 |
| Total commercial mortgage-backed securities | 241.0 | 0.5 | 263.3 | 0.5 |
| Total mortgage-backed securities | 1209.2 | 18.8 | 1249.2 | 22.7 |
| Total asset and mortgage-backed securities | $2048.0 | $51.4 | $2157.3 | $41.6 |

---

(1)Investment grade securities are considered rated BBB or higher.

(2)Non-investment grade securities are considered rated below BBB.

------

*Investment Results*

Net investment income for the three months ended March 31, 2026 and 2025 consisted of the following:

---

| | | |
|:---|:---|:---|
| | **2026** | **2025** |
| | **($ in millions)** | **($ in millions)** |
| Debt securities, available for sale | $64.7 | $61.3 |
| Debt securities, trading | 1.8 | 3.1 |
| Short-term investments | 0.3 | 1.2 |
| Other long-term investments | 0.3 | 1.6 |
| Cash, cash equivalents and other | 5.3 | 9.3 |
| &nbsp;&nbsp;Gross investment income | 72.4 | 76.5 |
| Investment expenses | (6.0) | (5.3) |
| &nbsp;&nbsp;Net investment income | $66.4 | $71.2 |

---

Net investment gains (losses) for the three months ended March 31, 2026 and 2025 consisted of the following:

---

| | | |
|:---|:---|:---|
| | **2026** | **2025** |
| | **($ in millions)** | **($ in millions)** |
| Debt securities, available for sale |  |  |
| &nbsp;&nbsp;Gross realized gains | $10.0 | $7.1 |
| &nbsp;&nbsp;Gross realized losses | (3.0) | (9.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net realized gains (losses) on Debt securities, available for sale | 7.0 | (2.0) |
| Debt securities, trading |  |  |
| &nbsp;&nbsp;Net realized gains (losses) |  | (1.5) |
| &nbsp;&nbsp;Net unrealized gains (losses) | (1.6) | 1.8 |
| Other long-term investments |  |  |
| &nbsp;&nbsp;Net realized gains (losses) | 14.4 | (2.1) |
| &nbsp;&nbsp;Net unrealized gains (losses) | (8.4) | 2.6 |
| Other <sup>(1)</sup> |  | 0.9 |
| Net investment gains (losses) | $11.4 | $(0.3) |

---

(1)Includes short-term investments, cash and cash equivalents, and derivatives.

The decrease in net investment income for the three months ended March 31, 2026 compared to the three months ended March 31, 2025 is primarily the result of lower yields in the current period. The increase in net investment gains (losses) for the three months ended March 31, 2026 compared to the three months ended March 31, 2025 was primarily due to gains on private equity funds classified in Other long-term investments.

Refer to Part I, Item 3. "Quantitative and Qualitative Disclosures about Market Risks" of this Form 10-Q for a discussion of certain risks and factors that could adversely impact our investments results.

***Other Revenues***

For the three months ended March 31, 2026, other revenues primarily consisted of $25.2 million from the gain on the sale of Arcadian and $30.9 million of service fee revenue from MGAs, compared to $31.9 million of service fee revenue from MGAs for the three months ended March 31, 2025. The slight decrease in service fee revenue is primarily driven by the deconsolidation of ArmadaCorp Capital, LLC ("Armada"), partially offset by increases in International Medical Group, Inc. ("IMG") from continued growth of its travel business and the acquisition of Assist America.

***Net Corporate and Other Expenses***

Net corporate and other expenses include costs associated with operating as a publicly-traded company and non-underwriting activities, including services expenses from our MGA subsidiaries, and current expected credit losses from our insurance and reinsurance balances receivable and loss and loss adjustment expenses recoverable.

------

The increase in net corporate and other expenses for the three months ended March 31, 2026 compared to the three months ended March 31, 2025 was primarily driven by increases in share compensation expense attributable to the recent gains on sales of Armada and Arcadian and expenses associated with non-recurring projects, as well as increases in services expenses.

For the three months ended March 31, 2026, services expenses increased to $46.1 million compared to $43.1 million for the three months ended March 31, 2025, primarily driven by increases in expenses from IMG from continued growth of its own business and the acquisition of Assist America, partially offset by the deconsolidation of Armada.

***Amortization of Intangible Assets***

Amortization of intangible assets for the three months ended March 31, 2026 was $2.6 million (2025 - $2.9 million). The change in amortization are due to the use of amortization patterns which are based on the period over which they are expected to generate future net cash inflows from the use of the underlying intangible assets.

***Interest Expense***

Interest expense and finance costs are related to interest due on our senior and subordinated notes, as well as interest associated with certain reinsurance contracts.

Interest expense for the three months ended March 31, 2026 was $16.8 million compared to $18.1 million for the three months ended March 31, 2025. The decrease was primarily driven by decreases in funds withheld interest on loss portfolio transfers.

***Foreign Currency Translation***

Except for the Canadian reinsurance operations of SiriusPoint America and certain subsidiaries of IMG, the U.S. dollar is the functional currency for our business. Assets and liabilities are remeasured into the functional currency using current exchange rates; revenues and expenses are remeasured into the functional currency using the average exchange rate for the period. The remeasurement process results in foreign exchange (gains) losses in the consolidated results of operations. Foreign exchange (gains) losses exclude investment generated net realized and unrealized investment gains as addressed in *Investment Results* above.

Foreign exchange losses were $1.3 million for the three months ended March 31, 2026 compared to foreign exchange gains of $2.2 million for the three months ended March 31, 2025. The change is primarily driven by the impact of certain foreign exchange exposures related to our underwriting activities, partially offset by the impact of our currency hedges.

On an aggregate basis, the effects of foreign exchange resulted in charges to net income of $2.3 million as well as charges to comprehensive income of $6.4 million for the three months ended March 31, 2026. The effects of foreign exchange are consistent with the recent market fluctuations in rates and our economic currency hedging strategy.

***Income Tax Expense***

The increases in income tax expense for the three months ended March 31, 2026 compared to the three months ended March 31, 2025 were consistent with the increases in pre-tax income.

**Segment Results — Three months ended March 31, 2026 and 2025**

The determination of our reportable segments is based on the manner in which management monitors the performance of our operations. We classify our business into two reportable segments - Insurance & Services and Reinsurance. Collectively, the sum of these two segments constitute "Core" results. Core underwriting income, Core net services income, Core income, and Core combined ratio are non-GAAP financial measures. We believe it is useful to review Core results as it better reflects how management views the business and reflects our decision to exit the run off business. The sum of Core results and Corporate results are equal to the consolidated results of operations.

Corporate results include all run off business, which represents certain classes of business that we ceased underwriting as part of fundamental changes to our business strategy, including the effect of the restructuring of the underwriting platform announced in 2022 and certain reinsurance contracts that have interest crediting features. Corporate results also include asbestos and environmental and other latent liability exposures on a gross basis, which have mostly been ceded, as well as specific workers' compensation and cyber programs which we no longer write.

------

The following tables set forth the operating segment results and ratios for the three months ended March 31, 2026 and 2025:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** |
| | **Insurance & Services** | **Reinsurance** | **Core** | **Eliminations** <sup>(2)</sup> | **Corporate** | **Segment Measure Reclass** | **Total** |
| Gross written premium | $684.6 | $319.2 | $1003.8 | $— | $(0.9) | $— | $1002.9 |
| Net written premium | 461.1 | 235.7 | 696.8 |  | (1.6) |  | 695.2 |
| Net earned premium | 380.1 | 258.2 | 638.3 |  | 0.6 |  | 638.9 |
| Loss and loss adjustment expenses incurred, net | 215.7 | 134.0 | 349.7 | (1.8) | 15.0 |  | 362.9 |
| Acquisition costs, net | 108.0 | 63.8 | 171.8 | (23.8) | (0.2) |  | 147.8 |
| Other underwriting expenses | 26.3 | 19.6 | 45.9 |  | 4.6 |  | 50.5 |
| **Underwriting income (loss)** | 30.1 | 40.8 | 70.9 | 25.6 | (18.8) |  | 77.7 |
| Services revenues | 54.0 |  | 54.0 | (23.1) |  | (30.9) |  |
| Services expenses | 46.1 |  | 46.1 |  |  | (46.1) |  |
| **Net services fee income** | 7.9 |  | 7.9 | (23.1) |  | 15.2 |  |
| Services noncontrolling loss | 0.5 |  | 0.5 |  |  | (0.5) |  |
| **Net services income** | 8.4 |  | 8.4 | (23.1) |  | 14.7 |  |
| **Segment income (loss)** | $38.5 | $40.8 | $79.3 | $2.5 | $(18.8) | $14.7 | $77.7 |
| Attritional losses | $230.8 | $145.7 | $376.5 | $(1.8) | $0.7 | $— | $375.4 |
| Catastrophe losses |  | 5.4 | 5.4 |  |  |  | 5.4 |
| Prior year loss reserve development | (15.1) | (17.1) | (32.2) |  | 14.3 |  | (17.9) |
| Loss and loss adjustment expenses incurred, net | $215.7 | $134.0 | $349.7 | $(1.8) | $15.0 | $— | $362.9 |
| **Underwriting Ratios:** <sup>(1)</sup> |  |  |  |  |  |  |  |
| Attritional loss ratio | 60.7% | 56.4% | 59.0% |  |  |  | 58.8% |
| Catastrophe loss ratio | —% | 2.1% | 0.8% |  |  |  | 0.8% |
| Prior year loss development ratio | (4.0)% | (6.6)% | (5.0)% |  |  |  | (2.8)% |
| Loss ratio | 56.7% | 51.9% | 54.8% |  |  |  | 56.8% |
| Acquisition cost ratio | 28.4% | 24.7% | 26.9% |  |  |  | 23.1% |
| Other underwriting expenses ratio | 6.9% | 7.6% | 7.2% |  |  |  | 7.9% |
| Combined ratio  | 92.0% | 84.2% | 88.9% |  |  |  | 87.8% |

---

(1)Underwriting ratios are calculated by dividing the related expense by net earned premium.

(2)Insurance & Services MGAs recognize fees for service using revenue from contracts with customers accounting standards, whereas insurance companies recognize acquisition expenses using insurance contract accounting standards. While ultimate revenues and expenses recognized will match, there will be recognition timing differences based on the different accounting standards.

------

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** |
| | **Insurance & Services** | **Reinsurance** | **Core** | **Eliminations** <sup>(2)</sup> | **Corporate** | **Segment Measure Reclass** | **Total** |
| | | **($ in millions)** | **($ in millions)** | **($ in millions)** | **($ in millions)** | **($ in millions)** | **($ in millions)** |
| Gross written premium | $635.1 | $354.8 | $989.9 | $— | $(5.2) | $— | $984.7 |
| Net written premium | 483.5 | 268.5 | 752.0 |  | (9.0) |  | 743.0 |
| Net earned premium | 336.2 | 289.6 | 625.8 |  | 0.9 |  | 626.7 |
| Loss and loss adjustment expenses incurred, net | 209.9 | 195.3 | 405.2 | (2.0) | (1.4) |  | 401.8 |
| Acquisition costs, net | 87.3 | 67.1 | 154.4 | (28.0) | 3.3 |  | 129.7 |
| Other underwriting expenses | 18.9 | 18.8 | 37.7 |  | 3.4 |  | 41.1 |
| **Underwriting income (loss)** | 20.1 | 8.4 | 28.5 | 30.0 | (4.4) |  | 54.1 |
| Services revenues | 62.1 |  | 62.1 | (30.2) |  | (31.9) |  |
| Services expenses | 43.1 |  | 43.1 |  |  | (43.1) |  |
| **Net services fee income** | 19.0 |  | 19.0 | (30.2) |  | 11.2 |  |
| Services noncontrolling income | (0.1) |  | (0.1) |  |  | 0.1 |  |
| **Net services income** | 18.9 |  | 18.9 | (30.2) |  | 11.3 |  |
| **Segment income (loss)** | $39.0 | $8.4 | $47.4 | $(0.2) | $(4.4) | $11.3 | $54.1 |
| Attritional losses | $207.6 | $164.0 | $371.6 | $(2.0) | $(1.5) | $— | $368.1 |
| Catastrophe losses | 4.8 | 63.1 | 67.9 |  |  |  | 67.9 |
| Prior year loss reserve development | (2.5) | (31.8) | (34.3) |  | 0.1 |  | (34.2) |
| Loss and loss adjustment expenses incurred, net | $209.9 | $195.3 | $405.2 | $(2.0) | $(1.4) | $— | $401.8 |
| **Underwriting Ratios:** <sup>(1)</sup> |  |  |  |  |  |  |  |
| Attritional loss ratio | 61.7% | 56.6% | 59.3% |  |  |  | 58.8% |
| Catastrophe loss ratio | 1.4% | 21.8% | 10.9% |  |  |  | 10.8% |
| Prior year loss development ratio | (0.7)% | (11.0)% | (5.5)% |  |  |  | (5.5)% |
| Loss ratio | 62.4% | 67.4% | 64.7% |  |  |  | 64.1% |
| Acquisition cost ratio | 26.0% | 23.2% | 24.7% |  |  |  | 20.7% |
| Other underwriting expenses ratio | 5.6% | 6.5% | 6.0% |  |  |  | 6.6% |
| Combined ratio | 94.0% | 97.1% | 95.4% |  |  |  | 91.4% |

---

(1)Underwriting ratios are calculated by dividing the related expense by net earned premium.

(2)Insurance & Services MGAs recognize fees for service using revenue from contracts with customers accounting standards, whereas insurance companies recognize acquisition expenses using insurance contract accounting standards. While ultimate revenues and expenses recognized will match, there will be recognition timing differences based on the different accounting standards.

***Core Premium Volume***

Gross written premium increased by $13.9 million, or 1.4%, for the three months ended March 31, 2026 compared to the three months ended March 31, 2025. Net written premium decreased by $55.2 million, or 7.3%, for the three months ended March 31, 2026 compared to the three months ended March 31, 2025. Net earned premium increased by $12.5 million, or 2.0%, for the three months ended March 31, 2026, compared to the three months ended March 31, 2025. The increases in gross written premium and net earned premium were driven by our Insurance & Services segment, including growth in A&H, General Liability, and Surety, partially offset by decreases in our Reinsurance segment, primarily in Property Catastrophe, Bermuda and London Specialty, and New York Casualty. The decrease in net written premium was primarily driven by the decreases in our Reinsurance segment and the ceded premium related to the inception of an aggregate reinsurance program in the current quarter, as well as a large one-time assumed reinsurance contract with a single MGA in our Surety business in the first quarter of 2025.

------

***Core Underwriting Results***

The improvement in net underwriting results of $42.4 million was primarily driven by decreased catastrophe losses and a lower attritional loss ratio, partially offset by a decrease in favorable prior year development and higher expense ratios. Catastrophe losses were minimal for the three months ended March 31, 2026, compared to $67.9 million, or 10.9 percentage points on the combined ratio, for the three months ended March 31, 2025, primarily from the California wildfires. For the three months ended March 31, 2026, favorable prior year loss reserve development was $32.2 million primarily driven by favorable development in Credit, mainly from better than expected loss experience, as well as favorable development in A&H, due to lower than expected reported attritional losses, compared to $34.3 million for the three months ended March 31, 2025 primarily driven by favorable development in Property, mainly from reserve releases relating to prior year's catastrophe events, as well as favorable development in A&H, due to lower than expected reported attritional losses. The increased acquisition cost ratio primarily resulted from profit commission accruals related to prior year programs, and the increased other underwriting expense ratio is largely driven by timing items.

***Core Services Results***

Services revenues decreased to $54.0 million for the three months ended March 31, 2026 compared to $62.1 million for the three months ended March 31, 2025 primarily due to the deconsolidation of Armada in the fourth quarter of 2025, partially offset by growth in the IMG travel business and the acquisition of Assist America.

Net services income decreased to $8.4 million for the three months ended March 31, 2026 compared to $18.9 million during the three months ended March 31, 2025, also due to the deconsolidation of Armada, partially offset by growth in IMG and the acquisition of Assist America. Service margin, which is calculated as Net service fee income as a percentage of services revenues, increased to 14.6% for the three months ended March 31, 2026 from 13.8% for the three months ended March 31, 2025, when adjusted to exclude Armada, driven by the acquisition of Assist America.

**Insurance & Services Segment**

In our Insurance & Services segment, we underwrite primary insurance in several sectors globally. We offer innovative insurance solutions to meet the changing risk circumstances of our clients. The Insurance & Services segment includes A&H, Property & Casualty, and Other Specialties.

As of March 31, 2026, we have equity stakes in 16 entities (MGAs, Insurtech and Other), which underwrite or distribute a wide range of lines of business, including general liability, professional liability, directors & officers, credit and bond, cyber, commercial automobile, workers' compensation, accident & health, and other specialty insurance classes. As of March 31, 2026, we consolidated two MGAs in our financial statements: Alta Signa Holdings ("Alta Signa") and IMG. Effective November 1, 2025, we deconsolidated Armada upon the sale to Ambac Financial Group Inc. We will continue our underwriting capacity partnership with Armada until the end of 2030. We provide underwriting capacity in the form of insurance or reinsurance to 8 non-consolidated entities in addition to the two consolidated MGAs. We also have investment stakes in 6 other entities where we have no underwriting relationships. The investment interests in the non-consolidated entities are included in strategic investments within Other long-term investments on the consolidated balance sheet.

------

The following table sets forth underwriting results, net MGA results, and ratios for the segment results, and the period over period changes, for the three months ended March 31, 2026 and 2025:

---

| | | | |
|:---|:---|:---|:---|
| | **2026** | **2025** | **Change** |
| | **($ in millions)** | **($ in millions)** | **($ in millions)** |
| Gross written premium | $684.6 | $635.1 | $49.5 |
| Net written premium | 461.1 | 483.5 | (22.4) |
| Net earned premium | 380.1 | 336.2 | 43.9 |
| Loss and loss adjustment expenses incurred, net | 215.7 | 209.9 | 5.8 |
| Acquisition costs, net | 108.0 | 87.3 | 20.7 |
| Other underwriting expenses | 26.3 | 18.9 | 7.4 |
| **Underwriting income** | 30.1 | 20.1 | 10.0 |
| Services revenues | 54.0 | 62.1 | (8.1) |
| Services expenses | 46.1 | 43.1 | 3.0 |
| **Net services fee income** | 7.9 | 19.0 | (11.1) |
| Services noncontrolling (income) loss | 0.5 | (0.1) | 0.6 |
| **Net services income** | 8.4 | 18.9 | (10.5) |
| **Segment income** | $38.5 | $39.0 | $(0.5) |
| **Underwriting ratios:** <sup>(1)</sup> |  |  |  |
| Loss ratio | 56.7% | 62.4% | (5.7)% |
| Acquisition cost ratio | 28.4% | 26.0% | 2.4% |
| Other underwriting expense ratio | 6.9% | 5.6% | 1.3% |
| Combined ratio | 92.0% | 94.0% | (2.0)% |

---

(1)Underwriting ratios are calculated by dividing the related expense by net earned premium.

***Premium Volume***

Gross written premium increased by $49.5 million, or 7.8%, for the three months ended March 31, 2026 compared to the three months ended March 31, 2025, primarily driven by growth in A&H, General Liability, and Surety.

*Consolidated MGAs*

Gross written premium by the consolidated MGAs in the aggregate decreased by $37.1 million, or 38.4%, to $59.4 million for the three months ended March 31, 2026 compared to $96.5 million for the three months ended March 31, 2025, primarily resulting from the deconsolidation of Armada in the fourth quarter of 2025, partially offset by growth in IMG, including the acquisition of Assist America.

Book value for the consolidated MGAs was $106.4 million as of March 31, 2026, compared to $80.3 million as of December 31, 2025. The increase in book value from December 31, 2025 was a result of the acquisition of Assist America, which was effective as of January 1, 2026.

***Underwriting Results***

The improvement in underwriting income of $10.0 million for the three months ended March 31, 2026 compared to the three months ended March 31, 2025 was primarily driven by a lower attritional loss ratio and increased favorable prior year loss reserve development, partially offset by increased expense ratios. For the three months ended March 31, 2026, favorable prior year loss reserve development was $15.1 million compared to $2.5 million for the three months ended March 31, 2025, primarily driven by increases in A&H due to lower than expected reported attritional losses. The increased acquisition cost ratio primarily resulted from profit commission accruals related to prior year programs, and the increased other underwriting expense ratio is largely driven by timing items.

------

***Services Results***

The decreases in services revenues of $8.1 million and net services income of $10.5 million for the three months ended March 31, 2026 compared to the three months ended March 31, 2025 were primarily due to the deconsolidation of Armada in the fourth quarter of 2025, partially offset by growth in the IMG travel business and the acquisition of Assist America.

**Reinsurance Segment**

The Reinsurance segment predominantly underwrites Casualty, Property and Other Specialties lines of business on a worldwide basis. The following table sets forth underwriting results and ratios and the period over period changes for the Reinsurance segment for the three months ended March 31, 2026 and 2025:

---

| | | | |
|:---|:---|:---|:---|
| | **2026** | **2025** | **Change** |
| | **($ in millions)** | **($ in millions)** | **($ in millions)** |
| Gross written premium | $319.2 | $354.8 | $(35.6) |
| Net written premium | 235.7 | 268.5 | (32.8) |
| Net earned premium | 258.2 | 289.6 | (31.4) |
| Loss and loss adjustment expenses incurred, net | 134.0 | 195.3 | (61.3) |
| Acquisition costs, net | 63.8 | 67.1 | (3.3) |
| Other underwriting expenses | 19.6 | 18.8 | 0.8 |
| **Underwriting income** | $40.8 | $8.4 | $32.4 |
| **Underwriting ratios:** <sup>(1)</sup> |  |  |  |
| Loss ratio | 51.9% | 67.4% | (15.5)% |
| Acquisition cost ratio | 24.7% | 23.2% | 1.5% |
| Other underwriting expense ratio | 7.6% | 6.5% | 1.1% |
| Combined ratio | 84.2% | 97.1% | (12.9)% |

---

(1)Underwriting ratios are calculated by dividing the related expense by net earned premium.

***Premium Volume***

Gross written premium in the Reinsurance segment decreased by $35.6 million, or 10.0%, for the three months ended March 31, 2026 compared to the three months ended March 31, 2025, primarily driven by decreases in Property Catastrophe, Bermuda and London Specialty, and New York Casualty.

***Underwriting Results***

The increase in net underwriting income for the three months ended March 31, 2026 compared to the three months ended March 31, 2025 was primarily driven by the decrease in catastrophe losses and a lower attritional loss ratio, partially offset by decreased favorable prior year development. Catastrophe losses were minimal for the three months ended March 31, 2026, compared to $63.1 million, or 21.8 percentage points on the combined ratio, for the three months ended March 31, 2025, primarily from the California wildfires. Favorable prior year development was $17.1 million for the three months ended March 31, 2026, primarily in Credit due to better than expected loss experience, compared to $31.8 million for the three months ended March 31, 2025, primarily in Property due to reserve releases relating to prior year's catastrophe events.

**Corporate**

Corporate results include all run off business, which represents certain classes of business that we ceased underwriting as part of fundamental changes to our business strategy, including the effect of the restructuring of the underwriting platform announced in 2022 and certain reinsurance contracts that have interest crediting features. Corporate results also include asbestos and environmental and other latent liability exposures on a gross basis, which have mostly been ceded, as well as

------

specific workers' compensation and cyber programs which we no longer write. The following table sets forth underwriting results and the period over period changes for the three months ended March 31, 2026 and 2025:

---

| | | | |
|:---|:---|:---|:---|
| | **2026** | **2025** | **Change** |
| | **($ in millions)** | **($ in millions)** | **($ in millions)** |
| Gross written premium | $(0.9) | $(5.2) | $4.3 |
| Net written premium | (1.6) | (9.0) | 7.4 |
| Net earned premium | 0.6 | 0.9 | (0.3) |
| Loss and loss adjustment expenses incurred, net | 15.0 | (1.4) | 16.4 |
| Acquisition costs, net | (0.2) | 3.3 | (3.5) |
| Other underwriting expenses | 4.6 | 3.4 | 1.2 |
| **Underwriting loss** | $(18.8) | $(4.4) | $(14.4) |

---

Minimal premium volume for the three months ended March 31, 2026 reflects the expiration and non-renewal of the classes of business that we no longer actively underwrite. The increase in the underwriting loss for the three months ended March 31, 2026 compared the three months ended March 31, 2025 was driven by adverse prior year loss reserve development of $14.3 million primarily from one large claim settlement related to a claim that had previously been denied in a line of business that has not been written since 2023.

**Non-GAAP Financial Measures**

We have included certain financial measures that are not calculated under standards or rules that comprise U.S. GAAP. Such measures, including Core underwriting income, Core net services income, Core income, Core combined ratio, accident year loss ratio, accident year combined ratio, attritional loss ratio and tangible book value per diluted common share, are referred to as non-GAAP financial measures. These non-GAAP financial measures may be defined or calculated differently by other companies. We believe these measures allow for a more complete understanding of our underlying business. These measures are used by management to monitor our results and should not be viewed as a substitute for those determined in accordance with U.S. GAAP. Reconciliations of non-GAAP measures to the most comparable U.S. GAAP measures are included below.

***Core Results***

Collectively, the sum of the Company's two segments, Insurance & Services and Reinsurance, constitute "Core" results. Core underwriting income, Core net services income, Core income and Core combined ratio are non-GAAP financial measures. We believe it is useful to review Core results as it better reflects how management views the business and reflects our decision to exit the run off business. The sum of Core results and Corporate results are equal to the consolidated results of operations.

Core underwriting income - calculated by subtracting loss and loss adjustment expenses incurred, net, acquisition costs, net, and other underwriting expenses from net premiums earned.

Core net services income - consists of services revenues which include commissions, brokerage and fee income related to consolidated MGAs, and other revenues, as well as services expenses which include direct expenses related to consolidated MGAs and services noncontrolling income which represent minority ownership interests in consolidated MGAs. Net services income is a key indicator of the profitability of the Company's services provided.

Core income - consists of two components, core underwriting income and core net services income. Core income is a key measure of our segment performance.

Core combined ratio - calculated by dividing the sum of Core loss and loss adjustment expenses incurred, net, acquisition costs, net and other underwriting expenses by Core net premiums earned. Accident year loss ratio and accident year combined ratio are calculated by excluding prior year loss reserve development to present the impact of current accident year net loss and loss adjustment expenses on the Core loss ratio and Core combined ratio, respectively. Attritional loss ratio excludes catastrophe losses from the accident year loss ratio as they are not predictable as to timing and amount. These ratios are useful indicators of our underwriting profitability.

See Note 4 "Segment reporting" to our unaudited consolidated financial statements included elsewhere in this Form 10-Q for additional information and a calculation of Core results.

------

***Tangible Book Value Per Diluted Common Share***

Tangible book value per diluted common share, as presented, is a non-GAAP financial measure and the most directly comparable U.S. GAAP measure is book value per common share. Tangible book value per diluted common share excludes goodwill and intangible assets. Management believes that effects of goodwill and intangible assets are not indicative of underlying underwriting results or trends and make book value comparisons to less acquisitive peer companies less meaningful. Tangible book value per diluted common share is useful because it provides a more accurate measure of the realizable value of shareholder returns.

The following table sets forth the computation of book value per common share, book value per diluted common share and tangible book value per diluted common share as of March 31, 2026 and December 31, 2025:

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| | **($ in millions, except share and per share amounts)** | **($ in millions, except share and per share amounts)** |
| Common shareholders' equity attributable to SiriusPoint common shareholders | $2302.4 | $2269.8 |
| Intangible assets | 139.8 | 121.2 |
| Goodwill | 18.6 |  |
| Tangible common shareholders' equity attributable to SiriusPoint common shareholders | $2144.0 | $2148.6 |
| Common shares outstanding | 115936935 | 116989799 |
| Effect of dilutive stock options, restricted share units and warrants | 5065622 | 4983345 |
| Book value per diluted common share denominator | 121002557 | 121973144 |
| **Book value per common share** | $**19.86** | $**19.40** |
| **Book value per diluted common share** | $**19.03** | $**18.61** |
| **Tangible book value per diluted common share**  | $**17.72** | $**17.62** |

---

**Liquidity and Capital Resources** 

***Liquidity Requirements***

Liquidity is a measure of a company's ability to generate cash flows sufficient to meet short-term and long-term cash requirements of its business operations. SiriusPoint's insurance and reinsurance operations are subject to regulation and supervision in each of the jurisdictions where they are domiciled and licensed to conduct business. Generally, regulatory authorities have broad supervisory and administrative powers over such matters as licenses, standards of solvency, premium rates, policy forms, investments, security deposits, methods of accounting, form and content of financial statements, reserves for unpaid loss and loss adjustment expenses, reinsurance, minimum capital and surplus requirements, dividends and other distributions to shareholders, periodic examinations, and annual and other report filings. In general, such regulation is for the protection of policyholders rather than shareholders. SiriusPoint manages its liquidity needs primarily through the maintenance of a short duration and high quality fixed income portfolio.

SiriusPoint is a holding company and has no substantial operations of its own and its assets consist primarily of its investments in subsidiaries. Its cash needs primarily consist of the payment of corporate expenses, interest and principal payments on debt obligations and investment opportunities. SiriusPoint may also require cash to repurchase shares of our common stock pursuant to the share repurchase program or redeem other securities issued by us. For further details, see Note 14 "Shareholders' equity" in our unaudited consolidated financial statements included elsewhere in this Form 10-Q. Cash at the subsidiaries is used primarily to pay loss and loss adjustment expenses, reinsurance premiums, acquisition costs, interest expense, taxes, general and administrative expenses and to purchase investments. The insurance and reinsurance business of our operating subsidiaries inherently provide liquidity, as premiums are received in advance of the time losses are paid. However, the amount of cash required to fund loss payments can fluctuate significantly from period to period, due to the low frequency/high severity nature of certain types of business we write.

For additional commitments and contingencies that may affect our liquidity requirements see Note 17 "Commitments and contingencies" in our unaudited consolidated financial statements included elsewhere in this Form 10-Q.

------

***Dividend Capacity and Capital***

We are subject to regulations and other constraints that affect our ability to pay dividends. During the three months ended March 31, 2026, SiriusPoint paid dividends of $2.6 million to the Series B preference shareholders (2025 - $4.0 million). The Series B preference shares were fully redeemed on February 26, 2026. See Note 14 "Shareholders' equity" in our unaudited consolidated financial statements included elsewhere in this Form 10-Q for further discussion on the redemption. During the three months ended March 31, 2026, SiriusPoint did not pay any dividends to its common shareholders.

For the three months ended March 31, 2026, SiriusPoint did not receive distributions from SiriusPoint Bermuda Insurance Company Ltd. ("SiriusPoint Bermuda"), its immediate wholly-owned subsidiary (2025 - $425.0 million). We believe the dividend/distribution capacity of SiriusPoint's subsidiaries, which was approximately $694.7 million as of December 31, 2025, provides SiriusPoint with sufficient liquidity for the foreseeable future. For a further discussion of the various restrictions on SiriusPoint Bermuda's ability to pay dividends, see Part I, Item 1 "Business - Regulation" in our 2025 Form 10-K.

In addition to the regulatory and other contractual constraints to paying dividends, we manage the capital of the group and each of our operating subsidiaries to support our current ratings from AM Best, Fitch, S&P and Moody's. This could further reduce the ability and amount of dividends that could be paid from subsidiaries to SiriusPoint. In addition, the Company annually files the prescribed form of capital and solvency return, which comprises the insurer's Bermuda Solvency Capital Requirement ("BSCR") model. The BSCR model is a risk-based capital model which provides a method for determining a Class 3A and Class 4 insurer's capital requirements (statutory economic capital and surplus) by taking into account the risk characteristics of different aspects of the Class 3A and Class 4 insurer's business. We are currently completing our group BSCR for the year ended December 31, 2025, which must be filed with the BMA on or before May 31, 2026. Our estimated 2025 BSCR ratio is 256%. The Company is also currently completing its first quarter 2026 Bermuda Quarterly Financial Return, with an estimated ratio of 242%.

***Sources of Liquidity***

Our operating subsidiaries sources of liquidity have primarily consisted of net written premium, reinsurance recoveries, investment income and proceeds from sales of or dividends or distributions attributable to investments. Other potential sources of liquidity include borrowings under our credit facilities, the Federal Home Loan Bank of New York ("FHLBNY") advance program and issuances of securities.

Effective December 19, 2024, we entered into a four-year, $400.0 million senior unsecured revolving credit facility (the "Facility") with JPMorgan Chase Bank, N.A. as administrative agent. The Facility includes an option for the Company to request a 12-month extension, subject to satisfaction of certain conditions including, but not limited to, the consent of lenders representing a majority-in-interest of commitments, of the Facility maturity date. Subject to customary conditions precedent upon any borrowing request, the Facility provides access to loans for working capital and general corporate purposes, as well as letters of credit to support obligations under insurance and reinsurance agreements, retrocessional agreements and for general corporate purposes. As of March 31, 2026, the Company was in compliance with all of the covenants under the Facility and there were no outstanding borrowings under the Facility.

Effective September 2025, we became a member of the FHLBNY. As a member, we may borrow through the advance program of the FHLBNY. The FHLBNY advance program provides short- and long-term, fully collateralized loans, called advances, to their members. We have the ability to obtain this funding based on a percentage of the value of our admitted assets in the State of New York, subject to availability of eligible collateral. As of March 31, 2026, there were no outstanding FHLBNY borrowings.

***Financing***

We expect that our cash and cash equivalents on the balance sheet and cash flow from operations will provide us with the financial flexibility to execute our strategic objectives. Our ability to generate cash, however, is subject to our performance, general economic conditions, industry trends, and other factors. To the extent cash and cash equivalents on the balance sheet, investment returns and cash flow from operations are insufficient to fund our future activities and requirements, we may need to raise additional funds through public or private equity or debt financing. If we issue equity securities in order to raise additional funds, substantial dilution to existing shareholders may occur. If we raise cash through the issuance of additional indebtedness, we may be subject to additional contractual restrictions on our business. There is no assurance that we would be able to raise the additional funds on favorable terms or at all.

------

The following table represents a summary of our debt obligations as of March 31, 2026 and December 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** |
| | **Amount** | **Effective rate** <sup>(1)</sup> | **Amount** | **Effective rate** <sup>(1)</sup> |
| 2024 Senior Notes, at face value | $400.0 | 7.4% | $400.0 | 7.4% |
| &nbsp;&nbsp;&nbsp;Unamortized discount and issuance costs | (3.7) |  | (4.0) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2024 Senior Notes, carrying value | 396.3 |  | 396.0 |  |
| 2017 SEK Subordinated Notes, at face value | 288.7 | 6.1% | 298.2 | 7.1% |
| &nbsp;&nbsp;&nbsp;Unamortized discount | (5.4) |  | (5.6) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017 SEK Subordinated Notes, carrying value | 283.3 |  | 292.6 |  |
| Total debt | $679.6 |  | $688.6 |  |

---

(1)Effective rate considers the effect of the debt issuance costs, discount, and premium.

For further details and discussion with respect to the 2024 Senior Notes and 2017 SEK Subordinated Notes, please refer to Note 14 "Debt and letter of credit facilities" of Part II, Item 8. "Financial Statements and Supplementary Data" included in our 2025 Form 10-K.

*Debt Covenants*

As of March 31, 2026, we were in compliance with all of the covenants under the 2024 Senior Notes and the 2017 SEK Subordinated Notes.

***Letter of Credit Facilities***

As of March 31, 2026, letters of credit in the amount of $854.9 million had been issued by the Company to various insurance and reinsurance counterparties. Each of the facilities contain customary events of default and restrictive covenants, including but not limited to, limitations on liens on collateral, transactions with affiliates, mergers, and sales of assets, as well as solvency and maintenance of certain minimum pledged equity requirements and a minimum rating from rating agencies. Each restricts issuance of any debt without the consent of the letter of credit provider. Additionally, if an event of default exists under any of the letter of credit facilities, our subsidiaries could be prohibited from paying dividends. We were in compliance with all of the covenants under the aforementioned letter of credit facilities as of March 31, 2026.

For further details and discussion with respect to letter of credit facilities, see Note 12 "Debt and letter of credit facilities" in our unaudited consolidated financial statements included elsewhere in this Form 10-Q.

***Cash Secured Letter of Credit Agreements***

Under the cash secured letter of credit facilities, we provide collateral that consists of cash and cash equivalents and debt securities. As of March 31, 2026, total cash and cash equivalents and debt securities with a fair value of $959.6 million were pledged as collateral against the letters of credit issued.

We believe that we have adequate capacity between our existing cash secured letter of credit agreements as well as available investments to post in reinsurance trusts to meet our collateral obligations under our existing and future reinsurance business.

For further details and discussion with respect to cash secured letter of credit agreements, see Note 12 "Debt and letter of credit facilities" in our unaudited consolidated financial statements included elsewhere in this Form 10-Q.

***Cash, Restricted Cash and Cash Equivalents and Restricted Investments***

Cash and cash equivalents consist of cash held in banks and other short-term, highly liquid investments with original maturity dates of 90 days or less. We invest a portion of the collateral securing certain reinsurance contracts in U.S. treasury securities and sovereign debt. This portion of the collateral is included in debt securities in the consolidated balance sheets and is disclosed as part of restricted investments. In addition, restricted investments also pertain to limited partnership interests in Third Point funds securing the Company's contractual obligations under certain reinsurance contracts that the Company will not be released from until the underlying risks have expired or have been settled.

------

Restricted cash and cash equivalents and restricted investments decreased to $2.0 billion as of March 31, 2026 from $2.2 billion as of December 31, 2025. The decrease was primarily due to the release of collateral pledged against prior underwriting years' contracts.

For additional information on restricted cash, cash equivalents and investments, see Note 5 "Cash, cash equivalents, restricted cash and restricted investments" in our unaudited consolidated financial statements included elsewhere in this Form 10-Q.

***Cash Flows***

Our cash flows from operations generally represent the difference between: (1) premiums collected and investment income and (2) loss and loss expenses paid, reinsurance purchased, underwriting and other expenses paid. Cash flows from operations may differ substantially from net income and may be volatile from period to period depending on the underwriting opportunities available to us and other factors. Due to the nature of our underwriting portfolio, claim payments can be unpredictable and may need to be made within relatively short periods of time. Claim payments can also be required several months or years after premiums are collected. In addition, as discussed above, SiriusPoint has access to the $400.0 million Facility that provides access to loans for working capital and general corporate purposes, and letters of credit to support obligations under insurance and reinsurance agreements and retrocessional agreements.

Operating, investing, and financing cash flows for the three months ended March 31, 2026 and 2025 were as follows:

---

| | | |
|:---|:---|:---|
| | **2026** | **2025** |
| | **($ in millions)** | **($ in millions)** |
| Net cash provided by (used in) operating activities | $141.9 | $(88.9) |
| Net cash provided by investing activities | 189.0 | 610.9 |
| Net cash used in financing activities | (222.6) | (491.4) |
| Net increase in cash, cash equivalents and restricted cash | 108.3 | 30.6 |
| Cash, cash equivalents and restricted cash at beginning of period | 902.4 | 894.6 |
| Cash, cash equivalents and restricted cash at end of period | $1010.7 | $925.2 |

---

*Operating Activities* 

Cash flows provided by operating activities can fluctuate due to timing differences between the collection of premiums and reinsurance recoverable, the payment of losses and loss expenses, and the payment of premiums to reinsurers. The increase in cash flows provided by operating activities for the three months ended March 31, 2026 was primarily driven by an increase in the collection of premiums consistent with the underlying growth of the business, compared to cash flows used in operating activities for the three months ended March 31, 2025 primarily relating to payments for California wildfire claims.

*Investing Activities*

Cash flows provided by investing activities for the three months ended March 31, 2026 were driven by higher proceeds from sales and maturities of debt securities compared to purchases during the period, offset by cash flow used to complete the acquisition of Assist America. The decrease in cash flows provided by investing activities for the three months ended March 31, 2026 compared to the three months ended March 31, 2025 was driven by changes in our investment portfolio, primarily purchases and sales of fixed income and short-term investments.

*Financing Activities* 

Cash flows used in financing activities for the three months ended March 31, 2026 primarily consisted of a $203.9 million payment for the redemption of the Series B Preference share and $21.9 million in payments for share repurchases. Cash flows used in financing activities for the three months ended March 31, 2025 primarily consisted of $490.8 million in payments for share repurchases.

**Financial Condition** 

As of March 31, 2026, total shareholders' equity was $2,303.4 million, compared to $2,470.9 million as of December 31, 2025. The decrease was primarily driven by the redemption of the Series B preference shares of $203.9 million and the accumulated other comprehensive loss from unrealized losses from AFS debt securities of $57.3 million, partially offset by net income of $99.6 million for the three months ended March 31, 2026.

------

**Contractual Obligations**

There have been no material changes to our contractual obligations from our 2025 Form 10-K.

**Critical Accounting Policies and Estimates** 

For a summary of our significant accounting and reporting policies, please refer to Note 2 "Significant accounting policies" of Part II, Item 8. "Financial Statements and Supplementary Data" included in our 2025 Form 10-K.

Our consolidated financial statements are prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect the reported and disclosed amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and such differences could be material to the financial statements. As of December 31, 2025, the accounting policies that required the most significant judgments and estimations by management include, but are not limited to: (1) premium revenue recognition, (2) loss and loss adjustment expense reserves, (3) fair value measurements related to our investments and (4) income taxes. If actual events differ significantly from the underlying judgments or estimates used by management in the application of these accounting policies, there could be a material adverse effect on our results of operations and financial condition. Refer to Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations," included in our 2025 Form 10-K.

**ITEM 3. Quantitative and Qualitative Disclosures About Market Risk**

Our consolidated balance sheets include a substantial amount of assets and liabilities whose fair values are subject to market risk. The term market risk refers to the risk of loss arising from adverse changes in interest rates, credit spreads, equity markets prices, and other relevant market rates and prices. Due to our sizable investment portfolio, market risk can have a significant effect on our consolidated financial position.

We believe we are principally exposed to the following types of market risk:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ interest rate risk; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ foreign currency exchange risk.

***Interest Rate Risk***

Interest rate risk is the price sensitivity of a security to changes in interest rates. Our investment portfolio includes fixed income investments, whose fair values will fluctuate with changes in interest rates. Increases and decreases in prevailing interest rates generally translate into decreases and increases in fair values of fixed income investments, respectively. Additionally, fair values of interest rate sensitive instruments may be affected by the creditworthiness of the issuer, prepayment options, relative values of alternative investments, the liquidity of the instrument, and other market factors.

We manage the interest rate risk associated with our portfolio of fixed income investments by matching assets backing reserves with that of our economic liabilities, in addition to monitoring the average yield of investment-grade corporate securities; U.S. government and agency securities; foreign government, agency and provincial obligations; preferred stocks; asset-backed and mortgage-backed securities; and municipal obligations.

------

The following table summarizes the estimated effects of hypothetical increases and decreases in market interest rates on our debt securities as of March 31, 2026:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fair value** | **Assumed change in interest rate** | **Estimated fair value after change in interest rate** | **Pre-tax increase (decrease) in carrying value** |
| | **($ in millions)** | **($ in millions)** | **($ in millions)** | **($ in millions)** |
| Debt securities | $4978.9 | 300 bp decrease | $5397.0 | $418.1 |
|  |  | 200 bp decrease | 5256.1 | 277.2 |
|  |  | 100 bp decrease | 5115.3 | 136.4 |
|  |  | 50 bp decrease | 5044.8 | 65.9 |
|  |  | 50 bp increase | 4896.9 | (82.0) |
|  |  | 100 bp increase | 4818.6 | (160.3) |
|  |  | 200 bp increase | 4659.6 | (319.3) |
|  |  | 300 bp increase | 4497.5 | (481.4) |

---

The magnitude of the fair value decrease in rising rates scenarios may be more significant than the fair value increase in comparable falling rates scenarios. This can occur because (i) the analysis floors interest rates at a de minimis level in falling rate scenarios, muting price increases, (ii) portions of the fixed income investment portfolio may be callable, muting price increases in falling interest rate scenarios and/or (iii) portions of the fixed income investment portfolio may experience cash flow extension in higher interest rate environments, which generally results in lower fixed income asset prices.

Interest payments on our 2017 SEK Subordinated Notes are required to be serviced in Swedish kronor by reference to Stockholm Interbank Offered Rate, a floating interest rate benchmark. This benchmark rate has increased year to date and it is possible that it will continue to do so, which could result in increasing our interest expense in U.S. dollars.

***Foreign Currency Exchange Risk***

In the ordinary course of business, we hold non-U.S. dollar denominated assets and liabilities, which are valued using period-end exchange rates. Non-U.S. dollar denominated foreign revenues and expenses are valued using average exchange rates over the period. Foreign currency exchange-rate risk is the risk that we will incur losses on a U.S. dollar basis due to adverse changes in foreign currency exchange rates. We aim to mitigate foreign currency exchange risk through the use of foreign currency forwards. Refer to Note 8 "Derivatives" to our unaudited consolidated financial statements included elsewhere in this Form 10-Q for additional information on foreign currency hedging.

The following table, presented net of currency hedges, summarizes the estimated effects of a hypothetical 10% increase and decrease in the value of the U.S. dollar against select foreign currencies would have had on the carrying value of our net assets as of March 31, 2026:

---

| | | |
|:---|:---|:---|
| | **10% increase** | **10% decrease** |
| | **($ in millions)** | **($ in millions)** |
| Swedish Krona to U.S. Dollar | $(3.9) | $3.9 |
| British Pound to U.S. Dollar | (2.7) | 2.7 |
| Swiss Franc to U.S. dollar | (0.4) | 0.4 |
| Euro to U.S. Dollar | (0.3) | 0.3 |
| Canadian Dollar to U.S. Dollar | $(0.2) | $0.2 |

---

**ITEM 4. Controls and Procedures**

**Evaluation of Disclosure Controls and Procedures**

Management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended) as of March 31, 2026. Based upon this evaluation, our Chief Executive

------

Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of March 31, 2026.

**Changes in Internal Control Over Financial Reporting**

There have been no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and Rule 15d-15(f) under the Exchange Act) that occurred during the three months ended March 31, 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**PART II - Other Information**

**ITEM 1. Legal Proceedings**

The Company and its subsidiaries are subject to lawsuits and regulatory actions in the normal course of business that do not arise from or directly relate to claims on reinsurance treaties or contracts or direct surplus lines insurance policies. In the Company's industry, business litigation may involve allegations of underwriting or claims-handling errors or misconduct, disputes relating to the scope of, or compliance with, the terms of delegated underwriting agreements, employment claims, regulatory actions, or disputes arising from the Company's business ventures. The Company's operating subsidiaries are subject to claims litigation involving, among other things, disputed interpretations of policy coverages. Generally, the Company's direct insurance operations are subject to greater frequency and diversity of claims and claims-related litigation than its reinsurance operations and, in some jurisdictions, may be subject to direct actions by allegedly injured persons or entities seeking damages from policyholders. These lawsuits, which involve or arise out of claims on policies issued by the Company's subsidiaries, are typical to the insurance industry in general and in the normal course of our business. These claims are considered in the Company's loss and loss expense reserves. In addition, the Company may from time to time engage in litigation or arbitration related to its claims for payment in respect of ceded reinsurance, including disputes that challenge the Company's ability to enforce its underwriting intent. Such matters could result, directly or indirectly, in providers of protection not meeting their obligations to the Company or not doing so on a timely basis. The Company may also be subject to other disputes from time to time relating to operational or other matters distinct from insurance or reinsurance claims. Any litigation or arbitration, or regulatory process, contains an element of uncertainty, and the value of an exposure or a gain contingency related to a dispute is difficult to estimate. The Company believes that no individual litigation or arbitration to which it is presently a party is likely to have a material adverse effect on its results of operations, financial condition, business, or operations.

**ITEM 1A. Risk Factors** &nbsp;&nbsp;&nbsp;&nbsp;

Our business is subject to a number of risks, including those described in the Company's risk factors disclosed in Part I, Item 1A of our 2025 Form 10-K, that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, cash flows and results of operations. There have been no material changes to the risk factors disclosed in our 2025 Form 10-K.

------

**ITEM 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities**

Under the share repurchase program, the Company may repurchase its common stock from time to time, in amounts, at prices and at times the Company deems appropriate in its sole discretion, subject to market conditions and a variety of factors, including legal requirements, price and economic conditions. Shares of common stock may be repurchased in open market purchases, privately negotiated transactions or otherwise. The Company expects that the program will be in effect until the maximum approved dollar amount has been used. The program does not require the Company to repurchase any specific number of shares of common stock, and the program may be suspended, modified or discontinued at any time.

The following table summarizes our repurchase of common shares during the three months ended March 31, 2026:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **(a) Total number of shares purchased** | **(b) Average price paid per share (1)** | **(c) Total number of shares purchased as part of publicly announced plans or programs** | **(d) Maximum $ value of shares that may yet be purchased under the plans or programs (2)** |
| January 1, 2026 - January 31, 2026 |  | $— |  | $174309722 |
| February 1, 2026 - February 28, 2026 | 31800 | 21.23 | 31800 | 173634656 |
| March 1, 2026 - March 31, 2026 | 1020810 | 20.76 | 1020810 | 152440349 |
| Total | 1052610 | $20.78 | 1052610 | $152440349 |

---

(1)Including commissions.

(2)Maximum value of common shares that may yet be purchased under the share repurchase programs previously authorized on May 4, 2016, February 28, 2018, and July 31, 2024.

**ITEM 3. Defaults Upon Senior Securities**

None.

**ITEM 4. Mine Safety Disclosures**

Not applicable.

**ITEM 5. Other Information**

During the three months ended March 31, 2026, none of the Company's directors or officers adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K of the Securities Act of 1933, as amended).

------

**ITEM 6. Exhibits** 

---

| | |
|:---|:---|
| 10.1\* | <u>[Settlement Agreement, dated March 17, 2026 (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on March 23, 2026)](https://www.sec.gov/Archives/edgar/data/1576018/000157601826000041/rgsettlementagreement17m.htm)</u> |
| 10.2\* | <u>[Employment Letter, dated July 11, 2023, with Thomas C. Leonardo](employmentletterdatedjuly1.htm)</u> |
| 10.3\* | <u>[Employment Letter, dated December 8, 2025, with Patrick J. Charles](employmentletterdateddecem.htm)</u> |
| 31.1 | <u>[Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](exhibit31133126.htm)</u> |
| 31.2 | <u>[Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](exhibit31233126.htm)</u> |
| 32.1\*\* | <u>[Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](exhibit32133126.htm)</u> |
| 32.2\*\* | <u>[Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](exhibit32233126.htm)</u> |
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Labels Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL with applicable taxonomy extension information contained in Exhibits 101) |

---

\*&nbsp;&nbsp;&nbsp;&nbsp;Management contracts or compensatory plans or arrangements.

\*\*&nbsp;&nbsp;&nbsp;&nbsp;This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

------

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
| | SiriusPoint Ltd. |
| Date: May 7, 2026 | |
| | /s/ Scott Egan |
| | Scott Egan |
| | Chief Executive Officer |
| | (Principal Executive Officer) |
| | /s/ Jim McKinney |
| | Jim McKinney |
| | Chief Financial Officer |
| | (Principal Financial Officer and Principal Accounting Officer) |

---

## Exhibit 10.2

December 8, 2025 Patrick Charles

Patrick.Charles@siriuspt.com

Dear Patrick,

As a critical member of our team, I am pleased to recognize your ongoing contributions and growth in the role by making the following changes to your employment at SiriusPoint (the "Company"). Provided you sign and return this letter, these changes will be effective January 1, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Position and Duties. Though you will remain in your current role, I am minded to increase your responsibilities in 2026 as we discussed. These changes to your terms and conditions reflect my intention to increase your responsibilities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Base Salary. Effective January 1, 2026, you will be paid a base salary at an annual rate of $535,000, payable in accordance with the normal payroll practices of the Company and subject to all withholdings and deductions. Your base salary will next be reviewed in 2027.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Annual Bonus. You will continue to be eligible to receive a performance-based cash bonus with a target of 100% of your new base salary, subject to generally applicable threshold and maximum levels set by the Company as to individual and corporate performance goals. Payment of the annual bonus will generally occur in the first quarter of the year following the Performance Year, provided you are still an active employee of the Company on the day that the annual bonus is paid. Your 2025 annual bonus will be based on your current annual base salary rate of $477,000.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Long -Term Incentive Awards. You will be eligible to participate in the Company's long-term incentive ("LTI") program with other members of senior management of the Company. Your annual LTI award will have an annual target grant value equal to 175% of your new base salary from 1 January 2026. Your LTI award will be calculated in the same manner as awards granted to other LTI award recipients and will be granted at the same time as awards are granted to other participants in the LTI program and will be subject to the terms set forth in the applicable equity plans and related implementing award agreements and award notices. The above LTI will be granted in Q2 2026.

Except as noted above, all other terms and conditions of your employment remain unchanged including, but not limited to, your status as an at will employee of the Company.

<u>/s/ Scott Egan</u>

Scott Egan

Chief Executive Officer, SiriusPoint

If you have any questions, please let me know. Sincerely,

One WTC, 285 Fulton Street, Suite 47J, New York, NY 10007. T: +1212 312 2500 W: www.siriuspt.com

------

**<u>Acceptance of Offer</u>**

I have read, understood and accept all the terms of the offer of employment as set forth above.

/s/ Patrick Charles&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;January 10, 2026

**Employee Signature&nbsp;&nbsp;&nbsp;&nbsp;Date**

One WTC, 285 Fulton Street, Suite 47J, New York, NY 10007. T: +1212 312 2500 W: www.siriuspt.com

------

***<u>Via Email</u>***

Patrick Charles [Redacted Address]

Dear Patrick:

In recognition of the work you have performed and continue to perform for SiriusPoint (the "Company'') and to provide you comfort and assurances as the Company has and continues to go through a period of change, the Company is offering you the Severance Benefits described in this Letter. For purposes of this Letter, you will be referred to as the ''Executive".

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.<u>Defined Terms.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1<u>''Base Pay"</u> means Executive's annual rate of base salary in effect immediately prior to the Termination Date. Base Pay shall be determined without regard to overtime, bonuses or other supplemental compensation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2<u>"Cause</u><u>"</u> has the meaning set forth in any applicable employment or other similar written agreement between Executive and the Company. If there is no such written agreement or if such agreement does not define "Cause," then "Cause" shall mean (i) a material and continued failure of Executive to perform Executive's duties which failure has continued for more than thirty (30) days following written notice of such nonperformance from the Company; (ii) conviction of or pleading guilty or no contest to an act of fraud, embezzlement, or misappropriation of assets or property (tangible or intangible) of the Company thereof; (iii) a material breach of any restrictive covenant or other written agreement Executive is subject to as a Company employee; (iv) commission of a felony, including a plea of guilty or nolo contendere, or an indictment or written admission thereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) gross negligence or willful misconduct in the performance of Executive's duties that is reasonably likely to have an adverse effect on the business, reputation or financial condition of the Company; or (vi) Executive's material violation of one or more Company policies.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3<u>"Good Reason"</u> has the meaning set forth in any applicable employment or other similar written agreement between Executive and the Company. If there is no such written

------

agreement or if such agreement does not define "Good Reason", then "Good Reason" shall mean (1) a material change, by the Company, in Executive's office location or place of work of at least one hundred (100) miles or (2) a material reduction of at least ten percent (10%) of Executive's total annual compensation opportunity (base salary + short term incentive target + long term incentive target). Executive may terminate employment on account of Good Reason only if: (a) Executive provides the Company with written notice of the event(s) alleged to constitute Good Reason within sixty (60) days of the date the event(s) first arose, (b) the written notice sets forth in reasonable detail the event(s) giving rise to Good Reason, and (c) the Company fails to cure such event(s) within thirty (30) days after the receipt of such notice (the <u>"Cure Period").</u> Executive must terminate employment within thirty (30) days after the expiration of the Cure Period in order for the termination to be on account of Good Reason.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4<u>"Termination Date</u><u>"</u> means the date upon which Executive ceases to be employed by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.**<u>Severance Benefits.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1Provided Executive's Employment is terminated without Cause or Executive terminates his or her employment for Good Reason, Executive will be entitled to the following Severance Benefits:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Cash severance equal to fifty-two (52) weeks of Executive's Base Pay paid in a single a lump sum.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)If the Termination Date is on or after April 1<sup>st</sup> of the year that includes the Termination Date, a pro-rata portion of Executive's annual cash bonus under the Company's then current short-term incentive plan paid at target in a lump sum and prorated based on the number of days worked in the relevant year through Executive's Termination Date. For the avoidance of doubt, if the Termination Date is before April 1<sup>st</sup> of the year that includes the Termination Date, Executive will be ineligible to receive their annual cash bonus (pro-rated or otherwise) for the year that includes the Termination Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)If the Termination Date occurs between January 1<sup>st</sup> and March 31<sup>st</sup> and as of the Termination Date, Executive has not received his or her annual cash bonus under the Company's then current short-term incentive plan for the year prior to the year that includes the Termination Date, Executive will remain eligible to receive this cash bonus which will be calculated based on the Company's actual performance against the financial targets that were established for that particular plan year, but

------

any applicable individual performance modifiers or metrics will be removed from the bonus calculation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)If, as of the Termination Date, Executive has any outstanding and unpaid cash sign-on or retention awards then, provided Executive has otherwise been in compliance the terms of any agreement(s) governing such sign-on or retention award(s), this or these cash awards will be paid in full in a lump sum.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)Executive's health and welfare benefits will be subject to the following treatment:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)For a U.S. based Executive, fifty-two (52) weeks of Executive's COBRA costs paid in a lump sum and calculated based on the difference between the active and inactive employee rate for the COBRA eligible benefits Executive has elected as of the date he or she is notified that they are being terminated without Cause or the date when Executive resigns for Good Reason; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)For an Executive based outside the U.S., continuation of the health and welfare benefits Executive has elected, as of the date s/he is notified that they are being terminated without Cause or the date when Executive resigns for Good Reason, for a period of fifty-two (52) consecutive weeks following the Termination Date or if such benefits cannot collectively be continued or maintained on Executive's behalf following the Termination Date, the costs the Company would incur to maintain such benefits for an additional fifty-two (52) weeks if Executive had remained employed with the Company, which will be calculated based on Executive's benefit elections as of the date s/he is notified that they are being terminated without Cause or the date when Executive resigns for Good Reason and paid in a lump sum.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)To the extent Executive has any equity grants, these grants will vest and forfeit as set forth below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)For purposes of any equity awards Executive has received, including any awards of restricted stock units (''RSUs"), restricted stock awards ("RSAs"), performance stock units ("PSUs"), and options, other than as set forth below, these awards will continue to vest and forfeit consist with the controlling plan document(s), grant agreement(s), and/or grant notice(s) (or other similar documents, plans, or agreements) through the Termination Date.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)For purposes of any grants of RSUs or RSAs with time-based vesting Executive received at or within sixty (60) days of his or her hire date as a sign-on, or other similar, award and not as part of the Company's annual grant cycle of RSUs or RSAs, this or these grant(s) of RSUs or RSAs will vest in full as of the Termination Date and, unless a different delivery timeline is required by applicable law, be delivered within thirty (30) days of the effective date of the severance and general release agreement (or other similar agreement), described below, Executive will be required to sign.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)Other than as potentially amended above, the terms of any plan document(s), grant agreement(s), and/or grant notice(s) that apply to any equity awards Executive received, including any awards of RSUs, RSAs, PSUs, or options, remain in full force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2The severance payments and benefits described in Section 2.1 (a) through (f) will collectively be referred to as the "Severance Benefits."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3In order to be eligible to receive the Severance Benefits, Executive will be required to execute and not revoke (if applicable) a severance and general release agreement (or other similar agreement) with and satisfactory to the Company. The terms and details of any potential severance and general release agreement (or other similar agreement) which will include, among other things, the timeline(s) to receive the Severance Benefits, will be provided to Executive by the Company closer to Executive's potential Termination Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4To the extent that Executive receives (1) statutory or other legally required severance pay from the Company in connection with the termination of Executive's employment (except unemployment benefits payable in the U.S. in accordance with state law and payment for accrued but unused vacation) or (2) payment in lieu of any statutory or contractual notice period, the fifty-two (52) weeks of cash Severance Benefits under this Letter will be correspondingly reduced on a dollar-for dollar-basis.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.<u>Other Rules Relating to Severance Benefits.</u>** No right or benefit provided in this Letter will be transferable by Executive. No right or benefit under this Letter will be subject to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, attachment, or garnishment by creditors of the Executive or the Executive's estate. Any attempts to anticipate, alienate, sell, assign, pledge, encumber, or charge the same will be void.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.<u>Successors and Assigns.</u>** This Letter shall inure to the benefit of, and shall be binding upon, the Company and its successors and assigns, including any successor entity by merger, consolidation or transfer of all or substantially all of the Company's assets. The Company shall require and cause any person, group or entity that acquires all or

------

substantially all of the assets of the Company to accept and be bound by the terms of this Letter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.<u>Miscellaneous Provisions.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1<u>Governing Law.</u> For a U.S. based Executive, this Letter shall be construed in accordance with and governed by the laws of the state of New York. For Executives based outside the U.S., this Letter shall be constructed in accordance with and governed by the laws of the country and/or jurisdiction where Executive is employed by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*5.2*<u>Entire Agreement.</u> This Letter constitutes the entire agreement and understanding between Executive and Company concerning Executive's severance rights and supersedes all prior negotiations, understandings, or agreements between the parties, whether written or oral, concerning such matters.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3<u>Employment at Will.</u> To the extent Executive is a U.S. based employee, Executive's employment with the Company shall remain and continue to be at will. Nothing in this Letter shall provide Executive with any right to continued employment with the Company for any specific period of time or interfere with or restrict the right of either Executive or the Company to terminate Executive's employment with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4<u>Waiver: Amendment.</u> No waiver of any breach of this Letter shall be construed to be a waiver of any other breach of this Letter. No waiver or amendment of this Letter shall be effective unless set forth in a written document signed by Executive and an authorized representative of the Company.

We hope the Severance Benefits described in this Letter provide you with security and peace of mind as the Company continues to go through a period of change.

***Dan Malloy***

Dan Malloy

/s/ Dan Malloy

Chief Executive Officer SiriusPoint

Patrick Charles

Date: August 15, 2022

## Exhibit 10.3

July 11, 2023

Tom Leonardo [Redacted Address]

Dear Tom,

As a critical member of our team, we are pleased to recognize your ongoing contributions and expanded responsibilities by making the following changes to your employment at Sirius America Insurance Company (the "Company"). Provided you sign and return this letter, these changes will be effective July 13, 2023 (the "Effective Date").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Position and Duties.** Your title will be Global Head of Accident & Health and in this role, you will perform such duties, services, and responsibilities as may be reasonably assigned to you. You will report directly to Scott Egan, Chief Executive Officer, SiriusPoint Ltd.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Base Salary.** You will be paid a base salary at an annual rate of $550,000, payable in accordance with the normal payroll practices of the Company and subject to all withholdings and deductions. As this is an exempt position, you are not eligible for overtime pay.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Annual Bonus.** You will be eligible to receive a performance-based cash bonus with a target of 100% of your base salary, subject to generally applicable threshold and maximum levels set by the Company as to individual and corporate performance goals. Payment of the annual bonus will generally occur in the first quarter of the year following the Performance Year, provided you are still an active employee of the Company on the day that the annual bonus is paid.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Long-Term Incentive Awards.** You will be eligible to participate in the Company's long-term incentive ("LTI") program with other members of senior management of the Company. Your annual LTI award will have an annual target grant value equal to 175% of your base salary. Your LTI award will be calculated in the same manner as awards granted to other LTI award recipients and will be granted at the same time as awards are grated to other participants in the LTI program and will be subject to the terms set forth in the applicable equity plans and related implementing award agreements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Make Whole LTI Award.** Within sixty (60) days of the Effective Date, you will be granted a mix of (25%) RSUs and (75%) PSUs of SiriusPoint Ltd. with a grant date value of $492,047 USD (the "Make Whole LTI") which will be subject to the Plan, and related implementing award agreements (collectively, the "LTI Grant Documents"). The LTI Grant Documents will be separately provided on terms that are consistent with this Agreement. The Make Whole LTI will vest ratably in three equal instalments on each anniversary of the grant date, subject to your continued employment through each of the vesting dates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Incentive (Sign-On) LTI Award.** Within sixty (60) days of the Effective Date, you will be granted RSUs of SiriusPoint Ltd. with a grant date value of $500,000 USD which, subject to the Plan and the LTI Grant Documents, will vest ratably on the first and second anniversaries of the grant date, subject to your continued employment through each of the vesting dates. The LTI Grant Documents will be separately provided on terms that are consistent with this Agreement.

------

Except as noted above, all other terms and conditions of your employment remain unchanged including, but not limited to, your status as an at will employee of the Company as well as your participation in the 2018 Severance and Change in Control Plan.

On behalf of SiriusPoint, I want to thank you for your continued service and look forward to your continued positive contributions.

If you have any questions about this letter, please reach out to me at any time. Sincerely,

/s/ Karen Caddick

**Karen Caddick**

Chief Human Resources Officer SiriusPoint Ltd.

**<u>Acceptance of Offer</u>**

I have read, understood and accept all the terms of the offer of employment as set forth above.

/s/ Tom Leonardo

Tom Leonardo

17 July 2023 \| 7:38 AM PDT

**&nbsp;&nbsp;&nbsp;&nbsp;Date**

------

Note: The Employment Letter, dated July 11, 2023, with Mr. Leonardo provides that, except as expressly set forth therein, all other terms and conditions of Mr. Leonardo's employment remain in effect. For reference, attached are the Sirius Group Severance and Change in Control Plan Participation Agreement, dated June 4, 2020, together with the Restrictive Covenant Agreement attached thereto and incorporated therein by reference as Exhibit A, and the Sirius Group Severance and Change in Control Plan, effective as of September 10, 2018.

------

**SIRIUS GROUP SEVERANCE AND CHANGE IN CONTROL PLAN PARTICIPATION AGREEMENT**

This Participation Agreement (this "<u>Agreement</u>") is entered into as of June 4, 2020 between Sirius International Insurance Group, Ltd., (the "<u>Company</u>") its successors and assigns, and Thomas Leonardo (the "<u>Executive</u>").

**WHEREAS**, the Company's Board of Directors has adopted the Sirius Group Severance and Change in Control Plan, effective as of September 10, 2018 (the "<u>Plan</u>"), to provide certain benefits to Participants upon a qualifying termination of Employment, as contemplated under the Plan;

**WHEREAS**, the Plan Administrator has decided to offer the Executive the opportunity to participate in the Plan, subject to the terms of this Agreement;

**WHEREAS**, as a condition of eligibility to participate in the Plan, the Executive must agree to be bound by the Restrictive Covenant Agreement (attached hereto as **<u>Exhibit A</u>**) and the Executive agrees that participation in the Plan is good and valuable consideration for being subject to the restrictive covenants contemplated in the Restrictive Covenant Agreement; and

**WHEREAS**, the Executive acknowledges that the Executive has carefully reviewed the Plan and this Agreement, and the Restrictive Covenant Agreement and has decided that the Executive wishes to enter into it on the terms and conditions set forth herein.

**NOW, THEREFORE**, in consideration of the mutual covenants, promises and obligations set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Executive agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.<u>Plan</u>. The terms of the Plan are specifically incorporated herein as a part of this Agreement, and this Agreement shall be a part of and governed by the terms of the Plan, as amended from time to time subject to the limitations on amendment and termination in <u>Section</u> <u>8(l)</u> of the Plan. The Executive is an intended third-party beneficiary of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.<u>Participation Subject to Acceptance and Entry into</u> **<u>t</u>**<u>he Restrictive Covenant</u> <u>Agreement.</u> This Agreement shall be null and void unless (i) the Executive agrees to be bound by and executes this Agreement and returns it to the Company on or before June 15, 2020 (the '<u>Execution Deadline'</u>) and (ii) the Executive agrees to be bound by and executes the Restrictive Covenant Agreement attached hereto as **<u>Exhibit A</u>** on or before the Execution Deadline.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.<u>Definitions</u>. The capitalized terms used, but not defined in this Agreement shall have the meaning set forth in the Plan. For purposes of this Agreement and the Plan, the following terms shall have the meaning set forth below:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)"<u>CIC Severance Multiple</u>" shall mean 2.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)"<u>Severance Period</u>" shall mean 1 year, which shall begin on the first day following the Termination Date.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.<u>Term</u>. Except as provided under <u>Section 8(i)</u> of the Plan, this Agreement shall terminate upon the earliest of (i) the date of termination of the Executive's Employment by the Company if no benefits are payable under the Plan; (ii) the date the Company satisfies its obligation, if any, to make payments and provide benefits to the Executive pursuant to the Plan; and (iii) the termination of the Plan in accordance with <u>Section 8(l)</u> of the Plan prior to the date the Executive terminates Employment with the Company. Notwithstanding the foregoing, the Restrictive Covenant Agreement shall survive the terms of the Plan and this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.<u>Counterparts</u>. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.<u>Adequacy of Consideration</u>. The Executive acknowledges and agrees that the severance benefits to which the Executive may be eligible under the Plan is good and valuable consideration for being subject to the terms of the Plan, as well as other consideration contemplated in the Restrictive Covenant Agreement, this Agreement and the restrictive covenants contemplated in the Restrictive Covenant Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.<u>Complete Agreement</u>. Except as provided under Section 8(i) of the Plan, this Agreement, the Restrictive Covenant Agreement and the Plan constitute the complete agreement between the Executive and the Company concerning the subject matter therein and they supersede and replace in its entirety any prior written or oral understandings entered into between the Executive and the Company. Notwithstanding the foregoing, to the extent the Executive was subject to restrictive covenants prior to the execution of this Agreement, such restrictive covenants shall continue to remain in full force and effect with respect to any conduct or actions prior to the execution of this Agreement.

------

**IN WITNESS WHEREOF**, the parties have executed this Agreement as of the 4<sup>th</sup> day of June, 2020.

**SIRIUS INTERNATIONAL INSURANCE GROUP, LTD.**

/s/ Gene Boxer By: <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> Name: <u>Gene Boxer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> Title: <u>Executive Vice President, Chief Strategy</u> <u>Officer & Group General Counsel&nbsp;&nbsp;&nbsp;&nbsp;</u>

**EXECUTIVE**

Name: Thomas Leonardo

------

**EXHIBIT A**

See Restrictive Covenant Agreement Attached

------

**RESTRICTIVE COVENANT AGREEMENT**

This Restrictive Covenant Agreement (this "<u>Agreement</u>") is entered into as of June 4, 2020 between Sirius International Insurance Group, Ltd., (the "<u>Company</u>") its successors and assigns, and Thomas Leonardo (the "<u>Executive</u>").

**WHEREAS**, as a condition of the Executive's participation in the Sirius Group Severance and Change in Control Plan, as evidenced by the Participation Agreement between the Company and the Executive dated as of June 4, 2020, and the Executive's receipt of severance-related benefits under the equity compensation awards granted under the Sirius Group 2018 Omnibus Incentive Plan (collectively, the "<u>Additional Compensation</u>"), the Executive has agreed to the terms of this Agreement;

**WHEREAS**, the Executive acknowledges that in the course of the Executive's employment with the Company or one of its affiliates (the "<u>Company Group</u>"), the Executive has and will become familiar with Confidential Information (as defined below) and have access to other valuable and unique information or persons concerning the Company Group and that the Executive's services will be of special, unique and extraordinary value to the Company Group; and

**WHEREAS**, the Executive acknowledges that the Executive has carefully reviewed the agreements governing the Additional Compensation and this Agreement and has decided that the Executive wishes to enter into it on the terms and conditions set forth herein.

**NOW, THEREFORE**, in consideration of the mutual promises and agreements contained herein, the Additional Compensation and the overall employment relationship between the Company and the Executive, the adequacy and sufficiency of which are hereby acknowledged, and in order to avoid irreparable harm to the Company Group, the Company and the Executive hereby agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>1. A</u><u>ccess to Confidential Information</u>. The Executive acknowledges that the Executive is employed by a member of the Company Group in a capacity in which the Executive will be provided the opportunity (and access) to develop and/or contribute to the Company Group's customers, Confidential Information (as defined herein), and the Company Group's goodwill, and the Executive and the Company mutually desire to provide for the protection of the Company's business, goodwill, trade secrets, Confidential Information, customer relationships and other legitimate business interests. Accordingly, in consideration of the overall employment relationship between the Company and the Executive, the Executive's eligibility for the Additional Compensation, the Company's agreement to provide the Executive with access to Confidential Information, the Company's customers and goodwill, and other good and valuable consideration, the sufficiency of which is hereby acknowledged, the Executive agrees that the foregoing is more than adequate consideration for the below restrictive covenants.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>2. Non-Competition</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.The Executive agrees that while employed with a member of the Company Group and for a period of **6 months** following the termination of such employment (such period, the "<u>Restriction Period</u>"), the Executive shall not directly or indirectly, own any interest in, manage, control, finance, participate in, consult with, or render any services to any activity or business, on the Executive's behalf or for any other person or entity, or affiliate, whether or not for remuneration (be such remuneration direct or indirect, contingent or otherwise), which (i) may result in a conflict of interest or otherwise adversely affect the proper discharge of the Executive's duties with and responsibilities to the Company or (ii) competes (in a line of business within the Executive's scope of authority or responsibilities) with, or interferes with the operation of, the Company Group, <u>provided</u>, <u>however</u>, that this provision shall not prohibit the Executive from being a passive owner of not more that 1% of the outstanding stock of any company that is publicly traded as long as the Executive has no active participation in the business of such company. Any provision of this Agreement to the contrary notwithstanding, it shall not be a violation of this <u>Section 2</u> for the Executive to provide services to a subsidiary, division or affiliate of a business that competes with the Company Group, <u>provided</u> <u>that,</u> such subsidiary, division or affiliate is not itself engaged, directly or indirectly, in competition with the Company one of its subsidiaries and the Executive does not, directly or indirectly, provide services to, or have responsibilities regarding, such business that competes with the Company Group.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.In any case where the Executive is not entitled to any severance benefits pursuant to the Sirius Group Severance and Change in Control Plan (the "<u>Severance Plan</u>"), as evidenced by the Participation Agreement between the Company and the Executive, then, subject to the exceptions stated below in <u>Section 2(d) below</u>, if the Company seeks to enforce the non-compete restrictive covenant set forth in <u>Section 2(a)</u> above, the Company shall, as compensation for the non-compete restrictive covenant as set forth above, (i) continue to pay to the Executive during the Restriction Period an amount equal to the Executive's base salary as in effect prior to the termination of the Executive's employment, reduced by the compensation (based on the total annual fixed and target compensation) which the Executive earns during the Restriction Period ("<u>New Monthly Compensation</u>") and (ii) if the Executive timely and properly elects health continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended ("<u>COBRA</u>"), reimburse the Executive for the difference between the monthly COBRA premium paid by the Participant during the Restriction Period, including any administrative fee, and the monthly premium paid by similarly situated active employees, which reimbursements shall be paid by the 10th of the month immediately following the month in which the Executive remits the premium payment. Additional Monthly Compensation shall not be paid in the event of the Executive's breach of the non-competition restrictive covenant in <u>Section 2(a)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.In any case where <u>Section 2(b)</u> applies, after the termination of employment, the Executive is required to inform the Company in writing of the level of the Executive's New Monthly Compensation. Such written information shall be provided to the Company no later than on the 15th day of each month. In the event such written information is not provided in accordance with this <u>Section 2(b)</u>, it shall be understood that the Executive has not suffered any loss of income with regards to the concerned month, but <u>Section 2(a)</u> shall still apply.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.In any case where <u>Section 2(b)</u> applies, compensation according to <u>Section 2(b)</u> shall not be paid if the employment expires (i) due to the Executive's death, disability or retirement or (ii) due to the termination of the Executive's employment for Cause, as defined in the Severance Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e.In any case where <u>Section 2(b)</u> applies, the Company may after the Executive's termination of employment and throughout the Restriction Period at any time unilaterally either limit the application of the non-competition restrictive covenant or completely release the Executive from the non-competition restrictive covenant. In the event of a full release from the non-competition restrictive covenant, the Company shall be released from the obligation to pay Additional Monthly Compensation in accordance with <u>Section 2(b)</u> above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>3. N</u><u>on-Solicitation</u>. The Executive further agrees that, during the Restriction Period, the Executive shall not directly or indirectly, on the Executive's behalf or for any other person or entity, or affiliate: (i) hire any employee of the Company Group, or induce or attempt to induce any employee of the Company Group to leave the employ of the Company Group; (ii) hire any person who was an employee of the Company Group at any time during the twelve-month period preceding such hiring; or (iii) induce or attempt to induce any Restricted Customer (as defined herein) to cease doing business with the Company Group, or to reduce the level of business conducted with the Company Group. "<u>Restricted Customer</u>," for purposes of this Agreement, means any former, existing or prospective customer, supplier, licensee, lender, licensor or other business relation of the Company Group, except that "Restricted Customer" shall not include any person with respect to whom Executive had no contact during Executive's employment or any person with whom Executive had a demonstrable pre-existing business relationship prior to entering the employ of the Company Group. Anything herein to the contrary notwithstanding, it shall not be a violation of this <u>Section 3</u> if (y) the Executive furnishes to a third party a reference as to any employee or former employee of the Company Group or (z) an entity with which the Executive is associated hires or engages any employee of the Company Group provided the Executive was not, directly or indirectly, involved in hiring or identifying such person as a potential recruit or assisting in the recruitment and the targeting or recruitment was done via a broad based (and not specifically targeted at such individual) approach, such as solely through a posting on a job(s) website.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>4.</u> <u>Confidential Information</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.The Executive shall use his or her best efforts and diligence, both during and after the Executive's employment with the Company Group, to protect the confidential, trade secret and/or proprietary character of all Confidential Information (as defined below) and the Executive shall not directly or indirectly (intentionally, negligently or otherwise) disclose any Confidential information without the prior written consent of a different duly authorized Company employee with such consent provided in good faith and not subject to any conflicts of interest, except as may be necessary for the performance of the Executive's duties for the Company. For purposes of this Agreement, "<u>Confidential Information</u>" means all information concerning trade secrets, knowhow, software, developments, inventions, processes, technology, designs, financial data, strategic business plans or any other proprietary or confidential information of the Company, in any form or media, including any of the foregoing relating to research, operations, finances, current and proposed products and services, vendors, customers, advertising and marketing. The Executive

------

understands that Confidential Information may or may not be labeled as such, and the Executive shall treat all information that appears to be Confidential Information as confidential. The Executive acknowledges that any Confidential Information that ceases to no longer not be generally known to the public due to Executive's breach of this Agreement shall continue to be considered and treated as Confidential Information by the Executive.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Notwithstanding anything else in this Agreement, this Agreement shall not prohibit the Executive from, in confidence, reporting possible violations of law or regulation to, or file a charge or complaint with, the Securities and Exchange Commission, the Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health Administration, the Department of Justice, Congress, any Inspector General, or any other federal, state or local governmental agency or commission (together, "<u>Government Agencies</u>"), or, in confidence, to an attorney, solely for the purpose of reporting or investigating a suspected violation of law or any disclosure that is protected under any whistleblower provision promulgated under federal law. The Executive further understands that this Agreement does not limit the Executive's ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. Additionally, without informing the Company prior to any such disclosure, if the Executive files a lawsuit against the Company for retaliation for reporting a suspected violation of law, the Executive may, in confidence, disclose Confidential Information to the Executive's attorney and use the Confidential Information in the court proceeding or arbitration, provided the Executive files any document containing the Confidential Information under seal and does not otherwise disclose the Confidential Information, except pursuant to court order. Without prior authorization of the Company, however, the Company does not authorize the Executive to disclose to any third party (including any government official or any attorney the Executive may retain) communications that are covered by the Company's attorney-client privilege.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Upon termination of the Executive's employment with the Company for any reason, with respect to any Confidential Information, the Executive agrees to promptly destroy, delete, and/or return to the Company all originals and copies in any form or medium (including memoranda, books, papers, plans, computer files, letters and other data) in the Executive's possession or control at the time of such termination (including any of the foregoing stored or located in the Executive's office, home, laptop or other computer or any cloud apparatus or remote storage capacity whether or not Company property) that contain Confidential Information. Anything to the contrary notwithstanding, nothing in this <u>Section 4(c)</u> shall prevent the Executive from retaining a computer, papers and other materials of a personal nature, including personal diaries, calendars and Rolodexes, information relating to the Executive's compensation or relating to reimbursement of expenses, information that the Executive reasonably believes may be needed for tax purposes, and copies of plans, programs and agreements relating to the Executive's compensation, provided that the Executive may only disclose Company related information, in confidence, to Executive's attorney or accountant. For the sake of clarity, if the Executive retains a computer or access to any storage location or device, he or she shall delete any information contained therein that the Executive is not permitted to retain under this <u>Section 4(c)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>5. Non-Disparagement</u>.&nbsp;&nbsp;&nbsp;&nbsp;Subject to applicable law, during and after the Executive's employment with the Company Group, (i) the Executive shall not make, either directly or

------

indirectly, any oral or written negative, disparaging or adverse statements or representations of or concerning any member of the Company Group, any of their clients, customers or businesses, or any of their current or former officers, directors, employees or shareholders; <u>provided</u>, <u>however</u>, that nothing in this <u>Section 5</u> shall prohibit (i) the Executive from disclosing truthful information if legally required (whether by oral questions, interrogatories, requests for information or documents, subpoena, civil investigative demand or similar process) or (ii) the Executive from acting in good faith to enforce Executive's rights under any compensation arrangement between Executive and the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>6. Intellectual Property</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.If, prior to the date hereof, the Executive has created, invented, designed, developed, contributed to or improved any works of authorship, inventions, intellectual property, materials, documents or other work product (including, without limitation, research, reports, software, databases, systems, applications, presentations, textual works, content, or audiovisual materials) ("<u>Works</u>"), either alone or with third parties via employment with the Company Group ("<u>Prior</u> <u>Works</u>"), the Executive hereby grants each member of the Company Group, to the extent of any rights the Executive possesses therein, a perpetual, non-exclusive, royalty-free, worldwide, assignable, sublicensable license under all rights and intellectual property rights (including rights under patent, industrial property, copyright, trademark, trade secret, unfair competition and related laws) therein for all purposes in connection with the Company Group's current and future business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.If the Executive creates, invents, designs, develops, contributes to or improves any Works, either alone or with third parties, at any time during the Executive's employment by the Company and within the scope of such employment ("<u>Company Works</u>"), the Executive shall promptly and fully disclose same to the Company and hereby irrevocably assigns, transfers and conveys, to the extent the Executive then possesses and to the maximum extent permitted by applicable law, all rights and intellectual property rights therein (including rights under patent, industrial property, copyright, trademark, trade secret, unfair competition and related laws) to each member the Company Group to the extent ownership of any such rights does not vest originally in a member of the Company Group.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.The Executive agrees to keep and maintain reasonable records of all Company Works. The records will be available to and remain the sole property and intellectual property of the Company at all times, as well as potentially being deemed to be Confidential Information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.The Executive shall, to the extent reasonable, take all actions and execute all requested documents (including any licenses or assignments required by a government contract) at the Company's expense (but without further remuneration) to assist the Company in validating, maintaining, protecting, enforcing, perfecting, recording, patenting or registering any of the Company's rights in the Prior Works and Company Works. If, to the extent the Company is unable to secure the Executive's signature on any document for this purpose, then the Executive hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as the Executive's agent and attorney in fact, to act for and on the Executive's behalf and stead to execute any documents and to do all other lawfully permitted acts in connection with the foregoing.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>7. Reasonableness of Restrictions</u>. The Executive acknowledges and agrees that the Company has invested substantial amounts of time, effort, and money developing legitimate business interests, including but not limited to Confidential Information; relationships with employees, customers and other counterparties; and highly valuable goodwill; and that these business interests are key to the Company's competitive advantages. The Executive also acknowledges and agrees that the Company's legitimate business interests will retain continuing vitality throughout and beyond the Executive's employment. Therefore, the Executive agrees that if a court holds that the restrictions stated herein are unreasonable under circumstances then existing, the parties hereto agree that the maximum duration, scope or geographical area reasonable under such circumstances shall be substituted for the stated period, scope or area and that the court shall be allowed to revise the restrictions contained herein to cover the maximum duration, scope and area permitted by law. The Executive further acknowledges that the Executive will be reasonably able to earn a living without violating the terms of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>8. Extension of Restrictions for Violation</u>. If the Executive violates any of the terms of this Agreement and the Company is required to take legal action to enforce such terms, the Restricted Period shall automatically be extended by the period the Executive was in breach, such that the Executive does not engage in any of the activities proscribed by this Agreement for the full period of the relevant restriction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>9. Remedies</u>. The Executive acknowledges and agrees that the Company has a legitimate interest in protecting and in preventing the Executive from violating this Agreement. The Executive further acknowledges that the Company would be immediately and irreparably harmed, and that such harm would not be readily susceptible to measurement in economic terms or economic compensation and therefore, money damages would not be an adequate remedy, if the Executive were to violate the terms of this Agreement or if any of sections of this Agreement were not specifically enforced. The Executive therefore agrees that in the event of a violation, threatened violation or inevitable violation of this Agreement, the Company and its successors or assigns may, in addition to other rights and remedies existing in their favor, are entitled to specific performance, preliminary and permanent injunctive relieve or other equitable remedies in order to enforce or prevent any violations of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>10. Warranty</u>. The Executive represents and warrants that the Executive is not a party to any non-compete restrictive covenant or related contractual limitation that would interfere with or hinder the Executive's ability to undertake the obligations and expectations of employment with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>11. Severability</u>. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of any other provision of this Agreement or the validity, legality or enforceability of such provision in any other jurisdiction, but this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>12. Notices</u>. Notices and all other communications provided for herein shall be in writing and shall be deemed to have been duly given when personally delivered or when mailed by United States registered or certified mail, return receipt requested, postage prepaid (or in a foreign country such similar method), addressed as follows:

**If to the Company:&nbsp;&nbsp;&nbsp;&nbsp;**Sirius International Insurance Group, Ltd.

14 Wesley Street, 5th Floor Hamilton HM11 Bermuda Attention: Group General Counsel

**If to the Executive:&nbsp;&nbsp;&nbsp;&nbsp;**At the most recent address

on file with the Company

or to such other address as either party may furnish to the other in writing in accordance herewith, except that notices of changes of address shall be effective only upon receipt.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>13. Survival</u>. The terms of this Agreement shall survive any termination of employment, and unless otherwise directly provided for in a superseding document, shall be deemed to survive any superseding such document with respect to periods prior to the effective date of such superseding document.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>14. Complete Agreement</u>. This Agreement and the agreements governing the Additional Compensation constitute the complete agreement between the Executive and the Company concerning the subject matter therein and they supersede and replace in its entirety any prior written or oral understandings entered into between the Executive and the Company. Notwithstanding the foregoing, to the extent the Executive was subject to restrictive covenants prior to the execution of this Agreement, such restrictive covenants shall continue to remain in full force and effect with respect to any conduct or actions prior to the execution of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>15. Successors and Assigns</u>. This Agreement shall be enforceable by the Executive and Executive's heirs, executors, administrators and legal representatives, and by the Company and its successors and assigns. In the event of the consummation of a transaction initiated by the Company involving the formation of a direct or indirect holding company of the Company for an internal legal or business purpose in which the holders of the outstanding voting securities of the Company become the holders of the outstanding voting securities of such holding company in substantially the same proportions, all references to the Company or the Company Group herein shall be deemed to be references to the new holding company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>16. Arbitration</u>. The Executive agrees that any and all disputes under this Agreement shall be subject to and be settled by binding arbitration by a panel of three arbitrators in accordance with the commercial arbitration rules of the American Arbitration Association. The arbitration proceedings will be located in New York City, New York. The arbitrators are not empowered to award damages in excess of compensatory damages and no party shall be entitled to any damages in excess of compensatory damages. Judgment upon any arbitration award may be entered into any court having jurisdiction thereof and the parties consent to the jurisdiction of any court of competent jurisdiction located in the State of New York. **BY EXECUTING THIS AGREEMENT, EXECUTIVE WAIVES ANY RIGHT THAT THE EXECUTIVE MAY**

------

**HAVE TO A JURY TRIAL OR, EXCEPT AS EXPRESSLY PROVIDED HEREIN, A COURT TRIAL OF ANY CLAIM ALLEGED BY EXECUTIVE.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>17.</u> **<u>GOVERNING LAW</u>. THIS AGREEMENT SHALL BE DEEMED TO BE MADE IN NEW YORK, AND, TO THE EXTENT NOT PREEMPTED BY EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974 OR OTHER FEDERAL LAW, THE VALIDITY, INTERPRETATION, CONSTRUCTION AND PERFORMANCE OF THIS AGREEMENT IN ALL RESPECTS SHALL BE GOVERNED BY THE LAWS OF NEW YORK WITHOUT REGARD TO ITS PRINCIPLES OF CONFLICTS OF LAW.** By

executing this Agreement, the Executive and the Company hereby irrevocably consent to, and agree not to object or assert any defense or challenge to, the jurisdiction and venue of the state and federal courts located in New York City, New York, and agree that any claim which, subject to <u>Section 16</u> above, may be brought in a court of law or equity may be brought in any such New York City, New York court.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>18. Amendment and Waiver</u>. The provisions of this Agreement may be amended or waived only by the written agreement of the Company and the Executive, and no course of conduct or failure or delay in enforcing the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>19. Counterparts</u>. This Agreement may be executed in two counterparts, each of which shall be deemed to be an original and both of which together shall constitute one and the same instrument.

------

**IN WITNESS WHEREOF**, the parties hereto have executed this Agreement as of the date first written above.

**SIRIUS INTERNATIONAL INSURANCE GROUP, LTD.**

/s/ Gene Boxer By:<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> Name: <u>Gene Boxer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> Title: <u>Executive Vice President, Chief Strategy</u> <u>Officer & Group General Counsel&nbsp;&nbsp;&nbsp;&nbsp;</u>

**EXECUTIVE**

Name: <u>Thomas Leonardo</u>

------

**<u>SIRIUS GROUP</u>**

**SEVERANCE AND CHANGE IN CONTROL PLAN**

(Effective September 10, 2018)

In order to advance the interests of Sirius International Insurance Group, Ltd., an exempted company organized and existing under the laws of Bermuda (the "<u>Company</u>"), and to encourage the attraction and retention of its key employees, the Compensation Committee of the Board of Directors (the "<u>Committee</u>") of the Company has adopted the Sirius Group Severance and Change in Control Plan (as it may be amended pursuant to the terms hereof, this "<u>Plan</u>").

SECTION 1. <u>Definitions</u>. For purposes of this Plan, the following terms shall have the meanings set forth below:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) "<u>Accountants</u>" shall have the meaning set forth in <u>Section 3(f)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) "<u>Accrued Rights</u>" shall have the meaning set forth in <u>Section 3(a)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) "<u>Affiliate(s)</u>" shall mean any corporation, partnership, limited liability company, limited liability partnership, association, trust or other organization that directly or indirectly controls, is controlled by or is under common control with the Company. For purposes of the preceding

sentence, "control" (including, with correlative meanings, the terms "controlled by" and "under common control with"), as used with respect to any entity or organization, shall mean the possession, directly or indirectly, of the power (i) to vote more than 50% of the securities having ordinary voting power for the election of directors of the controlled entity or organization, or (ii) to direct or cause the direction of the management and policies of the controlled entity or organization, whether through the ownership of voting securities, by contract or otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) "<u>Annual Base Salary</u>" shall mean, with respect to any Participant, such Participant's annual rate of base salary in effect immediately prior to such Participant's Termination Date (or, in the event of the Participant's resignation for Good Reason, the annual rate of base salary in effect immediately prior to the condition giving rise to such resignation if such annual rate of base salary is higher than the annual rate of base salary in effect immediately prior to such

Participant's Termination Date).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) "<u>Cause</u>" shall have the meaning set forth in any then applicable employment or other similar written agreement (including such similar term or concept, as determined by the Committee) between the Participant and the Company or an Affiliate. If there is no such written agreement or if such agreement does not define "Cause," then "Cause" shall mean (i) a material and continued failure of the Participant to perform Participant's duties, other than due to death or Disability, which failure has continued for more than 30 days following written notice of such nonperformance from the Company; (ii) conviction of or pleading guilty or no contest to an act of fraud, embezzlement, or misappropriation of assets or property (tangible or intangible) of the Company or any Affiliate thereof; (iii) a material breach of the Restrictive Covenant Agreement;

(iv) commission of a felony, including a plea of guilty or nolo contendere, or an indictment or written admission thereof; (v) gross negligence or willful misconduct in the performance by the Participant of his duties that is reasonably likely to have an adverse effect on the business,

------

reputation or financial condition of the Company or its Affiliates; or (vi) the Participant's material violation of the material written policies of the Company (e.g., sexual harassment, data protection policy, etc.).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) "<u>Change in Control</u>" shall have the same meaning as such term is defined under the Omnibus Plan, or any successor thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) "<u>CIC Severance Multiple</u>" shall be the multiple provided for in the Participation Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) "<u>Claimant</u>" shall have the meaning set forth in <u>Section 4(c)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) "<u>COBRA</u>" shall mean the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended from time to time, or any successor statute thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) "<u>Code</u>" shall mean the Internal Revenue Code of 1986, as amended from time to time, and the regulations promulgated thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) "<u>Disability</u>" shall mean, with respect to any U.S. Participant, such Participant becoming disabled under one of the Company's long-term disability plans or becoming eligible for benefits from the Social Security Administration. For all non-U.S. Participants, disability shall mean the Participant is incapacitated for a period of at least 180 days by accident, sickness or other circumstance that renders such Participant mentally or physically incapable of performing the

material duties and services required of the Participant in the Participant's position with the Company on a full-time basis during such period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) "<u>Effective Date</u>" shall mean September 10, 2018**.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) "<u>Employment</u>" shall mean employment with the Company or any Affiliate of the Company. A Participant's Employment shall be deemed to have continued notwithstanding a transfer of employment between the Company and any of its Affiliates, or between any two Affiliates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) "<u>ERISA</u>" shall mean the Employee Retirement Income Security Act of 1974, as amended from time to time, or any successor statute thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) "<u>Excise Tax</u>" shall have the meaning set forth in <u>Section 3(f)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) "<u>Good Reason</u>" shall have the meaning set forth in any then applicable employment or other similar written agreement (including such similar term or concept, as determined by the Committee) between the Participant and the Company or an Affiliate. If there is no such written agreement or if such agreement does not define "Good Reason," then "Good Reason" shall mean the Participant has complied with the Good Reason Process (as defined below) following the occurrence of any of the following conditions (without Participant's written consent or waiver):

(i) a material diminution in the Participant's responsibilities, authority or duties, unless such diminution is in connection with a Cause event; (ii) a diminution in the Participant's Annual Base Salary or target annual bonus opportunity; (iii) during the 24-month period following a Change in Control, a material diminution in the regular target annual long term incentive

------

opportunity or the annual target long-term incentive award subsequently granted to the Participant in an amount less than the regular target opportunity, but in all cases disregarding the equity awards granted in connection with the Company's going-public transaction in 2018 and other special cash or equity awards; (iv) a material change in the geographic location at which the Participant provides services to the Company; or (v) a material breach of any employment or other material agreement between the Company or one of its Affiliates and the Participant. For purposes of this Agreement, "<u>Good Reason Process</u>" shall mean that (i) the Participant reasonably determines in good faith that a Good Reason condition has occurred; (ii) the Participant notifies the Company in writing of the occurrence of the Good Reason condition within 60 days of the Participant having actual or constructive knowledge of the occurrence of such condition; (iii) the Participant cooperates in good faith with the Company's efforts, for a

period not less than 30 days following such notice (the "<u>Cure Period</u>"), to remedy the condition;

(iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) the Participant terminates Participant's Employment at least 10 days, but no more than 60 days, after the end of the Cure Period. For the avoidance of doubt, if the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q) "<u>Omnibus Plan</u>" shall mean the Sirius International Insurance Group, Ltd. 2018 Omnibus Incentive Plan or any successor thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r) "<u>Participant</u>" shall mean any employee of the Company (or one of its Affiliates) selected by the Plan Administrator in accordance with <u>Section 2</u> who has entered into a Participation Agreement and otherwise meets the requirements of <u>Section 2</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s) "<u>Participation Agreement</u>" shall mean the written agreement evidencing participation under this Plan between the Company and the recipient of such award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t) "<u>Payments</u>" shall have the meaning set forth in <u>Section 3(f)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u) "<u>Plan Administrator</u>" shall mean (i) the Committee with respect to any Participant who is subject to Section 16 of the Securities Exchange Act of 1934, as amended (the "<u>Exchange Act</u>") and (ii) the Company's Chief Executive Officer or such other person as may be designated by the Committee from time to time with respect to any Participant who is not subject to Section 16 of the Exchange Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) "<u>Restrictive Covenant Agreement</u>" shall mean a restrictive covenant agreement in the form prescribed by the Company and signed by each participant as a condition to participation in this Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(w) "<u>Section 409A Payment</u>" shall have the meaning set forth in <u>Section 5(d)</u>.

(x)"<u>Severance Benefits</u>" shall mean the severance benefits under <u>Section 3(b)</u> and <u>Section</u>

<u>3(c)</u>.

(y)"<u>Severance Period</u>" shall be the period of time provided for in the Participation

Agreement.

------

(z) "<u>Target Bonus</u>" shall mean, with respect to any Participant, such Participant's annual target bonus opportunity in effect immediately prior to such Participant's Termination Date (or, in the event of the Participant's resignation for Good Reason, the annual target bonus opportunity in effect immediately prior to the condition giving rise to such resignation if such annual target bonus opportunity is higher than the annual target bonus opportunity in effect

immediately prior to such Participant's Termination Date).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(aa) "<u>Termination Date</u>" shall mean, with respect to any Participant, the effective date of such Participant's termination of Employment, as determined in accordance with <u>Section 5(d)</u>.

SECTION 2. <u>Eligibility</u>. The Plan Administrator shall from time to time, in its sole discretion, select and designate in writing, which of the Company's (including any of its Affiliates) employees are eligible to participate in this Plan and such employee shall become a Participant under this Plan conditioned upon accepting and executing a Participation Agreement and a Restrictive Covenant Agreement within 30 days after a Participation Agreement is delivered to such employee.

SECTION 3. <u>Compensation, Benefits and Effect of Termination of Employment</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Effect of Termination of Employment on Compensation and Accrued Rights</u>. Except as provided under <u>Section 3(b)</u> or <u>Section 3(c)</u>, upon termination of a Participant's Employment for any reason, all compensation and all benefits to the Participant shall terminate, <u>provided</u> <u>that</u> the Company shall pay the Participant the following benefits (collectively the "<u>Accrued Rights</u>"):

&the earned but unpaid portion of the Participant's Annual Base Salary through the Termination Date;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) any fully-vested annual, long-term, or other incentive award that relates to a completed fiscal year or performance period, as applicable, and is payable (but not yet paid) on or before the Termination Date, which shall be paid in accordance with the terms of such award;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) a lump-sum payment in respect of accrued but unused vacation days at the

Participant's per-business-day Annual Base Salary rate in effect as of the Termination Date; and

&nbsp;&nbsp;&nbsp;&nbsp;(iv) any unpaid expense or other reimbursements due to the Participant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Effect of Termination without Cause or Resignation for Good Reason</u>. Subject to <u>Section 3(c)</u>, <u>Section 3(d)</u>, and <u>Section 3(e)</u>, upon a Participant's termination of Employment, which constitutes a termination by the Company without Cause or resignation for Good Reason, in addition to the Accrued Rights, the Company shall provide the Participant the following payments and benefits:

continued Annual Base Salary during the Severance Period payable in equal installments in accordance with the Company's normal payroll practices, but no less frequently than monthly, which shall commence within 60 days following the Termination Date, except as provided under <u>Section 5</u>;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) with respect to any annual bonus award that relates to a completed fiscal year or performance period, as applicable, ending on or before the Termination Date but which has not yet been paid, the Participant shall be treated as meeting any relevant service condition and shall be paid the annual bonus award at such time as annual bonuses are payable generally to bonus-eligible employees, with such bonus calculated based on actual performance results;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) a pro rata annual bonus for the year of such termination of Employment based on the number of days the Participant was employed during the year of termination, which shall be calculated based on actual performance results with such pro rata annual bonus being paid to the Participant in the fiscal year next following the year in which the

Participant's Employment terminates, at the same time annual bonuses for such preceding year are paid to the Company's other bonus eligible employees and in any event by no later than the 15th day of the third month following the close of such preceding year;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) during the Severance Period, if the Participant timely and properly elects health continuation coverage under COBRA, the Company shall reimburse the Participant for the difference between the monthly COBRA premium paid by the Participant, including any administrative fee and the monthly premium amount paid by similarly situated active Participants. Such reimbursement shall be paid to the Participant by the 10th of the month immediately following the month in which the Participant timely remits the premium payment; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) all outstanding equity compensation awards shall become vested to the extent provided under the terms of the applicable equity compensation plan or award agreement thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Effect of Termination without Cause and or Resignation for Good Reason Following a</u> <u>Change in Control</u>. Subject to <u>Section 3(d)</u> and <u>Section 3(e)</u>, upon a Participant's termination of Employment which constitutes a termination by the Company without Cause or a resignation for Good Reason and occurs within 24 months following the consummation of a Change in Control, in addition to the Accrued Rights, but in lieu of the Severance Benefits payable under <u>Section</u> <u>3(b)</u>, the Company shall provide the Participant the following payments and benefits:

&except as provided under <u>Section 5</u>, a cash payment equal to the CIC Severance Multiple times the Participant's Annual Base Salary, paid in a single lump sum within 60 days following the Termination Date;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) with respect to any annual bonus award that relates to a completed fiscal year or performance period, as applicable, ending on or before the Termination Date, but which has not yet been paid, the Participant shall be treated as meeting any relevant service condition and shall be paid the annual bonus award at such time as annual bonuses are payable generally to bonus-eligible employees, with such bonus calculated based on actual performance results;

(iii) except as provided under <u>Section 5</u>, a cash payment equal to a pro rata portion of the Participant's Target Bonus, based on the number of days the Participant was

------

employed during the year of termination, which shall be paid in a single lump sum within 60 days following the Termination Date;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) except as provided under <u>Section 5</u>, a cash payment equal to: (A) the CIC Severance Multiple times (B) 12 times (C) the difference between the monthly COBRA premium, which would have been paid by the Participant, including any administrative fee and the monthly premium amount paid by similarly situated active Participants; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) all outstanding equity compensation awards, except for those granted under the Sirius Group Long Term Incentive Plan, shall become fully vested (with the attainment or deemed attainment of any applicable performance conditions determined under the terms of the applicable equity compensation plan or award agreement thereunder).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Release of Claims</u>. The obligations of the Company and its Affiliates under this

<u>Section 3</u> (except upon such Participant's death) shall be subject to such Participant's execution, within 45 days after the Termination Date, of a general release and waiver substantially in a form prescribed by the Company, which has become irrevocable following any revocation period permitted by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Recoupment</u>. Notwithstanding any provisions in this Plan to the contrary, the Committee may, in its sole and absolute discretion, in the event of the Participant's material breach of a material obligation of the Participant to the Company pursuant to any award or agreement between the Participant and the Company, including a material breach of the Restrictive Covenant Agreement or a determination that a Cause event has occurred, regardless of whether this determination happened prior to or following the Termination Date: (A) terminate the right of such Participant to receive any payment under this <u>Section 3</u>, to the extent it has not been paid,

(B)seek the recoupment of any payment paid to such Participant under this <u>Section 3</u>, including through exercise rights of set-off, forfeiture or cancellation, to the full extent permitted by law, with respect to any other awards, benefits or payments otherwise due the Participant from the Company or any of its Affiliates, to the extent the Committee in its sole discretion deems appropriate after considering the relevant facts and circumstances. Notwithstanding the foregoing, the Company will not have the right to terminate or recoup any portion of the Accrued Rights. Any termination and/or recoupment of a Participant's benefits under this Plan shall be in addition and without prejudice to any other remedies that the Company might elect to assert.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Code Section 280G</u>. Except as provided for in any then applicable employment or other similar written agreement and notwithstanding anything to the contrary in this Plan, by participating in this Plan, each Participant expressly agrees that if it is determined that any benefits paid or payable under this Plan to a Participant would give rise to liability of the Participant for the excise tax imposed by Section 4999 of the Code or any successor provision

(the "<u>Excise Tax</u>"), then the amount payable to the Participant (the total value of such amounts, the "<u>Payments</u>") shall be reduced by the Company to the extent necessary so that no portion of

the Payments is subject to the Excise Tax; <u>provided</u>, <u>however</u>, such reduction shall be made only if it results in the Participant retaining a greater amount of Payments on an after-tax basis (taking into account the Excise Tax and applicable federal, state, and local income and payroll taxes). In the event Payments are required to be reduced pursuant to this <u>Section 3(f)</u>, then they shall be reduced in the following order of priority in a manner consistent with Section 409A of the Code:

------

(i) first from cash benefits (ii) next from equity benefits, with benefits having later payments dates being reduced first; and (iii) in the case of equity benefits having the same payments dates, pro-rata amongst all such benefits. The Committee shall, in its sole discretion, choose an independent public accounting firm or professional consulting services provider of national reputation and experience (the "<u>Accountants</u>") to make in writing in good faith all calculations and determinations under this <u>Section 3(f)</u> including the assumptions to be used in arriving at any calculations. For purposes of making the calculations and determinations under this <u>Section 3(f)</u>, the Accountants may make reasonable assumptions and approximations concerning the application of Sections 280G and 4999 of the Code. The Company shall furnish to the Accountants information and documents as the Accountants may reasonably request to make the calculations and determinations under this <u>Section 3(f)</u> and shall bear all costs the Accountants incur in connection with any calculations contemplated hereby.

SECTION 4. <u>Administration of Plan; Claims Procedure</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>General</u>. Except as specifically provided herein, this Plan shall be administered by the Plan Administrator. The Plan Administrator may delegate any administrative duties, including, without limitation, duties with respect to the processing, review, investigation, approval and payment of benefits under this plan to designated individuals or committees. The Plan

Administrator shall be the "administrator" and a "named fiduciary" under this Plan for purposes of ERISA.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Interpretations and Variations</u>. The Plan Administrator shall have the duty and authority to interpret and construe, in its sole discretion, the terms of this Plan in regard to all questions of eligibility, the status and rights of Participants, and the manner, time and amount of any payment under this Plan. The Plan Administrator or its representative shall decide any issues arising under this Plan, and the decision of the Plan Administrator shall be binding and conclusive on the Participants and the Company. Any variations from this Plan may be made only by the Plan Administrator in its sole discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Filing a Claim</u>. It is not normally necessary to file a claim in order to receive benefits under this Plan; however, if a Participant (the "<u>Claimant</u>") feels he or she has been improperly

denied benefits under this Plan, any claim for payment of such benefits shall be signed, dated and submitted to the Company in accordance with <u>Section 8(a)</u>. All claims relating to this Plan must be filed within 90 days following the Participant's Termination Date, unless the Plan Administrator otherwise specifies in writing. The Plan Administrator shall then evaluate the claim and notify the Claimant of the approval or disapproval in accordance with the provisions of this Plan not later than 90 days after the Company's receipt of such claim unless special circumstances require an extension of time for processing the claims. If such an extension of time for processing is required, written notice of the extension shall be furnished to the Claimant prior to the termination of the initial 90 day period which shall specify the special circumstances requiring an extension and the date by which a final decision will be reached (which date shall not be later than 180 days after the date on which the claim was filed). If the Claimant does not provide all the necessary information for the Plan Administrator to process the claim, the Plan Administrator may request additional information and set deadlines for the Claimant to provide that information.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Notice of Initial Determination</u>. The Claimant shall be given a written notice in which the Claimant shall be advised as to whether the claim is granted or denied, in whole or in part. If a claim is denied, in whole or in part, the Claimant shall be given written notice which shall contain (i) the specific reasons for the denial, (ii) specific references to pertinent Plan provisions on which the denial is based, (iii) a description of any additional material or information necessary to perfect the claim and an explanation of why such material or information is necessary and (iv) an explanation of this Plan's appeal procedures, which shall also include a

statement of the Claimant's right to bring a civil action under Section 502(a) of ERISA following a denial of the claim upon review.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Right to Appeal</u>. If a claim for payment of benefits under this Plan made in accordance with the procedures specified in this Plan is denied, in whole or in part, the Claimant shall have the right to request that the Plan Administrator review the denial, <u>provided that</u> the Claimant files a written request for review with the Plan Administrator within 60 days after the date on which the Claimant received written notification of the denial. The Claimant may review or receive copies, upon request and free of charge, any documents, records or other information "relevant" (within the meaning of Department of Labor Regulation 2560.503-1(m)(8)) to the Claimant's claim. The Claimant may also submit written comments, documents, records and other information relating to his or her claim.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Review of Appeal</u>. In deciding a Claimant's appeal, the Plan Administrator shall take into account all comments, documents, records and other information submitted by the Claimant relating to the claim, without regard to whether such information was submitted or considered in the initial review of the claim. If the Claimant does not provide all the necessary information for the Plan Administrator to decide the appeal, the Plan Administrator may request additional information and set deadlines for the Claimant to provide that information. Within 60 days after a request for review is received, the review shall be made and the Claimant shall be advised in writing of the decision on review, unless special circumstances require an extension of time for processing the review, in which case the Claimant shall be given a written notification within such initial 60 day period specifying the reasons for the extension and when such review shall be completed (<u>provided that</u> such review shall be completed within 120 days after the date on which the request for review was filed).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Notice of Appeal Determination</u>. The decision on review shall be forwarded to the Claimant in writing and, in the case of a denial, shall include (i) specific reasons for the decision,

(ii) specific references to the pertinent Plan provisions upon which the decision is based, (iii) a statement that the Claimant is entitled to receive, upon request and free of charge, reasonable access to, and copies of, all documents, records or other information relevant to the Claimant's claim and (iv) a statement of the Claimant's right to bring a civil action under Section 502(a) of ERISA following a wholly or partially denied claim for benefits. The Plan Administrator's decision on review shall be final and binding on all persons for all purposes. If a Claimant shall fail to file a request for review in accordance with the procedures herein outlined, such Claimant shall have no right to review and shall have no right to bring an action in any court, and the denial of the claim shall become final and binding on all persons for all purposes. Any notice and decisions by the Plan Administrator under this <u>Section 4</u> may be furnished electronically in accordance with Department of Labor Regulation 2520.104b-1(c)(i), (iii) and (iv).

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>Arbitration; Statute of Limitations</u>. No Claimant may bring any legal action to recover benefits under this Plan until he or she has exhausted the internal administrative claims and appeals process described above. No legal action may be commenced at all, unless commenced no later than one year following the issuance of a final decision on the claim for benefits, or the expiration of the appeal decision period if no decision is issued. This one-year statute of limitations on suits for all benefits available under this Plan shall apply in any forum where such legal action is initiated. Upon Claimant's exhaustion of the provisions set forth above, any Claimant with a continuing dispute arising out of or relating to this Plan or the adoption, breach, termination or validity thereof, will be settled by binding arbitration by a panel of three arbitrators in accordance with the commercial arbitration rules of the American Arbitration Association. The arbitration proceedings will be located in New York City, New York. The arbitrators are not empowered to award damages in excess of compensatory damages and no party shall be entitled to any damages in excess of compensatory damages. Judgment upon any arbitration award may be entered into any court having jurisdiction thereof and the parties consent to the jurisdiction of any court of competent jurisdiction located in the State of New York. **BY PARTICIPATING IN THIS PLAN, PARTICIPANT WAIVES ANY RIGHT THAT PARTICIPANT MAY HAVE TO A JURY TRIAL OR, EXCEPT AS EXPRESSLY PROVIDED HEREIN, A COURT TRIAL OF ANY CLAIM ALLEGED BY PARTICIPANT.**

SECTION 5. <u>Section 409A Compliance; Changes in Law</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) It is the intention of the Company that the provisions of this Plan comply with

Section 409A of the Code, and all provisions of this Plan shall be construed and interpreted in a manner consistent with Section 409A of the Code. The Company shall administer and operate this Plan in compliance with Section 409A of the Code and any rules, regulations or other guidance promulgated thereunder as in effect from time to time and in the event that the Company determines that any provision of this Plan does not comply with Section 409A of the Code or any such rules, regulations or guidance and that as a result any Participant may become subject to a tax under Section 409A of the Code, notwithstanding <u>Section 8(l)</u>, the Company shall have the discretion to amend or modify such provision to avoid the application of such tax, and in no event shall any Participant's consent be required for such amendment or modification. Notwithstanding any provision of this Plan to the contrary, each Participant shall be solely responsible and liable for the satisfaction of all taxes and penalties that may arise in connection with amounts payable pursuant to this Plan (including any taxes arising under Section 409A of the Code), and the Company not shall have any obligation to indemnify or otherwise hold such Participant harmless from any or all of such taxes.

(b) In the event that the Company determines that any provision of this Plan violates, or would result in any material liability (other than liabilities for the Severance Benefits) to the Company under, any law, regulation, rule or similar authority of any governmental agency the Company shall be entitled, notwithstanding <u>Section 8(l)</u>, to amend or modify such provision as the Company determines in its discretion to be necessary or desirable to avoid such violation or liability, and in no event shall any Participant's consent be required for such amendment or modification.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The payments under this Plan are designated as separate payments for purposes of the short-term deferral rule under Treasury Regulation Section 1.409A-1(b)(4), the exemption for involuntary terminations under separation pay plans under Treasury Regulation

Section 1.409A-1(b)(9)(iii), and the exemption for medical expense reimbursements under Treasury Regulation Section 1.409A-1(b)(9)(v)(B). As a result, (A) payments that are made on or before the 15<sup>th</sup> day of the third month of the calendar year following the year that includes the Participant's Termination Date, (B) any additional payments that are made on or before the last day of the second calendar year following the year of the Participant's Termination Date and do not exceed the lesser of two times the Participant's annual rate of pay in the year prior to his termination or two times the limit under Section 401(a)(17) of the Code then in effect, and

(C)continued medical expense reimbursements during the applicable COBRA period, are exempt from the requirements of Section 409A of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) To the extent any amounts under this Plan are payable by reference to a Participant's termination of Employment, such term and similar terms shall be deemed to refer to such Participant's "separation from service," within the meaning of Section 409A of the

Code. Notwithstanding any other provision in this Plan, to the extent any payments hereunder constitute "nonqualified deferred compensation," within the meaning of Section 409A of the Code (a "<u>Section 409A Payment</u>"), and the Participant is a specified employee, within the meaning of Treasury Regulation Section 1.409A-1(i), as determined by the Company in accordance with any method permitted under Section 409A of the Code, as of the date of the

Participant's separation from service, each such Section 409A Payment that is payable upon such Participant's separation from service and would have been paid prior to the six-month

anniversary of such Participant's separation from service, shall be delayed until the earlier to occur of (i) the six-month anniversary of Participant's separation from service and (ii) the date of Participant's death. Further, to the extent that any amount is a Section 409A Payment and such payment is conditioned upon Participant's execution of a release and which is to be paid or provided during a designated period that begins in one taxable year and ends in a second taxable year, then such Section 409A Payment shall be paid or provided in the later of the two taxable years.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Any reimbursements payable to a Participant pursuant to this Plan or otherwise shall be paid to such Participant in no event later than the last day of the calendar year following the calendar year in which such Participant incurred the reimbursable expense. Any amount of expenses eligible for reimbursement, or in-kind benefit provided, during a calendar year shall not affect the amount of expenses eligible for reimbursement, or in-kind benefit to be provided, during any other calendar year. The right to any reimbursement or in-kind benefit pursuant to this Plan shall not be subject to liquidation or exchange for any other benefit. Any tax gross-up payment payable to a Participant, whether under this Plan or otherwise, shall be paid to the

Participant or to the applicable taxing authorities on the Participant's behalf as soon as practicable after the related taxes are due, but in any event not later than the last day of the calendar year following the calendar year in which the related taxes are remitted to the taxing authorities.

SECTION 6. <u>Covenants.</u> Each Participant's participation in this Plan is conditioned upon the Participant's execution of a Restrictive Covenant Agreement within 30 days after a Participation Agreement is delivered to such Participant (or such later date as permitted by the

------

Plan Administrator). If a Participant breaches any of the covenants in the Restrictive Covenant Agreement, including any non-competition, non-solicitation, non-disparagement or

confidentiality covenants contained therein, (i) the Participant's entitlement to Severance Benefits shall be null and void, (ii) all rights to receive or continue to receive Severance Benefits shall thereupon cease and (iii) the Participant shall immediately repay to the Company all amounts theretofore paid to, and the value of all benefits theretofore received by, the Participant. The foregoing shall not limit any other rights or remedies the Company may have existing in its favor, including injunctive relief.

SECTION 7. <u>Offset; No Mitigation</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The amount of a Participant's payments under this Plan shall be reduced to the extent necessary to defray amounts owed by Participant due to unused expense account balances, overpayment of salary, awards or bonuses, advances or loans.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) In no event shall any Participant be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to the Participant under any of the provisions of this Plan and, such amounts shall not be reduced whether or not the Participant obtains other employment.

SECTION 8. <u>Miscellaneous</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Notices</u>. Notices and all other communications provided for herein shall be in writing and shall be deemed to have been duly given when personally delivered or when mailed by overnight mail via a reputable overnight carrier, or sent by registered or certified mail, return receipt requested, postage prepaid (or in a foreign country such similar method), addressed as follows:

**If to the Company:&nbsp;&nbsp;&nbsp;&nbsp;**Sirius International Insurance Group, Ltd.

14 Wesley Street, 5th Floor Hamilton HM11 Bermuda Attention: Group General Counsel

**If to a Participant:&nbsp;&nbsp;&nbsp;&nbsp;**At the most recent address on file with the Company

or to such other address as either party may furnish to the other in writing in accordance herewith, except that notices of changes of address shall be effective only upon receipt.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **<u>GOVERNING LAW</u>. THIS PLAN SHALL BE DEEMED TO BE MADE IN NEW YORK, AND, TO THE EXTENT NOT PREEMPTED BY ERISA OR OTHER FEDERAL LAW, THE VALIDITY, INTERPRETATION, CONSTRUCTION AND PERFORMANCE OF THIS PLAN IN ALL RESPECTS SHALL BE GOVERNED BY THE LAWS OF NEW YORK WITHOUT REGARD TO ITS PRINCIPLES OF**

**CONFLICTS OF LAW.** By participating in this Plan, each Participant and the Company hereby irrevocably consent to, and agree not to object or assert any defense or challenge to, the jurisdiction and venue of the state and federal courts located in New York City, New York, and agree that any claim which, subject to <u>Section 4</u> above, may be brought in a court of law or

------

equity may be brought in any such New York City, New York court. To the extent benefits provided under <u>Section 3(c)(v)</u> are subject to interpretation under Bermuda law due to the administration of the Omnibus Plan, then, if necessary and solely to the extent necessary to administer the Omnibus Plan, such governing law provision shall be deemed to supersede this <u>Section 8(b)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>No Waiver</u>. No failure by the Company or a Participant at any time to give notice of any breach by the Company or a Participant, or to require compliance with, any condition or provision of this Plan shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Severability</u>. If a court of competent jurisdiction determines that any provision of this Plan is invalid or unenforceable, then the invalidity or unenforceability of that provision shall not affect the validity or enforceability of any other provision of this Plan, and all other provisions shall remain in full force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Withholding of Taxes and Other Employee Deductions</u>. The Company may withhold from any benefits and payments made pursuant to this Plan all federal, state, city and other taxes as may be required pursuant to any law or governmental regulation or ruling and all other normal employee deductions made with respect to the Company's employees generally.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Headings</u>. The paragraph headings have been inserted for purposes of convenience and shall not be used for interpretive purposes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Interpretations</u>. For purposes of this Plan, the words "include" and "including," and variations thereof, shall not be deemed to be terms of limitation but rather shall be deemed to be followed by the words "without limitation". The term "or" is not exclusive. The word "extent" in the phrase "to the extent" shall mean the degree to which a subject or other thing extends, and such phrase shall not mean simply "if." Wherever the context so requires, the masculine gender includes the feminine or neuter, and the singular number includes the plural and conversely.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>Successors</u>. This Plan shall be binding upon and inure to the benefit of the Company and any successor of the Company, including without limitation any person, association, or entity which may hereafter acquire or succeed to all or substantially all of the business or assets of the Company by any means whether direct or indirect, by purchase, merger, consolidation, or otherwise and the Company shall require any such acquirer successor to assume this Plan and the obligations and liabilities contemplated thereunder, including, but not limited to the amendment and termination obligations contemplated under <u>Section 8(l)</u>. Participants' rights, benefits and obligations under this Plan are personal and shall not be voluntarily or involuntarily assigned, alienated, or transferred, whether by operation of law or otherwise, without the prior written consent of the Company.

(i) <u>Survival of Other Severance Benefits and Non-Duplication</u>. The Severance Benefits provided under this Plan are not meant to replace or supersede any severance benefits provided under any the Omnibus Plan, employment agreement, arrangement or award agreement or any other similar contractual arrangement ("<u>Other Severance Benefits</u>") and the Severance Benefits provided under this Plan are not intended to result in any duplicative benefits to the Participant

and this Plan shall be administered accordingly. Accordingly, the Committee, in good faith, shall exercise its discretion and to the extent permitted under applicable law, equitably offset

------

against the Participant's severance benefits under this Plan against any other severance, termination, or similar benefits payable to the Participant by the Company with respect to the

Other Severance Benefits or amounts paid to comply with, or satisfy liability under, the Worker Adjustment and Retraining Notification Act or any other foreign, federal, state, or local law requiring payments in connection with any termination of Employment, plant shutdown, or workforce reduction, including, but not limited to, amounts paid in connection with paid leaves of absence, back pay, benefits, and other payments intended to satisfy such liability or alleged liability. For the avoidance of doubt, this <u>Section 8(i)</u> is not meant to impinge or interfere with the Company's ability to require Participant to follow or adhere to any steps or requirements under this Plan or Other Severance Benefits to obtain severance benefits contemplated thereunder (e.g., executing any releases, complying with any restrictive covenants, etc.).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) <u>Deemed Resignations</u>. Any termination of a Participant's Employment shall constitute an automatic resignation of such Participant as an officer of the Company and each Affiliate of the Company, an automatic resignation from the board of directors, if applicable, of the Company and each Affiliate of the Company and from the board of directors or similar governing body of any corporation, limited liability company or other entity in which the Company or any Affiliate holds an equity interest and with respect to which board or similar governing body such Participant serves as the Company's or such Affiliate's designee or other representative.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) <u>No Guarantee of Employment</u>. This Plan shall not be construed as creating any contract of employment between the Company and its Affiliates, on the one hand, and any Participant, on the other hand, nor shall this Plan be construed as restricting in any way the rights of the Company or any of its Affiliates to terminate the Employment of any Participant at any time and for any reason subject, however, to any rights of a Participant under this Plan.

(l) <u>Amendment and Termination of this Plan</u>. Except as specifically provided in <u>Section 5</u>, the Committee may amend, modify or terminate this Plan at any time in its sole discretion; <u>provided</u>, <u>however</u>, that (i) no such amendment, modification or termination will be effective unless each affected Participant has received written notice thereof at least 6 months prior to such amendment, modification or termination becoming effective and (ii) no such amendment, modification or termination may materially impair the rights of a Participant whose Termination Date previously occurred. In addition, the Committee may not amend, modify or terminate this Plan after steps have been taken, and continue to be taken, that could lead to a Change in Control or within 24 months after a Change in Control without an impacted Participant's written consent. The failure of the Company or a Participant to insist upon strict adherence to any term of this Plan on any occasion shall not be considered as a waiver of the rights of the Company or such Participant or deprive the Company or such Participant of the right thereafter to insist upon strict adherence to that term or any other term of this Plan. No failure or delay by the Company or any Participant in exercising any right or power hereunder will operate as a waiver thereof, nor will any single or partial exercise of any such right or power, or any abandonment of any steps to enforce such right or power, preclude any other or further exercise thereof or the exercise of any other right or power.

SECTION 9. <u>Survival</u>. The provisions of this Plan, including <u>Sections 3</u>, <u>Section 4</u>, <u>Section</u> <u>5</u>, <u>Section 6</u>, <u>Section 7</u> and <u>Section 8</u> shall survive and remain binding and enforceable,

notwithstanding the expiration or termination of this Plan, the termination of a Participant's Employment for any reason or any settlement of the financial rights and obligations arising from

------

such Participant's participation hereunder, to the extent necessary to preserve the intended benefits of such provisions.

\* \* \* \* \* \*

------

IN WITNESS WHEREOF, the Company has caused this Plan to be executed on its behalf, to be effective as of the Effective Date.

GROUP, LTD.

/s/ Allan Waters

Allan Waters

**SIRIUS INTERNATIONAL INSURANCE**

Chief Executive Officer & President

## Exhibit 31.1

**Exhibit 31.1**

**SiriusPoint Ltd.**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**

**PURSUANT TO RULE 13a-14(a) OF THE EXCHANGE ACT, AS AMENDED, AS ADOPTED PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Scott Egan, certify that:

1.&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this Quarterly Report on Form 10-Q of SiriusPoint Ltd.;

2.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 7, 2026

---

| |
|:---|
| /s/ Scott Egan |
| Scott Egan |
| Chief Executive Officer |
| (Principal Executive Officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

**SiriusPoint Ltd.**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

**PURSUANT TO RULE 13a-14(a) OF THE EXCHANGE ACT, AS AMENDED, AS ADOPTED PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Jim McKinney, certify that:

1.&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this Quarterly Report on Form 10-Q of SiriusPoint Ltd.;

2.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 7, 2026

---

| |
|:---|
| /s/ Jim McKinney |
| Jim McKinney |
| Chief Financial Officer |
| (Principal Financial Officer and Principal Accounting Officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

**SiriusPoint Ltd.**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**

**PURSUANT TO** 

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO** 

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Scott Egan, Chief Executive Officer of SiriusPoint Ltd. (the "Company"), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;&nbsp;the Quarterly Report on Form 10-Q of the Company for the fiscal period ended March 31, 2026 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;&nbsp;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 7, 2026

---

| |
|:---|
| /s/ Scott Egan |
| Scott Egan |
| Chief Executive Officer |
| (Principal Executive Officer) |

---

## Exhibit 32.2

**Exhibit 32.2**

**SiriusPoint Ltd.**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

**PURSUANT TO** 

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO** 

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Jim McKinney, Chief Financial Officer of SiriusPoint Ltd. (the "Company"), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;&nbsp;the Quarterly Report on Form 10-Q of the Company for the fiscal period ended March 31, 2026 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;&nbsp;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 7, 2026

---

| |
|:---|
| /s/ Jim McKinney |
| Jim McKinney |
| Chief Financial Officer |
| (Principal Financial Officer and Principal Accounting Officer) |

---

<br>